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Abstract
Genome instability is an enabling characteristic of cancerous cells. It has recently
been discovered that the retinoblastoma protein (pRB), typically known for its role in cell
cycle regulation, also aids in the maintenance of genome stability. Intriguingly, mutations
to the pRB gene, RB1, can arise late in tumorigenesis in cancer cells whose cell cycle
regulation is already compromised by another mutation. This suggests that pRB’s
functions in genome stability could underlie cancer relevant characteristics that are
independent of its ability to negatively regulate proliferation. The overall aim of this
thesis is to characterize the different means through which pRB contributes to the
preservation of genome integrity. Using CRISPR/Cas9, isogenic RB1 mutant genotypes
were created in a number of cancer cell lines. Cells with at least one mutant copy of RB1
have increased basal levels of DNA damage and increased mitotic errors. When the
underlying origins of these phenotypes were investigated further, I discovered elevated
levels of reactive oxygen species as well as impaired homologous recombination repair in
cells with RB1 mutations. When xenografted into immune compromised mice, RB1
mutation also results in an increased capacity to seed new tumors in the lungs. This thesis
also investigates the functions of the pRB-condensin II complex in maintaining genome
stability, specifically in interphase cells. Using a gene-targeted mouse model that disrupts
the ability of pRB to recruit condensin II, Rb1L, locations of pRB-dependent condensin II
recruitment were investigated. I found that both condensin II and another architectural
protein complex, TFIIIC, are recruited to promoters between bidirectional genes by a
mechanism that is reliant on pRB. Recruitment of these architectural proteins at
bidirectional promoters is required to establish long-range chromosome interactions and
transcriptional insulation between gene pairs. In addition, pRB deletion in cancer causes
similar misregulation at divergent promoters, indicating that loss of insulation impacts the
transcriptome of cancer cells. Overall, this work demonstrates that beyond altered
proliferative control, loss of pRB can also contribute to cancer progression through
enhanced DNA damage and altered chromosome topology.
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Lay Abstract
In human cells, maintaining the integrity of DNA is critical to preserve proper
function and health. If genomic instability does occur, it can lead to cancer. It has recently
been discovered that the retinoblastoma protein (pRB), typically known for its role in
regulating cellular growth rates to provide protection against cancer, also aids in the
maintenance of genome stability. Intriguingly, mutations to pRB can arise in cancer cells
where cellular growth is already compromised. This suggests that pRB’s functions in
genome stability could underlie cancer relevant characteristics that are independent of its
ability to regulate cellular growth rates. The overall aim of this thesis is to characterize
the different means through which pRB contributes to the preservation of genome
integrity. To investigate this, pRB mutations were created in a number of cancer cell
lines. Cells with pRB mutations have increased basal levels of DNA damage and
increased errors when cells are dividing. When transplanted into immune compromised
mice, cells with pRB mutation have an increased capacity to form new tumors in the
lungs. This thesis also uses a mouse model with a targeted mutation to investigate the
genome stability functions of pRB when it is in a complex with another protein,
condensin II, which is known to fold DNA to package it tightly. I found that condensin II
and another protein known to alter DNA packaging, TFIIIC, are both reliant on pRB to be
recruited to the beginning of genes facing opposite directions. Recruitment of condensin
II and TFIIIC at these locations is required for proper DNA packaging and gene
expression. In addition, pRB deletion in cancer causes similar misexpression of genes at
these locations, indicating that loss of pRB and hence condensin II and TFIIIC
localization impacts gene expression in cancer cells. Overall, this work demonstrates that
beyond altered cellular growth rates, loss of pRB can also contribute to cancer
progression through enhanced DNA damage and altered DNA packaging. In the future,
these recently discovered characteristics could be used to select the best therapeutic tools
for patients with pRB loss.
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Chapter 1

1

Introduction

1.1 Retinoblastoma onset and the discovery of the
retinoblastoma gene
Retinoblastoma, or childhood cancer of the retina, can be inherited due to
germline mutation or can occur sporadically due to somatic mutation (Falls and Neel,
1951; Schappert-Kimmijser et al., 1966; Smith and Sorsby, 1958). Because many of the
collected pedigrees showed affected sibships, and some of the affected sibs themselves
transmitted the disease to their offspring, retinoblastoma was originally theorized to be
caused by a single dominant mutant gene that is not completely penetrant (Neel and Falls,
1951; Smith and Sorsby, 1958). Retinoblastoma can occur either as a unilateral disease,
affecting only one eye of the child, or as a bilateral disease, affecting both eyes. In 1971,
Dr. Alfred Knudson used statistics to analyze clinical data and determined that
retinoblastomas arise through a minimum of two mutational events, which later became
known as the “two hit hypothesis” (Knudson, 1971). In his study, Knudson realized that
bilateral retinoblastoma is generally found in children who have a family history of the
disease. It was also noted that children with bilateral cases have an earlier mean age at
diagnosis than those with unilateral cases. These observations, therefore, could be
explained by his hypothesis; affected children with familial retinoblastoma inherit one
mutational event in their genome, making them susceptible to retinoblastoma, but it is not
until they acquire a second mutation, or “hit”, that they succumb to the disease. Patients
who do not inherit the first mutation, however, need to have two independent mutational
events occur to develop retinoblastoma. This hypothesis, therefore, is built on the
assumption that there is a gene whose protein product is necessary to suppress
retinoblastoma incidence.
Early genetic studies of retinoblastomas revealed that there were occasionally
tumors with deletions in chromosome 13, more specifically at region 13q14 (Francke and
Kung, 1976; Lele et al., 1963; Sparkes et al., 1980; Yunis and Ramsay, 1978). It was then
postulated that the alleles found at this “retinoblastoma locus” were tumor suppressors
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and loss of function of these alleles is associated with malignancy (Murphree and
Benedict, 1984). This became the prototype to which other proposed tumor suppressor
genes were compared. Eventually, in 1986, two independent groups cloned a single gene
from this q14 segment of chromosome 13 which was shown not only to be deleted in
retinoblastomas, but osteosarcomas as well (Friend et al., 1986; Lee et al., 1987). This
gene became known as the retinoblastoma susceptibility gene, abbreviated as RB1.

1.2 The retinoblastoma protein is a cell cycle regulator
The first biochemical evidence that the retinoblastoma gene could be important
for tumor suppression in other tissues outside of retina and bone came from studies of
viral oncoproteins. Adenovirus E1A, simian virus 40 T antigen, and human papilloma
virus E7 oncoproteins all require inactivation of the retinoblastoma protein (pRB) to
transform cells, which suggested a broader tumor suppressive function of pRB (DeCaprio
et al., 1988; Dyson et al., 1989; Whyte et al., 1988; Whyte et al., 1989). Shortly after
these discoveries, it was also seen that loss of pRB function leads to loss of cellular
proliferation control, as demonstrated in various cancer samples (Bookstein et al., 1990a;
Huang et al., 1988; Takahashi et al., 1991). By utilizing human cancer cells with mutant
versions of RB1 and subsequently expressing exogenous wild type RB1, cells were shown
to have reduced proliferation, colony formation in agar, and tumorigenicity in nude mice,
further demonstrating the proliferative control of pRB (Bookstein et al., 1990b; Huang et
al., 1988; Takahashi et al., 1991). pRB was also shown to be phosphorylated in late G1
phase just before cells enter S phase, which further suggested pRB may be acting as a cell
cycle regulatory element (DeCaprio et al., 1989). Ultimately, pRB was shown to inhibit
E2F transcription factors in G1 of the cell cycle, but pRB is unable to do so when it
becomes hyperphosphorylated or when it is deregulated by viral oncoproteins
(Chellappan et al., 1991; Helin et al., 1992; Hiebert et al., 1992; Nevins, 1992). These
studies led to the identification of the G1 checkpoint of the cell division cycle which is
controlled by pRB through binding to and inhibiting E2Fs and their target gene
transcription (Dyson, 1998).
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1.3 The pocket domain defines the pRB family
Two additional proteins were discovered that also have the ability to bind to viral
oncoproteins and have sequence homology with pRB (Cobrinik et al., 1993; Ewen et al.,
1991; Hannon et al., 1993; Li et al., 1993; Mayol et al., 1993; Zhu et al., 1993). These
proteins are p107 and p130, encoded by RBL1 (retinoblastoma like 1) and RBL2
(retinoblastoma like 2), respectively. pRB, p107 and p130 are collectively referred to as
the “pocket proteins” because of the pocket domain that is found in all three proteins
(Figure 1.1A). This pocket domain itself contains a small pocket and a large pocket. The
large pocket consists of an unstructured C-terminal domain along with the small pocket.
This large pocket is necessary for binding E2F in vivo, inhibiting E2F target gene
transcription and is also the minimal growth suppressing domain (Figure 1.1B) (Bremner
et al., 1995; Hiebert et al., 1992; Qin et al., 1992; Yang et al., 2002). The small pocket
can also be further divided into the A and the B subdomains which are separated by an
unstructured, flexible linker region (Chow and Dean, 1996). These A and B subdomains
each form a single cyclin fold which interact with each other to form the globular small
pocket domain (Gibson et al., 1994; Lee et al., 1998). This small pocket is the minimal
domain capable of interacting with viral oncoproteins and is sufficient to repress
transcription (Chow and Dean, 1996; Chow et al., 1996; Hu et al., 1990; Kaelin et al.,
1990; Sellers et al., 1995). Crystal structures revealed that the LXCXE motif found in
viral oncoproteins is what binds a shallow groove in the B subdomain, which is now
commonly referred to as the LXCXE binding cleft (Figure 1.1B) (Lee et al., 1998). Since
then, it has been discovered that a number of cellular proteins bind to the LXCXE binding
cleft, many of which are able to alter chromatin structure and act as co-repressors of
transcription. Examples of proteins binding to pRB through the LXCXE binding cleft
include histone deacetylases (HDAC1 and HDAC2), DNA methyl transferases
(DNMT1), histone methyl transferases (Suv39h1), histone binding proteins (HP1), and
condensin II (Brehm et al., 1998; Longworth et al., 2008; Magnaghi-Jaulin et al., 1998;
Nielsen et al., 2001; Robertson et al., 2000).
Despite all of the structural similarities between the pocket proteins, there are also
some key differences. Both p107 and p130 contain an insertion within their B
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Figure 1.1: Interaction surfaces of pocket proteins and the unique interaction
between pRB and E2F1.
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Figure 1.1: Interaction surfaces of pocket proteins and the unique interaction
between pRB and E2F1.
(A) The A, B and C-terminal subdomains are shown for all three pocket proteins. The
large and small pockets are denoted by blue and green lines, respectively. (B) The three
different interaction sites within the large pocket of pRB are shown. The E2F1 specific
interaction is formed between the E2F1 marked box domain (MBD) and a minimal
interaction site in the C-terminus of pRB, while the E2F general interaction is facilitated
by the transactivation domains (TADs) of E2F1-4 and the large pocket domain of pRB.
The third interaction site, the LXCXE binding cleft, is located in the B subdomain of the
pocket. (C) The retinoblastoma protein binds to E2F-DP heterodimeric transcription
factors to repress transcription of cell cycle genes during the G1 phase of the cell cycle.
pRB also recruits chromatin remodeling proteins to these sites to assist in the formation
of repressive heterochromatin. Upon mitogen stimulation during the G1-S phase
transition, cyclin and cyclin-dependent kinase (CDK) complexes hyperphosphorylate
pRB causing it to dissociate from E2F transcription factors that were bound through the
E2F general interaction, leading to the activation of E2F cell cycle genes. However, the
E2F1 specific interaction with pRB exhibits resistance to CDK phosphorylation and
allows these proteins to continue to associate. This CDK-resistant complex of E2F1 and
pRB has been seen to bind at repetitive elements, but other locations in the genome are
largely unknown.
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subdomains, have longer spacer regions linking subdomains A and B which allows them
to interact with cyclin-cyclin dependent kinase (CDK) complexes, and they have a unique
N-terminal domain that can inhibit CDKs (Classon and Dyson, 2001). pRB, on the other
hand, has a specific E2F1 binding site within the pRB carboxy-terminal domain (Figure
1.1B) (Dick and Dyson, 2003; Julian et al., 2008). Also contained within the C-terminal
domain of pRB are binding sites for cyclin-CDK complexes and protein phosphatase 1
(PP1) (Adams et al., 1999; Durfee et al., 1993; Tamrakar and Ludlow, 2000; Vietri et al.,
2006).

1.4 The pRB family is recruited to DNA by E2F transcription
factors
The first identification of any E2F transcription factor came from studying cell
factors that could mediate transcriptional activation of the adenovirus E2 promoter,
leading to the name E2 promoter binding factor (E2F) (Kovesdi et al., 1987). Further
studies of transcriptional control showed that there were human genes regulated in not
only an E2F-dependent manner but also a cell cycle-dependent manner; the first of which
were MYC, which is involved in cellular proliferation, and the dihydrofolate reductase
gene (DHFR), which is involved in metabolism of nucleic acids (Blake and Azizkhan,
1989; Hiebert et al., 1989; Thalmeier et al., 1989). This helped form the basis that the
growth suppressive role of pRB was mediated through inhibiting E2F target gene
transcription, which could become deregulated by viral oncoproteins (Nevins, 1992).
Since the initial discovery, it has become clear that the E2F transcriptions factors
are a family of proteins essential for eukaryotic cell proliferation (Chen et al., 2009;
Johnson and Degregori, 2006). The E2Fs can be divided based on their cellular activities;
E2F1, E2F2 and E2F3 are generally described as “activator E2Fs” due to their ability to
strongly activate E2F transcriptional targets to promote cell cycle progression, while
E2Fs 4-8 are classified as “repressor E2Fs” and are believed to be required for cell cycle
exit and differentiation (Chen et al., 2009).
All of the E2F members have a highly conserved DNA binding domain, while
only E2Fs 1-6 have a highly conserved dimerization domain that is required for
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interaction with DP family members (Girling et al., 1993; Morgunova et al., 2015; Wu et
al., 1995; Zheng et al., 1999). The DP family of proteins consists of DP1, DP2/3 and
DP4, each of which has preferred E2F associations. Notably, DP1 forms heterodimers
with the activator E2Fs and together they bind to promoters of genes involved in DNA
synthesis and cell cycle progression (DeGregori and Johnson, 2006). E2F7 and E2F8,
however, have two DNA binding domains and interact with DNA as homodimers or
heterodimers independently of DP family members (Morgunova et al., 2015). E2F1-5
each contain a transactivation domain that allows them to activate transcription of their
gene targets, and also contain a pocket protein binding domain (Dimova and Dyson,
2005). Since pocket proteins lack intrinsic DNA binding activity, they rely on the E2Fs
that they are able to interact with to be recruited to DNA. The pocket of pRB binds to
E2Fs 1-4, while p107 and p130 can both interact with E2F4 and E2F5, and E2F6-8 do not
have pocket protein binding domains (Dimova and Dyson, 2005; van den Heuvel and
Dyson, 2008).
The pocket of pRB creates a docking site which is responsible for binding to the
C-terminal transactivation domain of E2Fs, physically inhibiting transcriptional activation
(Figure 1.1B) (Dick and Rubin, 2013). However, because pRB contains distinct binding
sites for E2Fs and transcriptional repressor complexes, it can also enable the silencing of
gene expression through recruiting chromatin remodeling factors (Giacinti and Giordano,
2006).

1.5 Pocket proteins have overlapping and unique roles
In theory, pRB, p107 and p130 are all capable of forming inhibitory complexes
with E2Fs and recruiting co-repressors through their LXCXE binding clefts. However,
the pocket proteins work in a concerted effort to assist in maintaining proliferative control
as certain pocket protein-E2F complexes predominate in different phases of the cell cycle.
Not only do the pocket proteins have preferred E2F binding partners, but they also
have differential expression throughout the cell cycle which also helps to explain their
differential activity (Classon and Dyson, 2001). p107 is an E2F target gene; expression of
p107 is low in quiescent cells and is most highly expressed in S phase (Xiao et al., 1996;
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Zhu et al., 1995). The expression of p130 also fluctuates during the cell cycle, but it is
expressed at high levels in quiescent and terminally differentiated cells and its expression
decreases as cells progress through G1 and S phases. pRB, on the other hand, is expressed
in both proliferating and non-cycling cells and for the most part, expression of pRB is
relatively stable throughout the cell cycle (Buchkovich et al., 1989; Classon and Dyson,
2001). This relative stability of pRB expression during the cell cycle indicates that instead
of its function being controlled by transcription, pRB is largely regulated by posttranslational modifications, chiefly phosphorylation (Dick and Rubin, 2013). Cyclin-CDK
complexes are largely responsible for the phosphorylation of pRB, as well as the other
pocket proteins, leading to conformational changes which ultimately disrupt various
protein interactions by masking binding surfaces (Dick and Rubin, 2013; Giacinti and
Giordano, 2006). For pRB specifically, cyclin D-CDK4/6, followed by cyclin E-CDK2
complexes phosphorylate pRB at the G1-S phase transition leading to alleviation of E2F
transcriptional repression through pRB dissociation (Figure 1.1C) (Burke et al., 2012;
Calbó et al., 2002).

1.6 E2F1 and pRB have a unique interaction interface
Although phosphorylation by cyclin-CDK complexes produces conformational
changes in pRB leading to dissociation from most of the activator E2Fs, a unique
interaction between pRB and E2F1 is still able to form (Figure 1.1B). This second E2F1
binding site is outside of the A and B subdomains within the large pocket of pRB (Dick
and Dyson, 2003). Within E2F1, a region termed the “marked box” domain (MBD),
which excludes the transactivation domain, is required for this interaction (Dick and
Dyson, 2003). This interaction is unique between pRB and E2F1, as it does not occur
between pRB and any of the other E2Fs or E2F1 and any of the other pocket proteins
(Cecchini and Dick, 2011; Dick and Dyson, 2003; Julian et al., 2008).
This specific interaction actually shows reduced affinity for a probe with the
“typical” E2F consensus sequence and is also not able to repress transcription from
luciferase reporters under the control of E2F promoters (Dick and Dyson, 2003; Julian et
al., 2008). This alternate pRB-E2F1 conformation is also resistant to classic pRB-E2F
dissociation signals (Figure 1.1C). Using this E2F1-specific binding site in pRB,

9

interactions with E2F1 are resistant to E1A-mediated displacement (Seifried et al., 2008).
This pRB-E2F1 complex has also been noted to be resistant to CDK phosphorylation
(Cecchini and Dick, 2011).
The pRB-E2F1 specific interaction, therefore, has been noted to play important
regulatory roles outside of cell division. One function of this interaction is to allow pRB
to regulate E2F1-induced apoptosis (Carnevale et al., 2012; Cecchini and Dick, 2011;
Dick and Dyson, 2003; Julian et al., 2008; Seifried et al., 2008). This pRB-E2F1 complex
is also important for recruiting condensin II to the genome to stabilize chromatin structure
and help facilitate replication of certain repetitive regions of the genome (Coschi et al.,
2014; Ishak et al., 2017). Another recently discovered function of this unique pRB and
E2F1 interaction is to inhibit repeat element expression in the genome, notably
endogenous retroviruses (Figure 1.1C) (Ishak et al., 2016).

1.7 Evidence for a separate role of pRB in tumor
suppression outside of cell cycle control
The central defining feature of cancer is uncontrolled cell division. In
multicellular organisms like humans, tissue homeostasis requires appropriate control of
the cell division cycle. Deregulation of proliferative control is one of the major hallmarks
of cancer therefore (Hanahan and Weinberg, 2011). Not surprisingly then, the activities of
the pocket proteins are disrupted in many human cancers through alterations of upstream
regulators (Burkhart and Sage, 2008; Sherr, 1996). While deregulated CDKs and CDK
inhibitors (CKIs) can inactivate all the pocket proteins, only pRB is also seen to be
commonly mutated in cancers while the other two pocket proteins, p107 and p130, are
rarely directly inactivated (Burkhart and Sage, 2008; Dick and Rubin, 2013; McNair et
al., 2018; Sherr, 1996). In addition, there are also some cancers that tend to be enriched
for pRB-pathway alterations, while other cancer types appear to have this pathway
relatively intact. For example, recent analyses using data from The Cancer Genome Atlas
demonstrates that the majority of lung and breast cancers have alterations within the pRBpathway, resulting from loss-of-function alterations in RB1, or gain-of-function
alterations in genes encoding D-type cyclins and their associated CDKs, or loss-offunction alterations in the upstream CKI which is encoded by the CDKN2A gene (Dick et
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al., 2018). Alternatively, there are some cancers like colorectal and prostate carcinomas,
where alterations within the pRB-pathway are relatively uncommon (Dick et al., 2018).
Because of its role in regulating the G1-S transition, it is not surprising that
deletion of the RB1 gene prevents cell cycle arrest in response to a variety of signals
(Knudsen and Knudsen, 2008). However, there have also been some interesting
observations regarding RB1 status and patient outcomes that have not been observed with
mutations of other components of the pRB-pathway. Studies in patients with high-grade
serous ovarian carcinoma (HGSOC) and lung adenocarcinoma have demonstrated that
RB1 loss is predictive of longer patient survival in response to chemotherapy (Cecchini et
al., 2015; Garsed et al., 2018; Ludovini et al., 2004; Zhao et al., 2012). In these studies
where proliferation was also investigated, loss of RB1 was not correlated with increased
proliferation (Cecchini et al., 2015; Garsed et al., 2018). In addition, studies that have
specifically looked at more advanced cancers, such as those that have metastasized or are
resistant to certain therapies, have observed that RB1 gene loss may be more prevalent
than in less advanced forms of the disease (Beltran et al., 2016; McNair et al., 2018;
Robinson et al., 2017; Thangavel et al., 2017). Along these same lines, mutation in RB1
has also been linked to transdifferentiation as a response to targeted therapeutics. In a
study of non-small cell lung cancer (NSCLC) samples with epidermal growth factor
receptor gene (EGFR) mutations where resistance to tyrosine kinase inhibitors occurred,
the lung cancers that transformed to small cell lung cancer (SCLC) invariably lost pRB
expression (Niederst et al., 2015). Similarly, prostate cancers that develop resistance to
the antiandrogen enzalutamide may do so by switching from an epithelial to a
neuroendocrine phenotype, which is enabled in part by loss of pRB expression (Ku et al.,
2017; Mu et al., 2017). Overall, these examples all suggest that RB1 mutation facilitates
more than alterations to proliferative control, and loss of RB1 may confer other cancer
relevant characteristics that are independent of classical pRB-pathway functions of
proliferative control in cancer.
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1.8 Genome instability is an enabling characteristic of
cancer
The failure of a cell to have efficient and error-free duplication of chromosomes
before appropriately segregating them to daughter cells broadly defines genome
instability. The genetic alterations that occur range from point mutations to chromosome
rearrangements, so the types of genomic instability can be separated into categories
depending on the event that has occurred. Some examples are chromosome instability
(CIN), micro- and minisatellite instability (MIN), and instability leading to mutations as
well as that leading to rearrangements.
Failures in either mitotic chromosome transmission or the spindle mitotic
checkpoint can lead to CIN, defined by gain and/or loss of whole chromosomes or
fractions of chromosomes (Draviam et al., 2004; Geigl et al., 2008). MIN results in
repetitive DNA expansions and contractions and can materialize due to replication
slippage, homologous recombination (HR), or impairment of mismatch repair (MMR) or
nuclear excision repair (Aguilera and Gomez-Gonzalez, 2008; Draviam et al., 2004; Yao
and Dai, 2014). Genome instability can also lead to mutations like base substitutions,
micro-insertions and micro-deletions and these mutations are generally linked to errors in
replication, impairment of base excision repair or MMR, or translesion DNA synthesis
which is inherently error prone. Gross chromosomal rearrangements, such as
translocations, duplications, inversions and deletions, are all generated by DNA breaks
which are most commonly the result of replication stress (Aguilera and Gomez-Gonzalez,
2008).
Because cancer cells acquire mutations in the genome to evolve progressively to a
neoplastic state, it should come as no surprise that genome instability is an enabling
characteristic of cancer (Hanahan and Weinberg, 2000, 2011). In healthy cells, genome
maintenance systems continuously monitor the genome to detect and resolve defects in
the DNA, which ensures that the rates of spontaneous mutations are low (Salk et al.,
2010). However, cancer cells usually have an increased rate of mutations, which is
generally due to defects affecting the “caretakers” of the genome, which are genes whose
products help to maintain the integrity of the genome (Kinzler and Vogelstein, 1997; Salk
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et al., 2010). These caretakers are involved in inactivating or diverting mutagenic
molecules before they lead to DNA damage, detecting DNA damage and stimulating the
appropriate repair machinery, and directly repairing DNA damage (Ciccia and Elledge,
2010; Harper and Elledge, 2007; Jackson and Bartek, 2009; Negrini et al., 2010).
As previously mentioned, genome instability can be initiated by replication stress
(Hanahan and Weinberg, 2011). Replication stress largely occurs during S phase of the
cell cycle, which can affect chromosome segregation and lead to unfaithful transmission
of genetic information to daughter cells. Endogenous or exogenous sources, including
polymerase inhibition, limiting replicative factors, oxidative damage, DNA secondary
structures, and RNA/DNA hybrids, can be sources of replication stress (Gelot et al.,
2015). Phenotypes resulting from replication stress can be detected in G1 and include
p53-binding protein 1 (53BP1) nuclear bodies, micronuclei and aneuploidy. Through use
of gene targeted mice, it has been discovered that pRB is part of a complex with
condensin II and E2F1 that aids in the maintenance of genome stability (Coschi et al.,
2014; Ishak et al., 2017).

1.9 Condensins are central components of mitotic
chromosome dynamics
The multisubunit protein condensin II is a member of the structural maintenance
of chromosomes (SMC) family. The SMC family also consists of the SMC5/6 complex,
cohesin, and condensin I (Losada and Hirano, 2005). These complexes are formed in
eukaryotic organisms using six different SMC family members that establish three
heterodimers. SMC1 and SMC3 are the core members of cohesin complexes, SMC2 and
SMC4 are the fundamental units of the condensin complexes (Figure 1.2), and SMC5 and
SMC6 are members of a complex associated with DNA repair and checkpoint responses
(De Piccoli et al., 2009; Losada and Hirano, 2005). SMC proteins are central components
needed for mitotic chromosome dynamics, regulation of gene expression and more, and
as such are evolutionarily conserved in prokaryotes and eukaryotes (Cobbe and Heck,
2004). These SMC subunits are approximately 100 nm long before folding at a “hinge”
domain in the middle of the protein, allowing the N- and C-termini to interact and form
an ATPase “head” domain (Figure 1.2). These two domains in the protein are separated
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by coiled coil domains that form the “arm” of the protein. For the most part, SMC
proteins dimerize through their hinge-hinge interactions, although they also interact
through head-head binding. While these complexes are chiefly defined based on their
SMC subunits, non-SMC subunits are also unique to each type of SMC complex
(Skibbens, 2019).
As previously mentioned, both condensin II and condensin I share the SMC
subunits SMC2 and SMC4, meaning condensin II is distinguished from the other
condensin complex by its unique, non-SMC subunits (Figure 1.2). Two of these subunits,
CAP-D3 and CAP-G2, contain HEAT repeats, which are highly degenerate repeating
motifs involved in protein-protein interactions and may also form a domain for binding
double-stranded DNA (Neuwald and Hirano, 2000; Piazza et al., 2014). Condensin
complexes lacking a single HEAT repeat subunit are unable to associate with
chromosomes (Piazza et al., 2014). A kleisin family member, CAP-H2, is also found
exclusively in condensin II. Kleisin proteins interact with SMC proteins at both N- and Cterminal domains to form a ring-like structure (Schleiffer et al., 2003). Condensin I, like
condensin II, also has three unique subunits, which are the HEAT repeat containing
proteins CAP-D2 and CAP-G, and the kleisin protein CAP-H.
In terms of their mitotic functions, in general, the SMC complex cohesin is
important for proper resolution of sister chromatids while condensins I and II are
important for mitotic chromosome condensation. In metazoans, cohesin is found on
chromosomes from telophase of one cycle until anaphase onset of the next (Gerlich et al.,
2006b). From telophase until replication commencement, cohesin binds DNA more
dynamically, which is thought to mediate the role of cohesin in transcription. However,
during DNA replication, a pool of cohesin binds DNA more stably where it establishes
and maintains sister chromatid cohesion (Gerlich et al., 2006b). During mitosis, cell cycle
regulated kinases control the removal of cohesin from chromosomes in a stepwise
process, where only some arm and most pericentric cohesin is initially protected from
removal (reviewed in (Nasmyth, 2011)). The cohesin that remains primarily at the
centromeres during pre-metaphase and metaphase is responsible for holding sister
chromatids together; it is this centromeric cohesion that is able to oppose the pulling
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Figure 1.2: Depiction of the structural maintenance of chromosomes (SMC) family
members cohesin, condensin I and condensin II.
Cohesin contains the SMC subunits SMC1 and SMC3, while both condensin proteins
contain SMC2 and SMC4. Each SMC protein has a head domain which contains the Nand C-terminus of the protein, as well as a hinge domain, which is globular and binds to
the hinge domain of another SMC protein. These two domains are separated by the arms
of the SMC proteins, which are coiled coils. Non-SMC subunits that comprise cohesin are
the kleisin RAD21 and stromal antigen (SA). Condensin I contains the kleisin CAP-H
and HEAT repeat containing proteins CAP-D2 and CAP-G, and the counterparts to these
proteins in condensin II are CAP-H2, CAP-D3 and CAP-G2, respectively.
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forces of the mitotic spindle, which allows for correct chromosome alignment in
metaphase. Meanwhile, in prophase, condensin II becomes more stably associated with
chromosomes than it was in interphase and facilitates chromosome condensation (Gerlich
et al., 2006a). After nuclear envelop breakdown, condensin I gains increased access to
chromosomes and assists in further chromosome condensation. The different timing of
condensin complexes binding to DNA is very much due to their different cellular
locations throughout the cell cycle. Historically, condensin I was thought to be
cytoplasmic during interphase and is only able to access chromosomes after nuclear
envelope breakdown in prometaphase (Ono et al., 2004). However, some recent evidence
has suggested that a small amount of condensin I is present in the nuclei of interphase
cells, although the majority does remain cytoplasmic (Li et al., 2015; Zhang et al., 2016).
Condensin II, on the other hand, is mostly nuclear throughout interphase and is loaded, to
some extent, on DNA throughout the cell cycle (Gerlich et al., 2006a; Ono et al., 2004).
At anaphase onset, after cohesin has been completely removed from chromatin, mitotic
chromosomes are pulled to opposite poles of the cell (Gruber et al., 2003; Losada and
Hirano, 2005). It is only after chromosomes have reached opposite poles that condensin I
is unloaded from chromatin and condensin II has a weaker chromatin interaction
(reviewed in (Jeppsson et al., 2014) and (Losada and Hirano, 2005)).

1.10 Condensin I and condensin II are differentially loaded
onto mitotic chromosomes
Condensins have been thought to mediate linkages between chromatin fibers to
organize them into higher order structures during chromosome segregation in mitosis
(Cuylen and Haering, 2011). Through the use of global mapping of chromosomal
interactions within mitotic chromosomes, it has been observed that when condensin is
inactivated, loop formation and compaction are drastically disrupted (Gibcus et al., 2018;
Kakui et al., 2017; Schalbetter et al., 2017). In human tissue culture cells, siRNA
knockdowns of components of condensins I and II demonstrated that these complexes
have different functions during mitosis (Hirota et al., 2004; Ono et al., 2004; Ono et al.,
2003). Condensin I is primarily involved with lateral compaction of chromatin, whereas
condensin II is chiefly responsible for its axial shortening (Shintomi and Hirano, 2011).
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How this is accomplished has been revealed by further study of the individual condensin
complexes; condensin II facilitates longer loops and lays the foundation for the axis of
mitotic chromosomes, while condensin I facilitates shorter loops which thickens mitotic
chromosomes (Green et al., 2012; Walther et al., 2018). Much of their action during
mitosis can be attributed to their localization, where condensin II is centrally confined at
the chromatid axis at the bases of chromatin loops and condensin I binds to the central
chromatid axis but also reaches more peripheral sites (Gibcus et al., 2018; Walther et al.,
2018). Condensin complexes have ATP-dependent DNA supercoiling activity and can
also assist in the reannealing of complementary DNA strands (Kimura et al., 1998; Sakai
et al., 2003; St-Pierre et al., 2009). It has been inferred that both these actions of
condensin promote the assembly of mitotic chromosomes (Akai et al., 2011; Kimura and
Hirano, 2000; St-Pierre et al., 2009; Sutani et al., 2015).
Phosphorylation is used to regulate condensin functions, and this mark is
increased on condensins in mitosis (Abe et al., 2011; Piazza et al., 2013; Takemoto et al.,
2004). Many phosphorylation sites have been identified on all of the condensin subunits
in human cells through the use of phosphoproteomic studies, and some of these have been
identified as crucial for proper condensin loading onto mitotic chromosomes (reviewed in
(Kagami and Yoshida, 2016)). In addition, some studies have identified “recruiter”
proteins that regulate mitotic chromosomal localization. One of these recruiter proteins
for condensin II is protein phosphatase 2A (PP2A), which performs this task independent
of its phosphatase activity (Takemoto et al., 2009). In addition to recruiter proteins, there
also appear to be “receptor” proteins that may also be needed for condensin loading.
CAP-G2 and CAP-D3, the HEAT repeat containing subunits of condensin II, for
example, can interact with H4K20me1, a mark which accumulates during early mitosis
(Liu et al., 2010). Altogether, these studies suggest that loading of condensin onto mitotic
chromosomes requires both recruiter and receptor factors, and that phosphorylation of
various condensin subunits may promote their association with these recruiters and/or the
receptors. This also hints that condensin II binding to interphase chromosomes similarly
requires a set of recruiter and receptor factors, some of which have been investigated in
this thesis.
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1.11 Condensins can translocate DNA and extrude DNA
loops
Unlike cohesin which has open V or ring-like structures, early analysis of
condensin structure generated images of lumen-less rod-like structures (Anderson et al.,
2002; Melby et al., 1998; Yoshimura et al., 2002). Both yeast and chicken condensins
have been subjected to chemical crosslinking followed with X-ray crystallography or
mass spectroscopy, respectively, which have demonstrated a number of intermolecular
crosslinks along the entire length of SMC2 and SMC4 coiled coil domains and is further
evidence of a closed rod-like structure (Barysz et al., 2015; Soh et al., 2015).
Interestingly, crosslinks between SMC ATPase heads have only been detected in ATPase
mutant versions of the proteins, suggesting that during cycles of ATP binding and
hydrolysis, SMC heads may adopt different conformations or may separate and re-close
(Barysz et al., 2015; Diebold-Durand et al., 2017). However, another study examining
only SMC2/SMC4 dimers using high-speed atomic force microscopy (AFM) in liquid
never observed rod-like structures (Eeftens et al., 2016). Instead, this analysis showed
that the SMC2/SMC4 coiled coils are highly flexible and the configuration of the dimers
is dynamic over time. In fact, not only were these researchers able to see the ATPase
heads of the dimers engaging and disengaging over time in a dynamic manner, but they
also saw the heads dynamically interacting with the hinge (Eeftens et al., 2016). It is
possible that a more rigid structure was not observed because the non-SMC subunits may
impact coiled coil interactions within the complex. Resolving the structure and dynamics
of the fully assembled and functional condensin complex, therefore, is important and will
help resolve how condensin interacts with DNA.
Additional insights into how condensins may compact DNA have come from the
finding that they are DNA translocases. In yeast, single-molecule imaging of condensin
revealed that it is an ATP hydrolysis-dependent molecular motor (Terakawa et al., 2017).
This assay used double-tethered DNA and showed condensin movement is largely
unidirectional, although there was no initial preference in direction. Further examination
also demonstrated that translocating condensins were able to bind and transport a separate
DNA molecule, which confirmed a key expectation of the loop extrusion model, a
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hypothesis that SMC protein complexes processively increase the size of loops in the
genome (Terakawa et al., 2017).
Through directly visualizing DNA compaction by yeast condensin in real time,
the loop extrusion model was able to be investigated more directly. In this study by Gangi
et al., a double stranded DNA molecule had both its ends tethered to a substrate, close
enough together that the DNA was not taught and initially flexible. This DNA was
visualized through staining and when fluorescently labelled condensin and ATP were
introduced, DNA loops formed that stemmed from the site where condensin was bound
(Ganji et al., 2018). These experiments also demonstrated that loop extrusion is
asymmetric; it was seen that the distance between the loop region and one side of the
DNA outside of the loop progressively got smaller as the loop increased in size, while the
DNA content on the other side of the loop remained fixed. This suggests that one domain
of condensin remains bound to DNA whereas another domain of condensin is able to
actively drive DNA migration, which ultimately leads to loop extrusion.
To fully amalgamate data from condensin structure and its translocation properties
into a functional model, step size analysis also needs to be accounted for. One set of
experiments, where a single end of a DNA molecule was tethered to a glass substrate and
the other end of DNA was attached to a streptavidin-coated magnetic bead, demonstrated
that when condensin and ATP were introduced, bead migration, and thus DNA
compaction, had average step sizes of between 177 and 210 nm (Keenholtz et al., 2017).
This step size is approximately four times the length of the 50 nm long condensin
complex. Another study also found that condensin can induce steps of hundreds of
nanometers in size, and this data also peaks at approximately 200 nm (Eeftens et al.,
2017). One explanation for larger step sizes is that condensin might translocate along
DNA through a myosin- or kinesin-like “walking” mechanism where condensin would
use cycles of ATP hydrolysis to yield head-over-head step sizes of up to 100 nm. Another
possibility is that condensin may oligomerize to produce these larger step sizes, and
although condensins exist in both monomeric and oligomeric complexes, condensin
monomers are typically studied for detailed descriptions (examples are (Barysz et al.,
2015; St-Pierre et al., 2009)).
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However, one study that used size exclusion chromatography (SEC) to purify
condensin studied both the monomeric form of the protein, which is approximately 600
kDa, as well as an earlier elution peak of approximately 2 MDa, which corresponds in
mass to multimeric forms of condensin (Keenholtz et al., 2017). After validating all
subunits of yeast condensin were present in both SEC peaks, further studies were
conducted to compare and contrast the two states of condensin. Of note, condensins
purified from the multimeric position were added to the flow cells described above,
where a single end of a DNA molecule was tethered so extension could be tracked in real
time from the other DNA end. When multimeric condensin was added to flow cells with
ATP the fraction of the DNA compacted was approximately 70%, whereas this was
reduced to 40-50% when monomeric condensin was used. This demonstrated, therefore,
that the multimeric fraction of condensin leads to more robust DNA compaction. These
differences could not be explained by differential abilities to bind ATP, different kinetics
of the reactions, or different dwell times between addition of protein and ATP and the
onset of compaction (Keenholtz et al., 2017).
Further evidence that condensins may oligomerize comes from the bidirectional
translocation of Bacillus subtilis. In B. subtilis, the SMC-condensin complex is necessary
to resolve and segregate newly replicated sister origins (Gruber et al., 2014; Wang et al.,
2014). To do so, condensin is recruited to the origin by ParB, the widely conserved
partitioning protein, which itself binds at centromeric parS sites adjacent to the
replication origin (Breier and Grossman, 2007; Gruber and Errington, 2009; Sullivan et
al., 2009). After showing that condensin stimulates DNA juxtaposition, or “zip-up”, that
initiates at parS and progressively accumulates down the flanking DNA, the rate of DNA
incorporated into the zip-up from ectopic parS sites was measured on either side of the
chromosome (Wang et al., 2017). At one of these parS sites, one side of the DNA
contained many highly transcribed genes, including an operon encoding for abundant
ribosomal proteins and translation factors, while the sequence flanking the other side of
the parS site was largely devoid of active transcription. Movement of condensin rings
through the operon was impaired compared to movement in the direction that was free of
active transcription, leading to asymmetric migration of condensin from the parS site. In
other words, convergent transcription on one DNA duplex impedes condensin movement
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along that DNA track, but on the partner DNA duplex, the rate of condensin movement is
not affected. Along with the observation of asymmetric enrichment of SMC on either side
of the ectopic parS sites, this is evidence for a model in which two condensin rings each
encircle a single DNA duplex on either side of parS sites such that these partner DNA
duplexes are tethered together by condensin “handcuffing”, or oligomerization.
Together, these studies have greatly advanced our knowledge of how condensin
complexes are interacting with DNA. However, it is still not clear how condensins
translocate DNA and extrude DNA loops within a dynamic DNA landscape. This makes
it exceptionally difficult to determine exactly how condensin II interacts with its binding
sites within the genome; is the same condensin II molecule able to interact simultaneously
with two distant sites in the genome, or do condensin II molecules interact as oligomers
between these sites, or do both scenarios occur, for instance.

1.12 Cohesins are important for organizing the interphase
genome
Cohesins used to be chiefly thought of in terms of their role in the trans-tethering
needed for sister chromatid segregation during mitosis (reviewed in (Jeppsson et al.,
2014; Marston, 2014; Morales and Losada, 2018; Rudra and Skibbens, 2013)), however,
two additional roles for cohesin were recognized based on research originally performed
in yeast and Drosophila. First, mutations in cohesin not only result in defects in sister
chromatid cohesion but also in drastic chromosome condensation defects, indicating that
cohesins are important for cis-based DNA looping (Guacci et al., 1997). The second
added role for cohesins is in transcriptional regulation; through DNA looping, cohesins
facilitate communication between distal DNA regulatory elements, like enhancers and
promoters (Rollins et al., 1999). Together, these studies have prepared the groundwork
for current models of how cohesins generate higher-order chromatin structures which are
indispensable for accurate transcription regulation. Because of the important role cohesins
play in chromatin structure, cohesin pathways are essential for human development and
mutations can have detrimental outcomes. Two cohesin based developmental disorders,
for example, Robert syndrome (RBS) and Cornelia de Lange syndrome (CdLS), have
common developmental defects including cleft palate, microcephaly, limb reduction

21

abnormalities, syndactyly and acute cognitive impairment (Skibbens, 2019). It is
anticipated that the number of cohesin-related disorders, or “cohesinopathies”, which are
more recently and generally classified with other “transcriptomopathies”, will increase
considerably over time due to the range of tissues impacted by cohesin mutation as well
as the genome-wide effect of cohesins on transcription (Banerji et al., 2017b; Yuan et al.,
2015).
To impart transcriptional effects, cohesins organize the interphase genome
through balancing the dynamic formation of two states: topologically associating domains
(TADs) and compartments (Figure 1.3). For the most part, TADs are described as DNA
loops of up to one megabase of DNA which usually have CCCTC-binding factor (CTCF)
and cohesin binding at the loop base (Figure 1.3C&D). One general theory is that TADs
insulate looped and non-looped DNA from transcriptional and chromatin-remodeling
machinery as these factors migrate along DNA. Compartments, on the other hand, range
in size from approximately 5 to 50 megabases of DNA and are untethered but selfinteracting domains of transcriptionally active (open or “A” domains) or repressed
(closed or “B” domains) chromatin states (Figure. 1.3B) (Haarhuis et al., 2017;
Lieberman-Aiden et al., 2009; Rao et al., 2017; Schwarzer et al., 2017). At the moment,
one theory of how genomic DNA is assimilated into compartments is that DNA-binding
proteins like transcription factors and coactivators condense into high-concentration
clusters in the nucleus. The condensation of these factors, mediated by low-complexity
disordered regions in these proteins, sometimes leads to condensates forming droplets,
producing a transient liquid phase separated from the rest of the nucleus (Plys and
Kingston, 2018). Another model is that clustering may also emerge due to the interaction
of histone modifications and transcription factors that possess similar characteristics
(Haarhuis et al., 2017; Rao et al., 2017; Schwarzer et al., 2017). Compartments are
normally dynamic and mobile, although they can become anchored. For example,
repressed B compartments tend to be localized more to the periphery of the nucleus and
may interact with the nuclear lamina (Hansen et al., 2018).
Although mice with mutations in cohesin and its regulators show some similarities
to human cohesinopathies, the phenotypes can be mild as a result of extensive

22

Figure 1.3: Chromatin is arranged in the nucleus using hierarchical architecture.
(A) The largest domain of chromatin architecture within the nucleus is chromosome
territories, in which each chromosome occupies a distinct nuclear space. (B)
Chromosome territories can be split into A and B compartments, which are
transcriptionally more active or inactive, respectively. A compartments make more
contacts than B compartments, and interchromosomal contacts between domains from the
same compartments (A/A and B/B) are more frequent than those between different
compartments (A/B). (C) Within compartments, there are topologically associated
domains (TADs) which are largely defined by their interaction frequencies; two regions
within a TAD associate on average more frequently with each other than regions outside
of the TAD. (D) Inside TADs, loop formation occurs, particularly between enhancers and
promoters. The most well-defined boundary factor and loop extrusion factor, respectively,
are CTCF and cohesin, although other proteins have been and continue to be investigated.
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upregulation of the wild type copy in heterozygotes; an example is the mutant mouse of
one of cohesin’s interacting partners, Nipbl (Kawauchi et al., 2009). One model organism
that has been useful in studying cohesin’s effects on transcription and development is
zebrafish, largely through the use of antisense morpholino oligonucleotides (MOs), which
allow not only for a greater range of gene knockdown but also the ability to delete
multiple cohesin associated proteins simultaneously (Muto and Schilling, 2017). For
example, the effects of cohesin on an important developmental process, the transition
from maternal to zygotic control of transcription, or zygotic genome activation (ZGA),
was successfully investigated in zebrafish. It was discovered that cohesins may be
important for maternal mRNA turnover and ensuing expression of zygotic mRNAs, as
embryos that have reduced levels of cohesin’s kleisin protein, Rad21, have higher levels
of maternal mRNAs (Meier et al., 2018). At post-ZGA stages, chromatin
immunoprecipitation followed by sequencing (ChIP-Seq) revealed thousands of new
genomic locations that recruit Rad21, many of which are promoters and transcriptional
start sites (TSSs) also occupied by H3K4me1, H3K4me3 and/or H3K27ac histone
modifications, indicative of active promoters and enhancers. However, transcripts from
many genes in post-ZGA are differentially expressed upon Rad21 depletion, many more
than those that are directly bound by Rad21 (Meier et al., 2018). Although it is likely that
some of the bound genes may be regulated directly, as seen in other studies (Banerji et al.,
2017a; Tsai et al., 2018; Yan et al., 2013), a larger fraction of genes in post-ZGA appears
to be regulated indirectly (Meier et al., 2018). Therefore, this observation indicates that
cohesin influences transcription through multiple mechanisms, including gene-specific
regulation through local chromatin structures as well as more global effects, likely
established by TADs and compartments.
Early ChIP studies in yeast showed that the density and distribution of cohesin
along DNA correlate with the size of DNA loops (Blat and Kleckner, 1999; Glynn et al.,
2004; Guacci et al., 1997). Since then, many studies in a variety of model organisms have
shown cohesin plays an active role in TAD formation. In mouse zygotes, TADs are
prevalent even at the one-cell stage, and when the gene that encodes Rad21 is knockedout, TADs are largely absent (Gassler et al., 2017). TADs were also greatly reduced in
both HeLa cells as well as in HCT-116 human colorectal carcinoma cells when RAD21
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was degraded (Rao et al., 2017; Wutz et al., 2017). Re-expression of RAD21 lead to rapid
reassembly of TADs, in particular near super enhancers, which are regions of the genome
that contain a very high density of enhancer elements and elevated levels of H3K27ac
(Rao et al., 2017).
Like with condensins, ATP is also important for cohesin-based looping and it is
generally thought that cohesins also use loop extrusion to compact DNA (Ganji et al.,
2018; Vian et al., 2018). The length of DNA loops seems to be defined based on cohesin
binding and colocalizing with CTCF at the base of TADs (Dixon et al., 2012; Rao et al.,
2014; Rao et al., 2017; Wutz et al., 2017). It is thought that when cohesin encounters
CTCF, cohesin pauses or stops loop extrusion and this is what defines loop lengths.
Further evidence of this is the fact that cohesin cannot translocate in vitro past DNAbound CTCF (Davidson et al., 2016). In addition, degradation of CTCF does not abolish
TADs but instead alters the length of TAD loops, further supporting the model that CTCF
acts as a boundary for cohesin and in doing so defines DNA loop length (Wutz et al.,
2017).
While cohesins are critical for the formation of TADs, they antagonize the
formation of compartments. Depletion of the cohesin component Rad21 in both mouse
zygotes and human colorectal carcinoma cells led to increased compartmentalization of
active and inactive chromatin (Gassler et al., 2017; Rao et al., 2017). The opposite
experiment can also be performed, where effects on compartmentalization can been
assayed after depleting Wapl, a protein required for the release of cohesin from interphase
chromatin (Kueng et al., 2006). Indeed, through increasing cohesin residency on
chromatin through Wapl depletion, genomic compartmentalization was diminished
(Gassler et al., 2017; Haarhuis et al., 2017; Wutz et al., 2017).
Altogether, these experiments demonstrate that cohesin is a key determinant of
chromatin structure in interphase cells. At regions bound by cohesins, DNA loops are
formed; the sizes of which seem to be regulated largely by CTCF. In regions devoid of
cohesin and CTCF, however, DNA melds into untethered, epigenetically defined
compartments of either transcriptionally active or repressed chromatin states.
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1.13 Condensin II binding has been associated with
increased boundary strength
Unlike compartments, whose interactions can have noticeable variability from
cell-to-cell, TAD structure is largely consistent between various cell types and are also
highly conserved across species (Dekker and Mirny, 2013; Dixon et al., 2012). This
suggests the sub-megabase scale organization of chromosomes into TADs may be a
conserved, bottom-up arrangement of chromatin organization and subsequently genome
function. As a result, identifying the complete mechanism of how TADs are established
and maintained has become an important area of investigation.
Despite the fact that most TAD boundaries have an enrichment of CTCF, only
15% of CTCF binding sites are located within boundary regions, suggesting that most
CTCF binding sites are unrelated to the formation of TAD borders (Dixon et al., 2012).
This also indicates that additional architectural proteins may complement CTCF binding
to help with the formation of TAD borders, and this may help differentiate borderassociated from non-border-associated CTCF binding sites.
A study performed in D. melanogaster discovered that the number of architectural
proteins present at a TAD border directly correlates with the strength of the topological
domain structure (Van Bortle et al., 2014). One of these architectural proteins
investigated was the multisubunit RNA polymerase (Pol) III transcription factor TFIIIC,
consisting of TFIIIC220, 110, 102, 90 63 and 35, and was previously shown to also bind
at Pol III-independent regions, called extra TFIIIC (ETC) loci (Teichmann et al., 2010;
Van Bortle et al., 2014). In mice, ETC sites were seen to be close in proximity to CTCF
and also have an enrichment of cohesin binding (Carriere et al., 2012), and in budding
yeast, ETCs were observed to underlie condensin binding to chromosomes (D'Ambrosio
et al., 2008). Therefore, the binding of cohesin, condensin, TFIIIC and CTCF and their
relation to TADs were investigated further (Van Bortle et al., 2014). Cohesin and
condensin II complexes were seen to be enriched at the borders of TADs, along with
TFIIIC and CTCF (Van Bortle et al., 2014). In mouse embryonic stem cells (mESCs), a
strong overlap in CTCF, cohesin, TFIIIC and condensin II binding was observed, as well
as a strong correlation between clustering of these architectural proteins and chromatin
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organization. From this work, it was proposed that the range of TAD border strengths,
which is associated with differences in protein occupancy, indicate the role of
architectural proteins in long-range interactions. For example, combined binding of the
architectural proteins TFIIIC and CTCF, along with SMC family proteins cohesin and
condensin II, may increase the propensity of all of these proteins to interact with one
another and also increase the strength of interactions with other regulatory elements,
supported by synergistic protein-protein and protein-DNA interactions. Fewer or less
stable interactions of these architectural proteins at TAD boundaries, therefore, can lead
to inter-TAD interactions resulting in weaker TAD boundaries (Van Bortle et al., 2014).
As previously mentioned, without cohesin, topological domains largely dissolve
(Gassler et al., 2017), suggesting that cohesin is one of the main protein complexes
responsible for this degree of chromosome organization. What role, then, is condensin II
playing at these boundary sites? It was recently suggested that TFIIIC serves as a binding
factor for condensin II within the mammalian genome, and that the more abundant
condensin II-TFIIIC binding sites are within a boundary region, the stronger the
insulation at this TAD boundary tends to be (Yuen et al., 2017). However, binding of
condensin II at these boundaries does not appear to affect the architecture of individual
TADs, but rather, the interaction between TAD boundaries to form compartments (Yuen
and Gerton, 2018; Yuen et al., 2017). This idea is further strengthened by the fact that
compartments are not lost upon cohesin loss, suggesting that additional proteins, like
condensin II, could regulate this higher level of chromosome organization (Rao et al.,
2017; Wutz et al., 2017).
Another recent study used Oligopaint FISH technology, which uses oligo libraries
as a renewable source of FISH probes, to investigate compartment, or chromosome
territory, organization in Drosophila cells (Beliveau et al., 2012; Rosin et al., 2018).
Depletion of individual condensin II components in these cells greatly increased the
amount of contact and intermixing between every tested pair of chromosome territories
(Rosin et al., 2018). Conversely, increasing condensin II levels increased interphase
compartment partitioning and chromosome compaction, leading to smaller “super
territories” that are further separated in three-dimensional space. Overall, this study found
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condensin II is essential for long-range chromatin interactions and offered a model in
which these contacts are established by condensin II early in interphase to act as an
“organizational bookmark” by giving precedence to intra-chromosomal folding directly
after mitotic exit (Rosin et al., 2018).
Overall, although a defined role for cohesins in the establishment and
maintenance of TADs in interphase cells has been recognized, further investigation into
how condensin II affects topology is necessary. The molecular basis of compartment
formation is not currently well-defined, but research is indicating that condensin II may
play a role. To better understand how SMC complexes shape and preserve genomes, it is
important to continue investigating how SMC complexes influence the three-dimensional
topology of the genome, gene expression, and chromosome transmission in various
situations. Because functions within the nucleus are spatially organized, altered chromatin
dynamics can lead to modified transcription and genome instability (Figure 1.4). In this
thesis, I investigate the role of condensin II at bidirectional promoters and its effects on
chromosome contacts and gene expression.

1.14 Condensin II has functional roles outside of mitosis
Beyond the more recent studies linking condensin II to global chromatin topology,
research in various model organisms have proposed condensin II mediates a variety of
processes within the cell, again not related to mitosis. For example, polytene
chromosomes, or maternal and paternal chromatids all aligned in register, are
disassembled in Drosophila ovarian nurse cells during mid-oogenesis (Dej and Spradling,
1999). Condensin II is required for this disassembly, and was also found to be a negative
regulator of transvection, a process in which certain mutant alleles are transcriptionally
influenced through association with their allelic counterparts (Hartl et al., 2008). A newer
study examined homologous chromosome pairing at high resolution using HiC, a
technique which uses high throughout sequencing after chromosome conformation
capture (3C) (Rowley et al., 2019). After examining homologous chromosome pairing
after CAP-H2 knockdown, a general increase in pairing signal was detected, in particular
within A compartment, or open chromatin, domains. Overall, this study verified that
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condensin II either inhibits pairing of homologous chromosomes, or may be actively
unpairing chromatin within A domains, at bound genomic regions (Rowley et al., 2019).
Another study in Arabidopsis thaliana investigated increased boron toxicity in
plants with mutations in either the CAP-G2 and or the CAP-H2 subunit of condensin II
(Sakamoto et al., 2011). The major cause of B toxicity in Arabidopsis is DNA damage,
and condensin II is required for tolerance to the induction of DSBs, as well as to
replication blocks induced by zeocin and aphidicolin. This implies that condensin II
maintains genomic stability through reducing DNA damage and two possible
mechanisms for how this occurs were suggested. The first was that condensin II might
physically protect chromatin from genotoxic stresses, inferred from studies of the sole
yeast condensin, which responds to nutrient starvation by compacting the genome in the
nucleolus to stabilize it (Tsang et al., 2007a; Tsang et al., 2007b). The other possibility
raised was that condensin II might be involved in the repair of DSBs and damaged
replication forks, pointing towards a role of condensin II in homologous recombination
repair (Sakamoto et al., 2011). Another piece of evidence that condensin II is important
for homologous recombination came from a study in human cells, where a complex of
condensin II and microcephalin/MCPH1 was proposed to mediate homologous
recombination repair (Wood et al., 2008).
Prior to its canonical role in mitosis, condensin II has also been implicated in the
resolution of sister chromatids in S phase, as seen in HeLa and a lymphoblastoid cell line
(Ono et al., 2013). When condensin II is depleted from cells treated with low doses of
aphidicolin to induce mild replication stress, chromatid axes have a very fragile
appearance and sister chromatids are not distinct from each other. This ultimately leads to
failure of the chromosomes to segregate. It is thought that under conditions of replication
stress, the activation of dormant origins leads to the need to organize and resolve smaller
chromatin loops, which could be a more challenging task for condensin II during S phase
and ultimately manifests as structurally distorted axes in metaphase (Ono et al., 2013).
Recent research has also shown both condensin I and condensin II are
simultaneously loaded at estrogen-responsive, enhancer RNA-positive (eRNA+)
enhancers to promote eRNA transcription, enhancer-promoter looping, and full activation
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Figure 1.4: Chromatin dynamics affect cellular processes within a nucleus.
(A) Schematic diagram of the locations of replication and transcription domains. Looped
poised and active loci tend to be close in three-dimensional space so transcriptional
machinery can be shared. Similarly, early replicating regions also tend to cluster together
and more inactive loci tend to be found near the nuclear lamina. (B) Altered chromatin
dynamics can lead to altered transcription and genome instability. The nucleus on the
right has many more looped poised and active loci, which can lead to an increase in
transcription. Also, less DNA found within the early replicating domain can lead to
delayed replication of certain parts of the genome, which can result in replication stress.
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of the enhancers themselves (Li et al., 2015). Condensins are able to control the activation
of ER-α-bound enhancers through maintaining a fine balance of co-activators and corepressors, which in turn license RNA Pol II binding, eRNA transcription and ultimately
complete activation of coding target genes. When condensin subunits are knocked down,
the intensity/stability of enhancer-promoter loopings are reduced. This could be
completely or partially due to reduced eRNA levels, as there is also the possibility that
condensins could directly control higher-order chromatin architecture as well (Li et al.,
2015).
Altogether, these studies highlight that condensin II has functional roles outside of
its well-known role in mitosis. Many times, however, it is difficult to determine exactly
how condensin II contributes to each process because of the complex inner-workings of
the nucleus; it can be challenging to parse out exactly which alterations are leading to
changes in phenotype, and if they are acting independently, synergistically, or additively,
for example. In addition, some of the paradigms that condensin II is important for in one
species may not translate to other organisms. This lack of clarity regarding more
universal condensin II functions from model organisms with specialized processes is a
strong motivator to study the roles of condensin II in mammalian organisms further.

1.15 Mutations in condensin components have been linked
to human disease
Condensins have also recently been linked to some human diseases. One study
performed in patients with extreme microcephaly discovered biallelic mutations in
NCAPD2 and NCAPG, genes for the CAP-D2 and CAP-G components of condensin I,
respectively, as well as NCAPD3, the condensin II CAP-D3 subunit (Martin et al., 2016).
All of these discovered mutations, however, are functionally hypomorphic, consistent
with the essentiality of condensins in cell division (Hagstrom et al., 2002; Hudson et al.,
2003; Oliveira et al., 2005; Ono et al., 2003; Siddiqui et al., 2006; Strunnikov et al.,
1995). Parallel studies performed in a mutant mouse with hypomorphic loss-of-function
Ncaph2, the gene encoding the CAP-H2 subunit of condensin II, confirmed that mutation
of condensin components also causes microcephaly in mice. In both the mouse model and
affected patient fibroblasts, anaphase bridges were observed which led to the formation of
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micronuclei and aneuploidy in these cells. Interestingly, one patient which had
heterozygous variants of NCAPD3 died of malignant anaplastic medulloblastoma at 11
years.
This was not the first time that a link between condensins and cancer was
established, however. A study from a year prior used an algorithm they developed in a
pan-cancer analysis to investigate mutated networks in 12 different cancer types from The
Cancer Genome Atlas (TCGA) (Leiserson et al., 2015). From this analysis, a subnetwork
of condensin I members, NCAPD2, SMC2, and SMC4, was found to be significantly
mutated in bladder cancer. Additionally, a subnetwork of condensin II members,
NCAPD3, NCAPG2, and NCAPH2, was significantly mutated in both lung
adenocarcinoma and lung squamous cell carcinoma (Leiserson et al., 2015). Although
these mutations were rare, this does suggest that condensins have a tumor suppressive
role. Further evidence of this comes from a gene expression characterization study in
prostate tumors, where NCAPD3 expression was associated with decreased tumor
recurrence after surgery (Lapointe et al., 2008). In addition, in the same hypomorphic
loss-of-function Ncaph2 mouse model utilized in the previously mentioned microcephaly
study, defects in T cell development and subsequent thymic hypoplasia occur (Gosling et
al., 2007). When this phenotype was investigated further, it was determined that
thymocytes from these mice have a cell cycle block impairing progression into successful
anaphase, which itself has an elevated frequency of abnormalities, such as anaphase
bridges and lagging chromosomes (Woodward et al., 2016). The abnormal mitoses seen
in these Ncaph2 mutant cells subsequently leads to an accumulation of cells containing
4N DNA content or greater. Interestingly, this phenomenon is also seen in T cells of
neonatal mutant mice, indicating these mitotic abnormalities precede malignant
transformation.
Although these analyses demonstrate that mutations in condensin II can contribute
to disease, the overall causal role of these mutations to diseases is unknown. With this
data, it is difficult, if not impossible, to determine if all of these effects are due solely to
mitotic abnormalities, or if other contributions of condensin II to processes outside of
mitosis also contribute to disease progression. One way in which I have been able to
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investigate the role of condensin II further within interphase cells is through the use of the
Rb1L/L mouse model.

1.16 The Rb1L/L mouse model reveals importance of
condensin II interactions with the LXCXE binding cleft
As previously described, the LXCXE binding cleft of the pocket proteins is
located in a shallow groove in the B subdomain of the small pocket and this is the binding
site used by many proteins that alter chromatin structure to bind pRB and act as corepressors of transcription (Dick, 2007; Lee et al., 1998). Consequently, binding of these
proteins to pRB assists in inhibiting cell cycle progression through inhibition of E2F
target gene transcription. Viral oncoproteins, on the other hand, also use this LXCXE
binding cleft to bind to and inactivate the pocket proteins (Dyson et al., 1992; Ewen et al.,
1989; Lee et al., 1998; Munger et al., 1989; Whyte et al., 1989). Despite the fact that the
LXCXE binding cleft on the pocket proteins leaves these proteins vulnerable to viral
oncoproteins, this region is the most highly conserved among the pocket proteins and
across several species of pRB (Lee et al., 1998). Therefore, interactions between cellular
proteins and the LXCXE binding cleft of pRB must perform central tasks for this site to
have remained so conserved over evolutionary time, and this may not be entirely
explained by contributions to cell cycle regulation.
To begin examining what the cellular interactions with the LXCXE binding cleft
are important for, point mutants that specifically disrupt this binding surface within pRB
were generated. These initial studies demonstrated that when LXCXE interactions are
disturbed, transcription from E2F-containing promoters can still be repressed and cell
cycle arrest can still be induced but cannot be permanently maintained (Chan et al., 2001;
Chen and Wang, 2000; Dahiya et al., 2000; Dick et al., 2000). To investigate the role of
interactions with the LXCXE binding cleft of pRB in vivo, our lab generated a targeted
mouse model where general E2F binding to the large pocket and specific E2F1 binding
within the pRB C-terminal domain is not disrupted, but binding to the LXCXE binding
cleft is abrogated. The Rb1LXCXE allele (Rb1L for short) encodes three alanine substitutions
at amino acids within the LXCXE binding cleft (I746A, N750A and M754A), which
disrupt protein interactions at this binding interface (Isaac et al., 2006).
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The Rb1L/L mouse model is viable, fertile, born at nearly the expected Mendelian
ratios and does not succumb to spontaneous tumors (Isaac et al., 2006). Rb1-/- mice, in
contrast, die embryonically due to defects in proliferation and differentiation of placental
cells (Wu et al., 2003). This implies LXCXE binding cleft interactions are not necessary
for early embryonic development. One overt phenotype that has been seen with these
mice, though, is a nursing defect in Rb1L/L females which is linked to hyperplasia of the
mammary ductal epithelium (Francis et al., 2009).
Studies in mouse embryonic fibroblasts (MEFs) from the Rb1L/L genetic
background revealed the level of mutant pRBL protein is equivalent to that in wild type
MEFs, and the levels of the other two pocket proteins are also not changed between
genotypes implying compensatory effects are unlikely. Importantly, interactions mediated
by the LXCXE binding cleft are defective in the pRBL mutant, while those with E2F
transcription factors are not altered. When these Rb1L/L MEFs are cultured, similar
growth rates to wild type are obtained, and these cells are also able to exit from the cell
cycle in response to confluence arrest as well as serum starvation. Transcriptional
repression of E2F target genes also remains largely intact in proliferating Rb1L/L MEFs
(Isaac et al., 2006).
However, there are also some apparent defects in Rb1L/L MEFs. Failure to create a
repressive chromatin environment at E2F target genes in senescent Rb1L/L MEFs leads to
defective inhibition of DNA replication so these cells fail to remain permanently arrested
in senescence (Isaac et al., 2006; Talluri et al., 2010). In proliferating Rb1L/L MEFs, there
is an increase in >4N DNA compared to wild type, which is indicative of aneuploidy.
This could be due to the fact that Rb1L/L cells have abnormal pericentromeric
heterochromatin that can lead to fusions of centromeres and ultimately errors in mitosis
(Isaac et al., 2006). There is also a general hypocondensation of chromatin within Rb1L/L
cells; they take longer to progress from chromosome condensation to a fully aligned
metaphase plate, which itself is also less compact than in wild type cells (Coschi et al.,
2010). When these phenotypes were investigated further, it was discovered that this
hypocondensation occurs prior to metaphase and this function of pRB is distinct from its
G1-S phase cell cycle regulatory abilities. It was also seen that pRB interacts with
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condensin II to maintain appropriate chromosomal structure, which led to the conclusion
that many of the mitotic defects in Rb1L/L cells could be caused by loss of this interaction
(Coschi et al., 2014; Coschi et al., 2010).

1.17 pRB interacts with condensin II to mediate genome
stability
Studies performed in Drosophila were the first to discover that pRB (named
RBF1 in Drosophila) is important for chromatin structure, largely due to its interaction
with the dCAP-D3 subunit of condensin II (Longworth et al., 2008). This study noted that
RBF1 promotes the chromatin association of dCAP-D3, a finding which was further
extended to human cells (Longworth et al., 2008). Longworth et al. also established the
dependency of pRB on its LXCXE binding cleft for binding to CAP-D3 (Longworth et
al., 2008).
Further investigation in Rb1L/L MEFs revealed that only condensin II levels are
reduced on chromatin, while the overall levels of chromatin bound condensin I and
cohesin remain unchanged, indicating that the LXCXE binding cleft of pRB likely only
affects the levels of condensin II binding (Coschi et al., 2010). However, in human RPE-1
cells depleted for pRB there is a reduction in both centromeric cohesin and condensin II,
leading to an increase in intercentromeric distance and deformed centromere structure
(Manning et al., 2010). These defects ultimately lead to merotelic attachments to
chromosomes, which is when one or both sister kinetochores are attached to microtubules
emanating from both spindle poles, and subsequently an increase in mitotic delay and in
lagging chromosomes, similar to what has been seen in cells from the Rb1L/L mouse
(Coschi et al., 2010; Manning et al., 2010).
Further investigation of pRB and condensin II has revealed that these proteins
form a complex along with E2F1 which localizes extensively to major satellite sequences
within pericentromeric heterochromatin to facilitate replication (Coschi et al., 2014). It
was also found that loss of even one wild type copy of RB1 reduces recruitment of
condensin II to pericentromeres and this also leads to aberrant replication and the ensuing
defects in mitotic chromosome segregation (Coschi et al., 2014). Additionally, this study
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demonstrated that the specific interaction between pRB and E2F1 is required for CAP-D3
to localization at pericentromeric heterochromatin (Coschi et al., 2014). In line with this,
in cells with an Rb1 mutant allele that disrupts the specific interaction between pRB and
E2F1, condensin II localization is decreased at genomic locations where DNA damage
accumulates and these cells also have replication abnormalities and aneuploidy (Ishak et
al., 2017). However, a thorough investigation of pRB-dependent condensin II binding
outside of repetitive regions of the genome has not been performed to investigate other
consequences due to loss of this interaction.

1.18 Objectives of the present study
Altogether, there have been some interesting studies associating pRB with
genome stability. First of all, there have been the paradoxical observations that the pRB
pathway is misregulated in the vast majority of cancers, yet pRB loss specifically has
been associated with better treatment outcome (Cecchini et al., 2015; Garsed et al., 2018;
Ludovini et al., 2004; Zhao et al., 2012). These findings suggest that pRB is not solely a
growth regulator and that loss of RB1 may lead to other cancer relevant characteristics
that are independent of classical pRB-pathway functions. Secondly, studies where
binding at the LXCXE binding cleft of pRB is abrogated has revealed defects in
chromosome structure, particularly at the centromeres of mitotic chromosomes (Coschi et
al., 2014; Coschi et al., 2010; Manning et al., 2010). Many mitotic defects in Rb1L/L cells
have been attributed to loss of interaction with condensin II. However, contributions of
this pRB-condensin II complex to interphase chromosome dynamics and cellular
processes outside of the pericentromere have not been investigated. Therefore, the overall
aim of this study is to characterize the different ways in which pRB contributes to the
maintenance of genome stability.
In chapter 2, CRISPR/Cas9 was used to create non-functional RB1 alleles in
cancer cells that already have mutations affecting the pRB-pathway to investigate the
specific role of RB1 deficiency. I hypothesized that RB1 mutations in pRB-pathway
disrupted cells would lead to a decrease in genome stability. To test this hypothesis, I
examined the levels of DNA damage in cells using γH2AX foci. To investigate sources of
DNA damage, I assessed their susceptibility to a number of chemical agents and explored
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these vulnerabilities further. Locations of DNA damage were determined using γH2AX
ChIP-Seq to investigate if damage occurred at specific locations within the genome.
Mouse xenograft experiments were also performed to assess if new cancer relevant
phenotypes arise in RB1 mutant cells.
In chapter 3, I investigate pRB-dependent condensin II localization genome-wide.
I hypothesized that condensin II localizes extensively throughout the genome in an pRBdependent manner within interphase nuclei and this has implications on transcriptional
regulation and chromatin dynamics. In order to test this hypothesis, condensin II
localization was resolved using ChIP-Seq in both wild type and Rb1L/L MEFs and data
were compared. To determine whether occupancy was functional, I performed RNA-Seq
analysis in Rb1+/+ and Rb1L/L MEF pairs. The influence of condensin II on local
chromatin contacts was investigated using 3C at locations of interest. Chromatin
interactions at these same locations were interrogated further using circularized
chromosome conformation capture (4C)-Seq. Finally, we examined whether functional
paradigms observed in Rb1L/L MEFs could be extended to humans by comparing
expression data from RB1 deleted to RB1 diploid lung adenocarcinoma samples.
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Chapter 2

2

RB1 deletion in pRB-pathway disrupted cells results in
DNA damage and cancer progression.

2.1 Abstract
Proliferative control in cancer cells is frequently disrupted by mutations in the
pRB-pathway. Intriguingly, RB1 mutations can arise late in tumorigenesis in cancer cells
whose pRB-pathway is already compromised by another mutation. In this study, we
present evidence for increased DNA damage and instability in cancer cells with pRBpathway defects when RB1 mutations are induced. We generated isogenic RB1 mutant
genotypes with CRISPR/Cas9 in a number of cell lines. Cells with even one mutant copy
of RB1 have increased basal levels of DNA damage and increased mitotic errors.
Elevated levels of reactive oxygen species as well as impaired homologous recombination
repair underlie this DNA damage. When xenografted into immune compromised mice
RB1 mutant cells exhibit an elevated propensity to seed new tumors in recipient lungs.
This study offers evidence that late arising RB1 mutations can facilitate genome
instability and cancer progression that are beyond the pre-existing proliferative control
deficit.

2.2 Introduction
Loss of proliferative control is a defining feature of human cancer. Most cancer
cells develop cell intrinsic mechanisms of supplying growth stimulatory signals as well as
disrupting the response to cell cycle arrest cues (Hanahan and Weinberg, 2011). To this
end, mutations in the retinoblastoma protein (pRB)-pathway are central to disrupting
proliferative control in tumorigenesis (Burkhart and Sage, 2008; Knudsen and Knudsen,
2008; Sherr and McCormick, 2002). Deletion of the pRB gene, RB1, prevents cell cycle
arrest in response to a broad range of signals (Knudsen and Knudsen, 2008). Similarly,
overexpression or hyperactivation of D-type cyclins and their associated cyclin-dependent
kinases (CDKs) can lead to constitutive pRB phosphorylation and cell cycle entry. Lastly,
deletion or promoter methylation of CDKN2A that encodes the CDK inhibitor p16 serves
to deregulate kinase activity, causing constitutive phosphorylation of pRB. Cancer cell
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genomes that sustain a single mutation in this pathway are considered to have disrupted
pRB-pathway function and are deficient for cell cycle control (Dyson, 2016; Knudsen and
Knudsen, 2008; Sherr, 1996). Historically, this concept of pRB-pathway inactivation
suggested that mutations in different components of the pathway are relatively equivalent
and additional mutations provide no subsequent advantage to cancer progression (Dick et
al., 2018; Knudsen and Knudsen, 2008; Sherr, 1996; Sherr and McCormick, 2002).
A number of recent clinical observations challenge the logic of single pRBpathway mutations in cancer. First, multiple studies have shown that RB1 loss is
specifically predictive of a favourable response to chemotherapy (Cecchini et al., 2015;
Garsed et al., 2018; Ludovini et al., 2004; Zhao et al., 2012), whereas p16 expression or
overall proliferative rates are not (Cecchini et al., 2015; Garsed et al., 2018; Zhao et al.,
2012). This suggests that pRB-pathway mutations are not necessarily equivalent. Second,
a number of studies have suggested that RB1 gene loss is more prevalent in advanced
cancers, or mechanistically contribute to progression or dissemination (Beltran et al.,
2016; McNair et al., 2017; Robinson et al., 2017; Thangavel et al., 2017), a stage where
cell autonomous proliferative control is presumably already deregulated. Collectively,
these examples suggest that RB1 mutation contributes more to tumor progression than
just alterations to proliferative control and that RB1 loss may confer other cancer relevant
characteristics. Remarkably, some studies even highlight that single copy loss of RB1
may be functionally significant (Coschi et al., 2014; Gonzalez-Vasconcellos et al., 2013;
McNair et al., 2017; Zheng et al., 2002).
Beyond pRB’s role in cell cycle control through E2F transcriptional regulation, it
has been reported to participate in a host of functions that contribute to genome stability
(Velez-Cruz and Johnson, 2017). These include chromosome condensation through pRBdependent recruitment of condensin II and cohesin (Longworth et al., 2008; Manning et
al., 2014). The pRB protein also influences repair of DNA breaks through both nonhomologous end joining (NHEJ) (Cook et al., 2015), and homologous recombination
(HR) (Velez-Cruz et al., 2016), and induction of mitochondrial biogenesis that impacts
cell metabolism (Benevolenskaya and Frolov, 2015; Jones et al., 2016; Nicolay et al.,
2015). Some of these functions, such as repair of DNA breaks by HR, are obligatorily
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outside of pRB’s role in G1-S phase regulation. In addition, other roles, such as effects on
mitochondrial biogenesis and metabolism take place in proliferating populations of cells
further suggesting that this is independent of G1-S regulation and the pRB-pathway. It is
noteworthy that some atypical pRB functions in genome stability, or late stage cancer
progression, may be sensitive to single copy loss (Coschi et al., 2014; GonzalezVasconcellos et al., 2013; Sharma et al., 2010; Zheng et al., 2002). Thus, the existence of
shallow RB1 deletions may indicate that pRB’s less well appreciated functions in genome
stability could underlie cancer relevant characteristics that are independent of classical
pRB-pathway function in cancer (Dick et al., 2018).
In order to test if RB1 loss is relevant to cancer cells that already possess pRBpathway disruption, we induced mutations in RB1 using CRISPR/Cas9 in U2OS and
NCI-H460 cell lines, that are reported to be defective for p16, as well as in the NCIH1792 cell line, which possesses a gain-of-function alteration affecting CDK4. These
cells displayed spontaneous DNA damage as evidenced by gH2AX foci and elevated
levels of reactive oxygen species. We also determined that RB1 mutations decreased the
ability to repair DNA breaks by homologous recombination, and this is supported by
elevated levels of anaphase bridges in mitosis. RB1 mutant cells were xenografted into
immune compromised mice and this revealed similar growth kinetics in subcutaneous
implantation, with RB1 null showing greater propensity to colonize lungs. These
experiments underscore the discovery that RB1 mutation in cells that already possess
pRB-pathway disruption creates DNA damage and fuels cancer progression.

2.3 Materials and Methods
2.3.1

Cell culture
U2OS cells and the resulting clones were grown in Dulbecco’s modified Eagle’s

medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
50 U/mL penicillin and 50 µg/mL streptomycin. H460 and H1792 cells and the resulting
clones were grown in Roswell Park Memorial Institute (RPMI) 1640 medium
supplemented with 10% FBS, 2 mM L-glutamine, 50 U/mL penicillin and 50 µg/mL
streptomycin. Cells were grown at 37°C in humidified air containing 5% CO2.
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2.3.2

Generation of RB1 deletions using CRISPR
For creation of RB1 deletions, single guide RNAs (sgRNAs) targeting exon 22 of

RB1 were selected by using the CRISPR Design tool at http://crispr.mit.edu/ (Cong et al.,
2013). The sgRNA sequences were as follows: 5’CACCGTATTATAGTATTCTATAACT-3’ (X22B-top), 5’AAACAGTTATAGAATACTATAATAC-3’ (X22B-bottom), 5’CACCGAGGATACTTTTGACCTACCC-3’ (X22C-top), 5’AAACGGGTAGGTCAAAAGTATCCTC (X22C-bottom). The X22B and X22C guides
were each cloned into the pX459 plasmid (with wild type Cas9; Addgene #48139) and
the pX462 plasmid (with the D10A mutant version of Cas9; Addgene #48141) Both
plasmids contain a puromycin resistance cassette. Cells were seeded at a density of 105
cells per well in a 6-well dish, and the next day a total of 1 µg per well of a 1:1 mix of
X22B and X22C CRISPR plasmids (either pX459 or pX462) was transfected by use of
X-tremeGENE HP DNA transfection reagent (Roche). The next day, each well was
replated onto a 15 cm dish, and the day after that cells were cultured in selection medium
with 2 µg/mL of puromycin for 2 days. Following that, cells were grown in normal cell
culture media for approximately 12 days, following which single colonies were picked
from the 15 cm plates using mechanical detachment with a pipette tip and placed into
wells of a 48-well dish and allowed to grow. Cells were further passaged onto larger
plates, and were genotyped using the following primers: X22F primer, 5’TTACTGTTCTTCCTCAGACATTCAA-3’; and X22R primer, 5’GGATCAAAATAATCCCCCTCTCAT-3’. PCR products (445 bp for the wild type
band) were run in an agarose gel, individual bands were gel purified using a Sigma
GenElute Gel Extraction kit and sent for Sanger sequencing using the X22F and X22R
primers shown above. For clones with multiple PCR products, bands were purified and
sent for sequencing separately to determine individual RB1 alleles in each clone. For
alleles that could not easily be resolved by gel electrophoresis, PCR products were cloned
into vectors using either the TOPO TA Cloning Kit for Sequencing (Invitrogen) or the
CloneJET PCR Cloning Kit (Thermo Scientific).
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The top scoring off-target intragenic locations determined for each sgRNA using
the CRISPR Design tool were also sequenced to probe for mutations. sgRNA X22B had a
potential off-target site in ZNF699 (X22B_OT_ZNF699_F, 5’GTGCCCTAAAACACTGAGGGA-3’; and X22B_OT_ZNF699_R, 5’TTTATGATCAACAAGGACCAGAGC-3’) while X22C has a potential off-target site
ALDH1L1 (X22C_OT_ALDH1L1_F, 5’-GCCACGCTATGCTTGTGATG-3’; and
X22C_OT_ALDH1L1_R, 5’-CACCCCAGAGAAGGGAACAC -3’). PCR products were
gel purified as above and sent for Sanger sequencing using their respective primers.
Nuclear extracts were prepared from U2OS CRISPR clones of interest and
western blotting was carried out using previously described protocols (Cecchini and Dick,
2011). Antibodies raised against pRB (clone G3-245, BD Pharmingen; C-15, Santa Cruz)
and Sp1 (H-225, Santa Cruz) were used for western blotting. Samples were western
blotted using standard techniques.
To generate additional RB1 knockout and control cell lines, sgRNAs targeting
either exon 2 of RB1 (5’-GGAGAAAGTTTCATCTG-3’) or a gene desert region of the
genome (5’-TGAGCCTATATTAATTGG-3’) were utilized. The sgRNAs were cloned
into the lentiCRISPR v2 vector (Addgene #52961), which also encodes Cas9. To generate
lentivirus, 293T cells were transfected with the sgRNA vector and a 1:1:1 mixture of
lentiviral packaging constructs (Addgene #12251, #12253, #8454) using
polyethylenimine transfection reagent. Twenty-four hours after transfection, the 293T
media was replaced, and recipient cells (U2OS, NCI-H1792, NCI-H460) were seeded for
infection. The following day, media on the recipient cells was replaced with lentiviral
media, and polybrene was added at a final concentration of 8 µg/mL. A second infection
was performed the next day. Infected cells were then selected with 2 µg/mL puromycin
for 3 days. To generate isogenic clones, populations of knockout (or control) cells were
FACS sorted as single cells in 96-well plates (BD FACSAria II) and allowed to grow for
approximately 2 weeks. Colonies were then expanded and screened for loss of pRB by
immunoassay using the Simple WesternTM system according to the manufacturer’s
instructions. Successful knockout clones were also genotyped to confirm clonogenic
origin. Genomic DNA was extracted using the PureLink Genomic DNA Mini Kit
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(Invitrogen), and the region surrounding the cut site was amplified by PCR using the
following primers: X2F, 5'-TCACAGAAGTGTTTTGCTGCTT-3'; X2R, 5’TTTGGTGGGAGGCATTTATGGA-3’. PCR products were purified using the DNA
Clean and Concentrator Kit (Zymo Research) and sent for Sanger sequencing.

2.3.3

Fluorescence microscopy
Cells grown either on glass coverslips or in glass bottom plates were fixed in

phosphate-buffered saline (PBS) containing 4% paraformaldehyde for 10 min and then
permeabilized with PBS-0.3% Triton X-100 for 10 min at room temperature. The fixed
cells were blocked in blocking buffer (PBS-0.3% Triton X-100 with either 5% donkey or
goat serum depending on the species in which the secondary antibodies were raised) for
at least 1 hr at room temperature. Cells were then incubated with primary antibody in
blocking buffer at room temperature for 1 hr or at 4°C overnight. Antibodies raised
against pRB (clone G3-245, BD Pharmingen), gH2AX (clone JBW301, EMD Millipore),
53BP1 (H-300, Santa Cruz) and BLM (C-18, Santa Cruz) were used for IF. After 3
washes with PBS-0.3% Triton X-100, cells were incubated with secondary antibody
diluted in blocking buffer for 1 hr at room temperature. Cells were washed twice with
PBS-0.3% Triton X-100, incubated with 100 ng/mL 4’,6-diamidino-2-phenylindole
(DAPI) in PBS-0.3% Triton X-100 for 5 min, washed twice more with PBS-0.3% Triton
X-100 and then washed once with PBS before mounting with Slowfade Gold Antifade
mountant (S36936, ThermoFisher Scientific).
For 8-oxoguanine (8-oxoG) staining, cells were fixed and blocked as above, then
washed with PBS-0.3% Triton X-100 and incubated in RNase solution (0.2 mg/mL
RNase A, 10 mM Tris-HCl (pH 7.5), 15 mM NaCl, 0.1% Triton X-100 in 1X PBS) for 1
hr at room temperature. Cells were washed with PBS-0.3% Triton X-100 and then
incubated in 2 M HCl for 10 min at room temperature, followed by a rinse with 50 mM
Tris-HCl (pH 8.0). Cells were washed with PBS-0.3% Triton X-100, and then primary
antibody incubation, using α-DNA/RNA Damage antibody raised against 8-oxoG (clone
15A3, ab62623, Abcam) and all subsequent steps were completed as above.
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For confocal microscopy of pRB, gH2AX and BLM, cells were examined on an
Olympus Fluoview FV1000 confocal microscope system. For confocal microscopy of
53BP1, a Nikon A1R confocal microscope was used. For non-confocal microscopy,
images were acquired using a Zeiss Axioskop 40 microscope and Spot flex camera. Foci
were quantified using the Focinator (Oeck et al., 2015), while overall staining intensity in
cells was quantified by ImageJ (Schneider et al., 2012).

2.3.4

Gamma irradiation of cells
Cells subjected to gIR were plated at 100,000 cells per well in 6 well dishes with

glass coverslips on the bottom. The next day, cells were exposed to a cobalt 60 source
until a dose of either 2 Gy or 1 Gy was received. Cells were placed back in the cell
culture incubator until the appropriate time point after treatment to fix cells for IF.

2.3.5

NHEJ and HR repair assays
For the HR repair assay, pDRGFP was used which was a gift from Maria Jasin

(Addgene plasmid #26475; http://n2t.net/addgene:26475; RRID:Addgene_26475) and for
the NHEJ assay, pimEJ5GFP was used which was a gift from Jeremy Stark (Addgene
plasmid #44026; http://n2t.net/addgene:44026; RRID:Addgene_44026). pDRGFP was
linearized using EcoRV and pimEJ5GFP was linearized using XhoI. These linearized
fragments were then individually used for transfection using Lipofectamine 3000
transfection reagent (Invitrogen) into U2OS cells. The next day, each well was replated
onto a 10 cm dish, and a day later, cells were cultured in selection medium with 2 µg/mL
of puromycin for 3 days. To isolate single cell colonies, limiting dilutions were then used
to seed cells into 96 well plates. After approximately 3 weeks, wells with growth from
single cell isolates were transferred to single wells of 12 well plates and after a few days
were treated with puromycin again to ensure the selected clones did still contain either the
NHEJ or HR constructs.
To determine the reporter efficiency in the isolated clones, 2 sets of transfections
were performed per clone, again using Lipofectamine 3000 transfection reagent
(Invitrogen). For the first set of transfections, each clone was transfected with a plasmid
expressing the I-SceI endonuclease, pCBASceI, which was a gift from Maria Jasin
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(Addgene plasmid #26477; http://n2t.net/addgene:26477; RRID:Addgene 26477), and a
blasticidin marker, pMSCV-Blasticidin, which was a gift from David Mu (Addgene
plasmid #75085 ; http://n2t.net/addgene:75085; RRID:Addgene_75085). The second set
of transfections was with an empty backbone plasmid, pCAG-FALSE, which was a gift
from Wilson Wong (Addgene plasmid #89689; http://n2t.net/addgene:89689;
RRID:Addgene_89689) and pMSCV-Blasticidin. For both of these transfections, the
blasticidin resistance plasmid was used in a 1:3 ratio with the complementary plasmid.
The next day, each well was replated onto a 10 cm dish, and the day after that cells were
cultured in selection medium with 10 µg/mL of blasticidin for 1 week. GFP positive cells
were then quantified by flow cytometric analysis (FACS). To prepare cells for FACS,
they were washed with PBS, trypsinized, resuspended in culture media, and washed twice
with PBS. Cell pellets were then resuspended in 0.5 mL of flow cytometry staining buffer
with propidium iodide (0.05% sodium azide and 0.5% BSA in 1X PBS with 0.01 mg/mL
propidium iodide). For each reporter construct, the clone with the highest ratio of GFP
signal when transfected with pCBASceI to GFP signal when transfected with pCAGFALSE was selected for future studies.
To introduce CRISPR constructs into selected clones for each repair reporter,
lentivirus particles were generated in HEK293T cells. Lentivirus was created for both
lentiCRISPR v2 with no guide RNA inserted, and for lentiCRISPR v2 with the X22B
sgRNA sequences for RB1 (from above) inserted. lentiCRISPR v2 was a gift from Feng
Zhang (Addgene plasmid #52961; http://n2t.net/addgene:52961; RRID:Addgene_52961).
The X22B RB1 guide sequences were inserted into the lentiCRISPR v2 plasmid as
previously described (Sanjana et al., 2014; Shalem et al., 2014). Culture media containing
lentiviral particles were transferred to appropriate U2OS HR and NHEJ reporter clones
for 48 hours, followed by selection with 4 µg/mL puromycin for at least 5 days.
The population of U2OS HR and NHEJ reporter clones that were infected with
lentiCRISPR v2 plasmids, either with or without the RB1 guide, were then transfected
with both pCBASceI and pMSCV-Blasticidin or pCAG-FALSE and pMSCV-Blasticidin
and selected, as above, and analyzed by FACS to determine repair efficiency. These
transfections were performed in the same transduced population of cells, but for
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experimental replicates, the cells were seeded at different times and then subsequently
transfected with plasmids. Cells grown in parallel to the transfected cells were used to
prepare nuclear extracts for western blotting.

2.3.6

Expression of HR factors
Total RNA from cells was isolated using TRIzol reagent according to the standard

protocol (Invitrogen). First-strand cDNA synthesis was performed using iScript cDNA
Synthesis Kit (Bio-Rad). Isolated cDNA was used in qRT-PCR reactions with iQ SYBR
Green Supermix (Bio-Rad) using the following primers: RPA2_F, 5’CGAAAGCTATGGCAGCTCCT-3’; RPA2_R, 5’-GGCTCGGGCTCTTGATTTCT-3’;
RAD54B_ F, 5’-GCGAGGGGATAGCTGGTTAC-3’; RAD54B_R, 5’AGTCGTGACCGGCGAAAAT-3’; BLM_F, 5’-GAGTCTGCGTGCGAGGATTA-3’;
BLM_R, 5’-AGTGTTCTGGCTGAGTGACG-3’; RAD51_F, 5’AGCTGGGAACTGCAACTCAT-3’; RAD51_R, 5’-CCACACTGCTCTAACCGTGA3’; RECQL_F, 5’-AGAGAAAGCCTATGAAGCAAGGA-3’; RECQL_R, 5’GGCTTCTGCCGAACCTCATA-3’; BRCA1_F, 5’CTGAAGACTGCTCAGGGCTATC-3’; BRCA1_R, 5’AGGGTAGCTGTTAGAAGGCTGG-3’; XRCC2_F, 5’GCGATGTGTAGTGCCTTCCA-3’; XRCC2_R, 5’TTCAAGAATATCACCATGCACAGG-3’; BRCA2_F, 5’AAGCACTCCAGATGGCACAAT-3’; BRCA2_R, 5’GGGTACACAGGTAATCGGCT-3’; RAD52_F, 5’-ATGCTTTGGACAGTGCCAGT3’; RAD52_R, 5’-ACATTCTGCTGCGTGATGGA-3’; GAPDH_F, 5’ATGACCACAGTCCATGCCAT-3’; and GAPDH_R, 5’TTGAAGTCAGAGGAGACCAC-3’. Resulting target Cq values were normalized to
GAPDH, then expressed as fold change relative to the global wild type mean.
Nuclear extracts were prepared from clones for western blots, and the following
antibodies were used: RPA32 (A300-244A, Bethyl), RAD54B (ab83311, Abcam), BLM
(C-18, Santa Cruz), and RAD51 (ab63801, Abcam).
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2.3.7

Determination of IC50 concentrations
For IC50 assays, U2OS cells were seeded at a density of 1,200 cells per well and

H460 and H1792 cells were seeded at a density of 1,500 cells per well in 96 well dishes.
Twenty-four hours after plating cells, media was replaced with media containing the
drugs of interest at the appropriate concentrations. Technical triplicates were analyzed for
each biological replicate. Serial dilutions of stock solutions of aphidicolin (APH),
hydrogen peroxide (H2O2), etoposide, hydroxyurea (HU) and cisplatin were created so
that a constant amount of drug was added to the media for each drug concentration used.
After 72 hr, alamarBlue was added to an amount equal to 10% of the volume in the well
(i.e. 10 µL per well with 100 µL of media and drug). After 4 hr of incubation,
cytotoxicity was measured using a Synergy H4 Hybrid Reader (BioTek, USA) using
excitation/emission wavelengths of 560 nm/590 nm. Values were corrected using a blank
of media and alamarBlue only. The amount of fluorescence of alamarBlue for each well
of drug treated cells was then normalized to the fluorescence value obtained for the
untreated cells of the same technical replicate. These normalized fluorescence values
relative to untreated cells were then analyzed using Prism. The drug concentrations were
log transformed and the data were subsequently fit to a curve using nonlinear regression
(log(inhibitor) vs. response (three parameters)). IC50 values were obtained from the best
fit values, and IC50 values from three biological replicates were compared using
Ordinary one-way ANOVA and Tukey’s multiple comparisons test or paired t-test.

2.3.8

ChIP-Sequencing
ChIP was conducted according to protocols adapted from Cecchini et al.

(Cecchini et al., 2014). Briefly, cross-linked chromatin was sonicated so most chromatin
was ≤400 bp. Sheared chromatin was then normalized between experimental groups and
pre-cleared with protein G Dynabeads and IgG. Pre-cleared chromatin was then incubated
with protein G Dynabeads and ChIP antibodies to immunoprecipitate proteins. Antibodies
raised against gH2AX (clone JBW301, EMD Millipore) and H4 (clone 62-141-13, EMD
Millipore) were used for ChIP. Cross-links were reversed at 65°C, and samples were
treated with RNase and proteinase K. DNA was isolated for library preparation, and 20
replicates per genotype for gH2AX ChIP-Seq were pooled to achieve DNA yield required
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for library preparation (NEBNext Ultra II DNA Library Prep Kit). ChIP libraries were
sequenced using an Illumina NextSeq (High output 75 cycle kit), and processed reads are
deposited in GEO (GSE125379).
Resulting FASTQ reads were aligned to the human genome build hg19 using
Bowtie2 version 2.3.0 (Langmead and Salzberg, 2012). The following command was
used: bowtie2 -t -p 4 -D 15 -R 2 -L 32 -i S,1,0.75 -x hg19 -U <reads>.fastq -S
<output>.sam. Peaks were identified using MACS2 version macs2 2.1.1.20160309
according to parameters stated below and the options to detect broad peak distributions
for histone marks (Zhang et al., 2008). For H4 ChIP-Seq, the corresponding inputs were
used as the control and for gH2AX ChIP-Seq, the first input replicate was used as the
control. The following command was used: macs2 callpeak -t <ChIP>.bam -c
<input>.bam -n <output> --outdir ./macs2/ -g hs --broad --broad-cutoff 0.1.
To find abundance of ChIP-Seq reads in common fragile sites (CFS), the
cytogenetically determined locations of CFS, as determined previously by Lukusa and
Fryns (2008), were converted to human genomic coordinates (hg19) using the UCSC
Genome Browser (Lukusa and Fryns, 2008; Tyner et al., 2017). Bedtools coverage was
then used to find the number of alignments for each ChIP-Seq sample within the
individual CFS (Quinlan, 2014). The abundance of reads that mapped to CFS were then
converted to proportions by dividing by the total number of mapped reads. The
proportion data were further normalized against input control and then ratios were made
comparing the mutant proportions to the wild type proportions. A two-tailed one-sample
t-test was performed to test if the normalized mean read count proportions of the RB1+/and the RB1-/- ChIP-Seq assays at each of the CFS is equal to the normalized read count
proportion of the corresponding CFS from the wild type control. A multi-test correction
was applied to the calculated P-values (using "fdr" method from "p.adjust" function in R).
Statistical analysis of sequence data was performed using R (version 3.4.2) and the
plotting function used was lattice (v0.20-35).
For repeat analysis, another set of alignments were performed. For this analysis,
reads were mapped using Bowtie version 1.2.1.1 with high stringency to the hg19
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genome (Langmead et al., 2009). The following command was used: bowtie -S --best -m
1 --chunkmbs 500 -p 4 -t --un <not_aligned_unique> --max <multiple_reads_unique>
hg19 <reads>.fastq <output>.sam. All remaining reads were mapped to repeat containing
indexes using previously reported methods (Day et al., 2010), with indices also being
derived from Repbase and Tandem Repeats Databases (Bao et al., 2015; Gelfand et al.,
2007). For these remaining repeat alignments, the –m 1 parameter of the Bowtie mapping
was changed to –k 1. Finally, all remaining reads were re-mapped to hg19 at low
stringency to exhaustively match sequence tags to the mouse genome. The abundance of
sequence tags that mapped to non-unique regions of the genome were compared by using
log2 ratios of γH2AX precipitable tags per million mapped reads in mutant versus wild
type and converted into heat maps using matrix2png (Pavlidis and Noble, 2003). To test
for significance of enrichment of reads mapped to various repeat categories, the same
analysis to test for significance within CFS was used (see above).

2.3.9

Flow cytometry
Cells were plated on 6 cm plates at a density of 100,000 cells per plate.

Approximately 24 hr after, cells were pulsed with BrdU for a duration of 30 min. Cell
cycle analysis was then carried out as previously described (Cecchini et al., 2012).

2.3.10 Nucleoside supplementation
For nucleoside complementation, cells were seeded at a density of 50,000 cells
per 6 cm plate for flow cytometry and at 25,000 cells per 6 well plate with glass
coverslips for immunofluorescence. Approximately 24 hr after seeding cells, media was
replaced, either with or without the addition of nucleosides. To prepare nucleosides,
uridine (Sigma) and cytidine (Sigma) were dissolved in autoclaved Milli-Q water to make
10 mM stocks, while adenosine (Sigma) and guanosine (Sigma) were dissolved to make 2
mM stocks. The suspensions were briefly boiled, filter sterilized, and added to complete
medium at a final concentration of either 50 μM or 10 μM. 48 hr after nucleoside
addition, cells were either fixed for gH2AX IF using non-confocal microscopy and the
Focinator (as above), or for flow cytometry. For analysis of DNA content by flow
cytometry, propidium iodide stained DNA content was analyzed.
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2.3.11 Measurement of reactive oxygen species
Cells were plated in 96 well plates at a density of 1,200 cells per well in DMEM
without phenol red (31053-028, ThermoFisher Scientific). H2O2 was added 24 hr after
seeding cells. Seventy-two hours later, 5(6)-carboxy-2',7'-dichlorodihydrofluorescein
diacetate (carboxy-H2DCFDA; CA-DCF-DA; (C400, ThermoFisher Scientific)) at a
stock concentration of 20 mM in DMSO was diluted in DMEM without phenol red to a
concentration of 40 µM. This master mix of media and CA-DCF-DA was added directly
to the wells already containing media and the drug of interest, to obtain a final
concentration of 20 µM CA-DCF-DA. The cells were then put in the incubator for 45 min
and readings were obtained using a Synergy H4 Hybrid Reader (BioTek, USA) using
excitation/emission wavelengths of 492 nm/525 nm. Technical triplicates were analyzed
for each biological replicate and the average background readings (cells treated with the
highest concentration of the drug of interest for 72 hr and DMSO in place of CA-DCFDA) from each cell line were subtracted from the average of each treatment reading for
analysis of fluorescence.

2.3.12 Mouse xenografts
U2OS clones were grown in cell culture to approximately 80% confluence. Cells
were washed with PBS, trypsinized, centrifuged and washed 3 times with Hanks’
Balanced Salt Solution (HBSS, 1X). Cells were then resuspended in HBSS at a
concentration of 5x106 cells/mL so that 200 µL contained the 1x106 cells required for
each injection.
For subcutaneous injections, mice were approximately 8 weeks old and for the tail
vein injections mice were approximately 13 weeks old when injected. All mice were
given at least 3 days to acclimatize. All mice were female NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (stock number 005557, The Jackson Laboratory) and were housed and
handled as approved by the Canadian Council on Animal Care, under an approved
protocol (2016-068).
For subcutaneous injections, 1x106 RB1+/+ cells were injected into the left flank of
all mice, and 1x106 RB1+/- or RB1-/- cells were injected into the right flank. The mice used
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for the subcutaneous injections were euthanized approximately 8 weeks after injection.
Necropsies were performed and tumor mass was determined. Tumors were then fixed in
formalin for 48 hr and processed for histological assessment.
For tail vein injections, 1 x 106 cells were injected into the lateral tail vein. Mice
were euthanized 8 weeks after tail vein injection. All animals were subjected to a
thorough necropsy and all lungs as well as any abnormal tissues or organs were fixed in
formalin for 48 hr and processed for histological assessment.
All tissues of interest from both studies were embedded, sectioned and stained
with hematoxylin and eosin according to standard methods. Slides were imaged using an
Aperio ScanScope slide scanner (Leica Biosystems).
For quantitative pathology of lungs from tail vein injected mice, images were
analyzed using QuPath (Bankhead et al., 2017). Briefly, annotations were drawn around
each individual lung. Within these annotated lungs, cells were detected using the cell
detection command. The features within these cells were then smoothed by using the add
smoothed features command (using 25 µm as the radius). Within the lungs, regions
containing different cell types were annotated and these annotations were used to train a
cell classifier. All possible 67 cell features were used to the build the random trees
classifier, using default parameters. A script was then made to determine the total cell
area of all cell types called by the classifier within each lung, and the percentages of
tumor cell area was calculated from these values. Tumor cell nodules were manually
counted using the cell types determined by the classifier; anything thought to have
derived from a single cell seeding event was considered a tumor cell nodule.
To determine the RB1 genotype of seeded U2OS cells of interest, embedded
mouse lung tissue was deparaffinized, lysed, formalin crosslinks were reversed, and DNA
was isolated according to manufacturer’s instructions (QIAamp DNA FFPE Tissue Kit,
Qiagen). DNA was genotyped as above using PCR using genotyping primers (X22F and
X22R).
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2.3.13 Data extraction from cBioPortal
Only TCGA studies used for the Pan-Cancer Atlas with 150 samples or more on
cBioPortal were selected to query (Cerami et al., 2012; Gao et al., 2013). Data from
cBioPortal was obtained in January 2019. Mutation and CNA data was analyzed, with the
gene set user-defined list being entered as “RB1: AMP HOMDEL HETLOSS mut”.

2.4 Results
2.4.1

Spontaneous DNA damage in RB1 deficient cancer cells
To investigate RB1 deficiency in pRB-pathway disrupted cells, we utilized a

number of cell lines that are reported to be defective for p16, the product of CDKN2A
gene, or that possess activation of cyclin D/CDK4. Initially we used p16 deficient U2OS
cells (Forbes et al., 2017), and Cas9 with single guide RNA (sgRNA) pairs that target
exon 22 of RB1 because loss of this exon creates null alleles in cancer (Horowitz et al.,
1990). Cells were transfected with plasmids to deliver pairs of sgRNAs and Cas9 (wild
type or the D10A mutant). Following transient drug selection, colonies were isolated,
expanded, and genotyped by PCR to search for RB1 deletions (Figure 2.1A). Candidates
were rigorously selected by checking pRB protein expression by western blotting (Figure
2.1B), ensuring heterozygous clones were not mixtures of wild type and knockout cells
using fluorescent pRB staining (Figure 2.1C), and confirming that the most likely off
targets were not mutated (Table 2.1). Using this approach, we selected four clones each
for wild type and knockout RB1 genotypes, and three clones for the RB1+/- genotype that
were used in subsequent experiments.
To determine if RB1 mutation status affects genome stability in these engineered
cell lines, DNA damage was assessed in untreated, proliferating cells by staining for
γH2AX. Foci were visualized by immunofluorescence microscopy and images were
captured using confocal microscopy (Figure 2.1D). The quantity of foci per nucleus was
determined and this revealed a significant increase in gH2AX in the knockout and
heterozygous lines compared to those that are wild type for RB1 (Figure 2.1E).
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Figure 2.1: CRISPR/Cas9 induced mutations in RB1 cause DNA damage.
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Figure 2.1: CRISPR/Cas9 induced mutations in RB1 cause DNA damage.
(A) An ethidium bromide stained, agarose gel shows examples of wild type,
heterozygous, and homozygous mutant RB1 genotypes that are detected by PCR
amplification of exon 22 sequences. (B) A representative western blot showing pRB
expression in control, heterozygous, and homozygous mutant cells is shown on top. Sp1
loading control is shown on the bottom. (C) Immunofluorescence microscopy was used to
detect pRB expression (green) in cultures of control, heterozygous, or homozygous
mutants. Cells were counterstained with DAPI to visualize nuclei (blue). (D)
Representative confocal microscopy images of gH2AX foci (red) in control,
heterozygous, and homozygous RB1 mutant cells. Cells were counterstained with DAPI
to visualize nuclei (blue). (E) gH2AX foci counts for each of the U2OS RB1 genotypes.
The average proportion of cells with discrete numbers of foci are shown as histograms,
while the cumulative frequency of foci for each genotype is shown as an inset. The
average distribution of foci for RB1 wild type (4 different clones), heterozygous (3
different clones) and knockouts (4 different clones) were compared using the
Kolmogorov-Smirnov test. (F) U2OS cells were transfected with CRISPR/Cas9
constructs targeting either a safe harbor site in the genome or exon 2 of the RB1 gene.
Three clones were selected for both control and knockout conditions and gH2AX foci
were quantified by fluorescence microscopy. The average proportion of γH2AX foci for
both RB1 wild type and knockout genotypes are shown as histograms, while the
cumulative relative frequency of foci is shown as an inset. Foci distributions were again
compared by Kolmogorov-Smirnov test. (G) H460 lung cancer cells were stained for
gH2AX foci and analyzed as in F. (H) H1792 non-small cell lung cancer cells were
analyzed as in F. All error bars are +1 SEM. *P < 0.05.
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Table 2.1: Characterization of the U2OS RB1 mutant clones generated by targeting
exon 22.

Clone

Cas9

RB1 Genotype

U2OS

N/A

wild type

21B2

D10A

wild type

21B4

D10A

wild type

11B5

D10A

wild type

4C1

D10A

heterozygous

21D5

D10A

heterozygous

21A1

D10A

heterozygous

12C3

D10A

null

5A5

WT

null

6B1

WT

null

5C4

WT

null

A

A

Predicted
proteinB
WT
WT
WT
WT
WT
WT
WT
WT
WT
p.Y771fsX8
WT
p.Q770HdelX10
WT
p.I753delX12
p.I752IfsX9
p.E748CdelX11
p.N757TX31
p.P776VdelX6
p.Y756YfsX14
p.S751SfsX10
p.S773FfsX14
p.Y756delX

Off-Target
GenotypesC
ALDH1L1 ZNF699
N/A

N/A

ND

ND

WT

WT

ND

ND

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Genotypes were determined by PCR and sequencing.
Amino acid coding changes were predicted based on nucleotide sequences.
C
The top scoring off-target intragenic locations determined for each sgRNA, ZNF699 for
sgRNA X22B and ALDH1L1 for sgRNA X22C, were also sequenced to probe for
unwanted mutations. ND=not determined.
B
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We quantified gH2AX foci abundance in additional pRB-pathway mutant cell
lines to determine if increased DNA damage is a common consequence of pRB loss. We
used cells that were modified with control non-targeting sgRNAs or that were produced
by targeting exon 2 of RB1. pRB deficiency in these cells was confirmed by western
blotting (data not shown). Using RB1 null U2OS cells produced in this manner we again
observed increased quantities of gH2AX foci in pRB deficient cells compared to their
controls (Figure 2.1F). In addition, clones of control and RB1 knockout NCI-H460
(H460; CDKN2A deleted) and NCI-H1792 (H1792; CDK4 amplified) lung cancer cells
also displayed differences in spontaneous DNA damage (Figure 2.1G&H). This analysis
demonstrated an elevation in the number of gH2AX foci in each of the RB1 deleted lines.
To further investigate the source of DNA damage in RB1 mutant cells, we
assessed their sensitivity to a number of chemical agents to determine if specific stresses
could amplify defects that cause increased DNA damage. We tested aphidicolin, a DNA
polymerase inhibitor that causes replication stress and etoposide, a topoisomerase
inhibitor that creates DNA double stranded breaks. Hydrogen peroxide (H2O2) was used
to induce oxidative damage, and cisplatin was used to create interstrand cross links,
among other damaging effects. Representative U2OS clones of each genotype were
treated for 72 hr with a range of chemical concentrations, after which alamarBlue was
used to quantitate the cytotoxicity of each agent. These assays revealed that both
heterozygous and homozygous RB1 mutations sensitize cells to hydrogen peroxide and
cisplatin, but not aphidicolin or etoposide (Figure 2.2A-D). Because platinum
therapeutics preferentially benefit patients with pRB deficient cancers (Cecchini et al.,
2015; Garsed et al., 2018), we also tested control and RB1-/- H460 and H1792 cells for
their sensitivity to cisplatin. This revealed increased sensitivity to cisplatin in H460 and
H1792 cells upon RB1 deletion (Figure 2.2E&F).
Overall, these drug sensitivities suggest that oxidative damage may underlie some
aspects of the DNA damage phenotype in RB1 mutant cells. We compared reactive
oxygen species (ROS) levels in wild type and RB1 mutant U2OS cells with and without
H2O2 using a ROS indicator, 5(6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate
(CA-DCF-DA). For both untreated and H2O2 treated cells, there was more fluorescence
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Figure 2.2: Cancer cells with RB1 mutations have elevated reactive oxygen species
and sensitivity to cisplatin.
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Figure 2.2: Cancer cells with RB1 mutations have elevated reactive oxygen species
and sensitivity to cisplatin.
(A) Aphidicolin, (B) etoposide, (C) cisplatin and (D) hydrogen peroxide were added to
cultures of the indicated genotypes of U2OS cells. Viability was assessed after 72 hr
using alamarBlue and dose response curves were used to calculate half maximal
inhibitory concentration (IC50) values for each genotype. Both RB1 mutant genotypes
have significantly lower IC50 values in response to cisplatin and hydrogen peroxide than
control U2OS cells (as determined by one-way ANOVA). (E and F) H460 and H1792
cancer cells with RB1 mutations were treated with cisplatin as in C. Differences in IC50
values were determined using a paired t-test. (G) To detect reactive oxygen species
(ROS), CA-DCF-DA was added to culture media at the end of 72 hr of mock or hydrogen
peroxide treatment. Normalized fluorescence was averaged for four clones of RB1 wild
type and knockout genotypes, and three clones for the heterozygous genotype. Mean
values were compared by two-way ANOVA. (H) Cells were fixed and stained for 8-oxoG
and DAPI and visualized by fluorescence microscopy. The average 8-oxoG signal per
nucleus was determined using ImageJ with DAPI staining defining nuclear area. Three
clones per genotype were used and data were normalized to the mean signal from RB1
wild type in duplicate experiments. Statistical significance in staining intensity was
determined by Kruskal-Wallis one-way analysis of variance and Dunn’s multiple
comparisons test. (I) 53BP1 foci were quantitated for each RB1 genotype using the
Focinator as with γH2AX. No significant differences were observed as determined by the
Kolmogorov-Smirnov test. All error bars are ±1 SEM. *P < 0.05.
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of the ROS indicator in RB1 mutant cells, and RB1-/- and RB1+/- were equivalent (Figure
2.2G). We also fixed and stained cells for 8-oxoguanine (8-oxoG), one of the most
abundant lesions resulting from oxidative modification of DNA (Furtado et al., 2012),
and quantified the staining in DAPI-defined nuclear area using ImageJ (Schneider et al.,
2012). Control U2OS values were used to normalize the 8-oxoG signal from RB1
mutants. Again, both RB1+/- and RB1-/- U2OS cells had more 8-oxoG staining than the
RB1+/+ cells (Figure 2.2H).
These experiments indicate that loss of RB1 in cells with pre-existing pRBpathway defects increases basal levels of DNA damage. Reactive oxygen species appear
to be one source of this damage. A chemical agent that directly induces breaks
(etoposide) did not selectively affect RB1 mutant cells, however, sensitivity to a DNA
cross linking agent (cisplatin) suggests a potential inability to repair DNA damage by
homologous recombination. Both observations are consistent with a lack of 53BP1 foci, a
marker of non-homologous end joining (NHEJ), in RB1 mutant U2OS cells compared to
controls (Figure 2.2I). This suggests the nature of DNA damage marked by gH2AX in
these RB1 mutant cells is not necessarily double stranded DNA breaks, and that NHEJ is
not the dominant pathway to repair damage in these cells. Overall, these experiments
indicate that RB1 loss contributes to an unstable genome, regardless of the proliferative
control status of the cell.

2.4.2

RB1 mutant cells have randomly distributed DNA damage
To further understand spontaneous DNA damage in RB1 mutant U2OS cells, we

sought to determine if damage occurred at specific locations within the genome. We
performed ChIP-sequencing to identify DNA sequences associated with gH2AX, as well
as histone H4 as a control. Because spontaneous damage in untreated cell cultures is
relatively rare, we pooled chromatin from 20 separate gH2AX ChIP experiments per
genotype to create each sequencing library (Figure 2.3A-E). We determined peak
locations and number using Model-based Analysis for ChIP-Seq (MACS) (Zhang et al.,
2008), and the quantity of gH2AX and H4 peaks were similar between genotypes (Figure
2.3A). Looking at a large region of chromosome 4 as a representative view of the
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Figure 2.3: gH2AX is randomly distributed in the genomes of RB1 mutant cells.

78

Figure 2.3: gH2AX is randomly distributed in the genomes of RB1 mutant cells.
(A) Total number of MACS peaks found for H4 control and gH2AX ChIP-Seq reads for
the indicated genotypes. (B) A 20 Mb region of chromosome 4 is shown with ChIP-Seq
read alignments for gH2AX and H4. Tracks were normalized by subtracting input reads.
Blue indicates more reads in the ChIP versus input, red indicates fewer reads. (C) The
number of ChIP-Seq reads mapping to repetitive sequences, as well as unique genome
regions, was determined. The heatmap shows the log2 ratios of the abundance of gH2AX
precipitable reads per million mapped reads versus input for each of the respective
genotypes at each element analyzed. (D) Aligned gH2AX ChIP-Seq read proportions
within common fragile sites (CFS) were first normalized to their respective inputs, and
then RB1+/- and RB1-/- were normalized to wild type and log2 transformed. A two-tailed
one-sample t-test was performed to determine if the normalized mean read count
proportions of the RB1 mutants at the various CFS is equal to the normalized read count
proportion of the corresponding CFS in the wild type. CFS where the false discovery rate
was less than 0.1 were grouped according to whether there were significantly more
alignments in the RB1 mutants, or significantly more alignments in the RB1+/+ sample.
There is no significant difference between these two categories (determined by unpaired
t-test). FRA2E had the most reads in RB1+/- and RB1-/- compared to control while FRA6G
had the most reads in the wild type compared to the mutants. Error bars are ±1 SEM. (E)
ChIP-Seq tracks for gH2AX and H4 at representative CFS are displayed. FRA2E and
FRA6G from D are shown, while FRA6D had no change in the proportion of gH2AX
reads that aligned between the genotypes. Regions of significant enrichment (MACS
peaks) are denoted by yellow bars.

79

genome, we did not observe consequential differences between genotypes for gH2AX or
H4 peaks (Figure 2.3B). Since peak-finding at a genome scale failed to indicate obvious
locations of DNA damage enrichment, we investigated individual genome sequence
categories in search of elevated gH2AX deposition. The proportion of aligned gH2AX
ChIP-Seq reads per million mapped reads versus input reads for each of the genotypes
were compared within each repetitive element category and log2 transformed for display
as a heat map (Figure 2.3C). Some categories, such as short interspersed nuclear elements
(SINEs) and multicopy genes appear to have slight enrichment of gH2AX localization in
RB1+/- and RB1-/- compared to RB1+/+ based on color, but a two-tailed one-sample t-test
with FDR multi-test correction did not score these as significant. Therefore, even within
repetitive sequences in the genome, there does not seem to be an enrichment of gH2AX
within RB1 mutant cells compared to control.
Previous studies suggest that gH2AX levels can be elevated at common fragile
sites (CFS) of cancer cells under standard cell culture conditions because of replication
stress (Harrigan et al., 2011). To investigate these locations, we quantified the number of
gH2AX ChIP-Seq reads and scaled them to the proportions of total aligned reads and
normalized them to input levels. RB1+/- and RB1-/- were compared to wild type using a
two-tailed one-sample t-test. This analysis revealed 23 CFS that had more gH2AX
alignments than the wild type and 24 CFS that had significantly less in RB1 mutant cells
compared to controls (Figure 2.3D). Figure 2.3E shows examples of CFS locations with
the greatest increase in gH2AX in RB1 mutants (FRA2E), the greatest reduction in
gH2AX in RB1 mutants (FRA6G), and unchanged gH2AX levels (FRA6D). These
examples appear highly similar between genotypes. Overall, it is possible that the
distribution of gH2AX within each CFS may be shifting slightly between the mutants and
the wild type. However, there does not appear to be more of a bias in general for gH2AX
elevation at CFS in RB1 mutant cells.
Collectively, our analysis of gH2AX distribution across the genome suggests there
is no particular chromosome location or sequence category that is preferentially enriched
for this mark of DNA damage. These data suggest that the increase in gH2AX foci
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observed in RB1+/- and RB1-/- cells is likely due to an overall increase in DNA damage,
and not newly arising locations, or “hotspots” of damage. This is in contrast to primary
cells with a normal pRB-pathway that experience pRB loss and preferentially damage
centromeric repeats (Coschi et al., 2014). The elevated sensitivity to peroxide and
cisplatin, and increased ROS and 8-oxoG are consistent with DNA damage being
randomly located in RB1 mutant U2OS cells.

2.4.3

Homologous recombination repair defects in RB1 deficient
cancer cells
Another potential source of intrinsic DNA damage is defective repair. For this

reason, we investigated the efficiency of HR and NHEJ repair using fluorescent reporters
(Bennardo et al., 2008; Pierce et al., 1999). In this assay a promoterless, but functional,
GFP is used to repair an adjacent break induced in a mutant, expressed, form of the GFP
gene (Figure 2.4A). We generated clonal U2OS lines bearing this reporter and created a
population of cells deleted for RB1 with lentiviral delivery of Cas9 and an RB1 specific
sgRNA (Figure 2.4B). Introduction of the restriction enzyme I-SceI into these cells
induced breaks, and RB1 deficient cells were defective for their repair (Figure 2.4C).
Similarly, we generated U2OS clones that stably maintain an NHEJ reporter for repair of
induced breaks that links a constitutive promoter with a GFP gene. Loss of pRB
expression was again confirmed by western blotting (Figure 2.4E), and induction of
breaks was used to test repair in an RB1 deficient background (Figure 2.4F). This failed to
reveal a defect in repair, suggesting that RB1 loss in U2OS cells specifically reduces HR
repair.
To investigate if this reduction in HR repair is related to changes in expression of
HR factors due to RB1 loss, we examined DNA damage repair genes that are known to be
regulated by E2Fs (Ren et al., 2002; Xu et al., 2007). Of these candidates, only one gene,
RPA2, was seen to have significantly lower transcript levels in RB1-/- U2OS cells (Figure
2.4G). However, when protein levels of a subset of these factors, including RPA2, were
investigated, no changes in expression between genotypes were evident (Figure 2.4H).
This suggests that the expression levels of key HR factors are not changed in these cells
as a result of RB1 loss.
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Figure 2.4: Defective homology directed repair of DNA breaks in RB1 mutant cells.
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Figure 2.4: Defective homology directed repair of DNA breaks in RB1 mutant cells.
(A) Schematic of the DR homology directed repair construct used. Cleavage of an I-SceI
site integrated into an expressed, but mutant, GFP gene (SceGFP), can be repaired from a
downstream internal GFP fragment (iGFP). (B) U2OS cells with clonal integration of the
HR reporter construct were ablated for RB1 expression with lentiviral delivery of Cas9
and an RB1 specific sgRNA. Relative expression of pRB in the population of cells was
determined by western blotting and Sp1 serves as a loading control. (C) HR repair
efficiency of RB1 mutant U2OS cells was determined by transfecting an expression
vector for I-SceI endonuclease (I-SceI +), or relevant negative control expression vector,
and quantitating PI- and GFP+ cells by flow cytometry (n=5). All error bars are ±1 SEM.
*P < 0.05. (D) Schematic of the EJ5 NHEJ reporter system. DNA breaks at tandem I-SceI
sites release the puromycin resistance gene, allowing NHEJ repair to join a promoter to
GFP expressing sequence. (E) After generation of a stable U2OS clone containing the
NHEJ reporter construct, RB1 was deleted as above and confirmed by western blotting.
(F) NHEJ repair efficiency was determined by transfecting an I-SceI endonuclease
expression vector (I-SceI +), or negative control, and PI- and GFP+ cells were quantitated
by flow cytometry (n=3). (G) RT-qPCR was performed to assess the transcript levels of
various HR factors in RB1 wild type (4 different clones), heterozygous (3 different
clones) and knockout cells (4 different clones). Statistical differences in means were
determined by one-way ANOVA. All error bars are ±1 SEM. *P < 0.05. (H) Western
blots showing expression of various HR factors in wild type, heterozygous, and
homozygous RB1 mutant clones are shown. Sp1 loading control is shown on the bottom.
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To assess how RB1 mutant U2OS cells respond to DNA breaks, each genotype
was exposed to 2 Gy of gamma radiation (gIR). Cells were fixed and stained for gH2AX
and DAPI to measure the amount of DNA damage. One hour after gIR, despite
pronounced gH2AX foci in all genotypes, the amount of DNA damage was significantly
greater in RB1-/- clones compared to heterozygous or wild type cells (Figure 2.5A). After
24 hr, most of the DNA damage was repaired, and the RB1-/- cells retained more gH2AX
foci than the other two genotypes (Figure 2.5B). This same increase in DNA damage in
the RB1 null background was seen in H460 cells (Figure 2.5C&D) and in H1792 cells
(Figure 2.5E&F), both 1 hr and 24 hr after exposure to 1 Gy of gIR. Overall, this indicates
that cells completely lacking pRB are more sensitive to gIR, likely because they are not
able to repair DNA breaks as efficiently by HR repair.
Next, we investigated the fidelity of mitosis to determine if the elevated levels of
DNA damage and impaired HR repair impacted chromosome segregation and aneuploidy
(Gelot et al., 2015). Flow cytometry was performed on RB1 deficient cells that were
labeled and stained with BrdU and propidium iodide (Cecchini et al., 2012). This analysis
failed to show statistically different changes in cell cycle phases between the different
genotypes (Figure 2.6A). However, when DNA content greater than 4N was analyzed,
there was a significant difference between wild type and RB1 knockout cells, with RB1+/cells showing an intermediate value (Figure 2.6B). This suggests that mitotic errors in
these cells may lead to aneuploidy.
To further investigate mitotic defects and their relationship with DNA damage and
replication stress, cells were stained with DAPI and antibodies to BLM to visualize
chromosome bridges, and mitotic figures were imaged using confocal microscopy (Figure
2.6C). We observed abundant chromosome bridges in RB1-/- and RB1+/- mutant cells
(Figure 2.6D). In the RB1 mutants there were some ultra-fine bridges (UFBs), which are
“thread-like” DNA structures that stain only with BLM (Chan and Hickson, 2011). In
RB1+/- anaphase cells, 5% (2/43) were seen to have UFBs and in RB1-/- cells, this was
increased to 8% (3/39), whereas in wild type cells, UFBs were not observed (0/30).
However, the majority of BLM bridges stained with DAPI, indicating that anaphase
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Figure 2.5: Defective repair of gIR induced DNA damage in RB1 knockout cells.
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Figure 2.5: Defective repair of gIR induced DNA damage in RB1 knockout cells.
(A) U2OS cells were treated with 2 Gy gIR and fixed 1 hr or (B) 24 hr after treatment and
stained for gH2AX. Three clones per genotype were used and gH2AX foci were
quantified. The proportion of cells with discrete numbers of foci are shown as histograms,
while the cumulative frequency of foci is shown as an inset. Differences in foci
distribution were determined using the Kolmogorov-Smirnov test. A green asterisk
indicates RB1-/- is statistically different than the other genotypes, while a black asterisk
indicates all genotypes are statistically significantly different from each other. (C) H460
cells were treated with 1 Gy gIR and fixed 1 hr or (D) 24 hr after treatment and stained
for gH2AX. (E) H1792 cells were treated with 1 Gy gIR and fixed 1 hr or (F) 24 hr after
treatment and stained for gH2AX. All error bars are +1 SEM. *P < 0.05.
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Figure 2.6: Increased mitotic errors in RB1 mutant cells.
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Figure 2.6: Increased mitotic errors in RB1 mutant cells.
(A) BrdU and propidium iodide staining followed by flow cytometry were used to
determine cell cycle phase distribution of asynchronous cultures of U2OS cells. Four
clones for the wild type and knockout genotypes and three clones for the heterozygous
genotype were analyzed. (B) Flow cytometry analysis shows the proportion of cells with
greater than 4N DNA content. Means were compared using a one-way ANOVA. (C)
Cells in anaphase were imaged by fluorescence microscopy using DAPI (blue) and BLM
(red) in cells from each RB1 genotype. Arrows indicate anaphase bridges that are stained
by both DAPI and BLM. (D) The number of anaphase cells with DAPI stained
chromosome bridges were quantitated. The proportion of cells with bridges is
significantly higher in the knockout and heterozygous clone compared to the wild type
2
clone as determined by the χ -test. (E) Representative clones from each RB1 genotype
were either left untreated or treated with 10 µM or 50 µM nucleosides for 48 hr. Flow
cytometry analysis of propidium iodide stained cells shows the proportion of cells with
greater than 4N DNA content. Mean differences were compared by one-way ANOVA
(n=3). (F) Nucleoside treated cells were fixed and stained for gH2AX after 48 hr of
culture. DNA damage is summarized in frequency plots. The blue dotted line in the
RB1+/- and RB1-/- cumulative frequency plots represents the wild type untreated cells.
Statistical significance between genotypes was determined by the Kolmogorov-Smirnov
test. All error bars are ±1 SEM. *P < 0.05.
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bridges were most common. Anaphase bridges are known to occur in HR-defective cells,
while UFBs can be induced by replication stress (Gelot et al., 2015).
Lastly, to investigate the link between UFBs in the RB1 mutant cells and a
possible increase in replication stress, we performed a nucleoside supplementation assay
and investigated changes in DNA content and DNA damage as surrogate markers for
nucleoside suppression of replication stress. Flow cytometry of cells stained with
propidium iodide was performed 48 hr after media replacement, either with or without the
addition of nucleosides. This analysis failed to show statistically different changes in
greater than 4N DNA content within genotypes when comparing the different nucleoside
treatment groups, although there was a trend towards decreased aneuploidy after
nucleoside supplementation in all genotypes (Figure 2.6E). However, when we looked at
DNA damage of cells grown in parallel, RB1-/- cells treated with 50 µM nucleosides did
have a significant reduction in gH2AX foci compared to untreated knockout cells (Figure
2.6F). Nevertheless, this reduction in DNA damage after nucleoside supplementation is
modest and did not restore the levels of gH2AX foci to those seen in the RB1+/+ controls.
Taken together with experiments earlier in this report, defects in mitosis are best
characterized as anaphase bridges that cause aneuploidy. These types of errors are
consistent with HR repair deficiency and sensitivity to a DNA cross linking agent such as
cisplatin. It appears that gH2AX foci can be suppressed slightly in RB1-/- cells with
nucleosides and RB1-/- cells exhibit some UFBs, implying that they experience modest
DNA replication stress. However, the lack of sensitivity to aphidicolin and the lack of
increased gH2AX deposition at repetitive regions of the genome argues that replication
stress in these cells is quite modest. Overall, our analysis of mitotic errors is consistent
with a defect in HR repair being the main source of chromosome bridges in anaphase of
these RB1 mutant cells.

2.4.4

Increased lung metastases in RB1 mutant xenografts
To further characterize the effects of induced RB1 mutations in cells that already

possess pRB-pathway defects, we performed xenograft experiments to determine if new
cancer relevant properties arise upon loss of pRB. We injected cells subcutaneously into
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immune compromised mice and allowed tumors to form for an eight-week period before
analyzing growth by mass and histology (Figure 2.7A). This analysis revealed highly
cellular tumors with abundant mitotic activity and foci of necrosis. Cells appeared
epithelioid with no definite features of osteoid differentiation and they had small areas
suggesting glandular differentiation. This phenotype was consistent among all genotypes
(Figure 2.7B). Tumor masses were determined at end point and were not statistically
different between genotypes, with RB1-/- even trending towards a smaller size (Figure
2.7C). Mice were also tail vein injected and cell dissemination and proliferation were
allowed to proceed for eight weeks at which time lungs were harvested, fixed, and
sectioned. Hematoxylin and eosin-stained sections were digitally analyzed to quantitate
cellular infiltration of U2OS cells (Figure 2.7D). This revealed a striking increase in RB1/-

U2OS cells in the lungs of these mice compared to control and RB1+/- cells as

determined by the percent of lung section area that is occupied by malignant cells (Figure
2.7E). There were significantly more individual nodules of RB1-/- cells per lung than the
other genotypes (Figure 2.7F), further suggesting that RB1 loss increased the efficiency of
dissemination or establishment in the lung. Lastly, the area occupied by tumor cells per
nodule is lower in both RB1 mutant genotypes indicating that control cells form rarer,
larger clusters of cells, whereas RB1 mutants tend to seed more efficiently and perhaps
proliferate more slowly (Figure 2.7G). We note that one mouse injected with RB1+/- cells
showed extensive dissemination and tumor burden that was highly reminiscent of mice
injected with RB1-/- cells (Figure 2.8A&B). To investigate this further we extracted DNA
from paraffin embedded tumor material from this mouse. PCR analysis was used to
genotype RB1 exon 22 in these cells (Figure 2.8C). It confirmed that these cells
maintained their wild type RB1 allele, suggesting they had not undergone loss of
heterozygosity as a means to acquire an RB1-/- phenotype.
These xenograft experiments indicate that RB1 mutations in U2OS cells have little
effect on growth rate of primary tumors. Interestingly, RB1-/- cells are much more
efficient in colonizing recipient mouse lungs, suggesting that in addition to the DNA
damage and genome instability phenotypes described earlier, RB1 loss in pRB-pathway
deficient cells imparts characteristics that enable cancer progression.
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Figure 2.7: Increased lung metastases with RB1 mutant cells in xenograft
experiments.
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Figure 2.7: Increased lung metastases with RB1 mutant cells in xenograft
experiments.
(A) Illustration of analysis of subcutaneous injections of RB1 mutant U2OS cells. Tumors
were allowed to form for eight weeks before analyzing tumor mass and histology. (B)
Representative H&E stained tissue sections from each genotype of tumor. (C) Tumor
masses from subcutaneous injected cells are shown. The means are not statistically
different. (D) Schematic of tail vein injections to study dissemination to the lungs. Mice
were injected and cell dissemination and proliferation were allowed to proceed for eight
weeks. Lungs were then isolated, sectioned and stained with H&E, and analyzed using
QuPath. (E) The percentage of lung area occupied by cancer cells was calculated from
tissue sections and averaged between mice. (F) Tumor cell nodules were counted using
the assistance of QuPath and averaged among recipient mice. (G) Percent tumor cell
burden was divided by the number of tumor nodules to determine the average tumor cell
area per nodule. Statistical significance between genotypes was determined with a t-test.
All error bars are +1 SEM. *P < 0.05.
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Figure 2.8: Single copy loss of RB1 can create cancer enabling phenotypes.
(A) H&E staining of lung tissue with the highest number of RB1+/- seeding events. (B)
QuPath coloring to denote tumor tissue within these lungs (red). (C) DNA was extracted
from nodules of tumor cells in paraffin embedded tissue containing these RB1+/- cells, or
a RB1+/+ control. PCR was performed to amplify exon 22 from recovered DNA and
controls isolated from cell culture to verify the final genotype of cells in this sample. (D)
The 10 most prevalent cancers were analyzed for RB1 gene alterations using TCGA and
Pan-Cancer Atlas data using cBioPortal. A deep deletion is consistent with biallelic loss
of RB1, whereas a shallow deletion is suggestive of heterozygous RB1 deletion.
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2.5 Discussion
To test if RB1 loss impacts cancer cells that already possess mutations disrupting
the pRB-pathway, we used CRISPR/Cas9 to create non-functional RB1 alleles. Using
gH2AX staining of cells, we found that even within cells deficient for one copy of RB1,
there is an increase in spontaneous DNA damage. Experiments that probe drug sensitivity
of RB1 mutant cells, along with ChIP-Seq analysis of gH2AX foci and analysis of DNA
damage repair pathways, suggest a complex picture of cellular defects. We did not detect
specific hotspots of DNA damage, but sensitivity to peroxide and cisplatin suggest that
oxidative damage may cause sporadic DNA damage as reactive oxygen species are
elevated in RB1 deficient cells. Mutant RB1 cells also have more abnormal mitoses
characterized by anaphase bridges, reporter assays detect defects in HR repair, and
nucleoside supplementation in culture media suppresses gH2AX foci, suggesting
additional endogenous sources of damage. Overall, this study reveals that RB1 mutations
lead to increased DNA damage that may enhance cancer progression.
The DNA damage phenotype caused by either single copy or homozygous
mutation to RB1 is unlikely to be attributable to a single root cause, and we expect that
RB1 deficiency may affect DNA damage in different cancer cells in varied ways. We
report that RB1 deletion compromises HR repair but not NHEJ and this is consistent with
one previous report (Velez-Cruz et al., 2016), but contradicts another (Cook et al., 2015).
Given that we observe more than 70% of U2OS cells incorporating BrdU in a brief pulse,
they are likely biased towards HR repair pathways because of their cell cycle position.
This is consistent with gH2AX foci not being accompanied by 53BP1, and the activity
levels of NHEJ reporters being almost an order of magnitude less than HR values,
suggesting that U2OS cells are primed to use the HR repair pathway and thus phenotypes
in these cells reflect this reality. We expect that DNA damage and defective repair
described in this report are relevant to cancer progression phenotypes because graded
differences between RB1 wild type, heterozygous, and homozygous genotypes are
reflected in 8-oxoguanine abundance, aneuploidy, and anaphase bridges. This stepwise
trend in severity of phenotype in the molecular alterations resulting from RB1 loss is
similarly evident in the behaviour of RB1+/+, RB1+/-, and RB1-/- mutant tail vein xenograft
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experiments, suggesting that this increase in metastatic burden is related to a stepwise
increase in DNA damage experienced by these different genotypes.
Single copy loss of RB1 may contribute to cancer in a number of ways. Primary
RB1+/- cells from a number of sources are prone to mitotic errors (Coschi et al., 2014;
Gonzalez-Vasconcellos et al., 2013; Zheng et al., 2002), and precursor lesions to
retinoblastoma are characterized by aneuploidy (Dimaras et al., 2008), suggesting this is
an early step in this disease. Therefore, partially defective RB1 can contribute to the early
stages of cancer through a distinct set of effects. However, a number of studies have
highlighted that RB1 loss is statistically enriched in advanced stages of cancer
progression (Beltran et al., 2016; McNair et al., 2017; Robinson et al., 2017). In addition,
analysis of the landscape of cancer alterations in TCGA consortia reveals so called
“shallow deletions” of RB1 as relatively commonplace (Figure 2.8D), and these events
are unlikely to be explained by random, unselected events (Beroukhim et al., 2010). From
this perspective, our study offers critical proof of concept that late stage loss of one copy
of RB1 can create cancer enabling phenotypes in the host cell, even if it already possesses
pRB-pathway mutations. Complete elimination of RB1 has a stronger effect on DNA
damage phenotypes and dissemination to the lungs, as demonstrated in this study,
however, highly abundant single copy RB1 loss may represent a mutational compromise
in which advantageous phenotypes are acquired with an economy of mutational changes
(Davoli et al., 2013).
A number of studies correlate absence of pRB expression with improved patient
survival following treatment that includes platinum-based chemotherapy (Cecchini et al.,
2015; Garsed et al., 2018). Loss of pRB correlated with improved survival of lung
adenocarcinomas treated by resection and adjuvant cisplatin or carboplatin, and a vinca
alkaloid (Cecchini et al., 2015). More recently patients with high-grade serous ovarian
carcinoma (HGSOC) that experienced exceptionally good clinical outcomes were studied
(Garsed et al., 2018). These patients were treated with platinum-based agents, and loss of
pRB was associated with long-term survival. From this perspective, U2OS cells
engineered to be deficient for RB1 demonstrate that pRB loss increases sensitivity to
cisplatin. Given that RB1 mutant cells were not more sensitive to another agent that
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induces DNA breaks, etoposide, we interpret RB1 deficiency to create a unique sensitivity
to cisplatin that may relate to defective HR and higher endogenous ROS levels that create
a highly specific sensitivity to this class of chemotherapy.
In conclusion, although there are many cancers that have mutations in the pRBpathway that spare the RB1 gene itself, further mutations to RB1 surprisingly create
cancer relevant characteristics that may influence disease progression. The frequency of
shallow deletions of RB1 across many cancers suggests that disease progression may
select for these characteristics.
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Chapter 3

3

An pRB-condensin II complex mediates long-range
chromosome interactions and regulates expression at
divergently paired genes

3.1 Abstract
Interphase chromosomes are organized into topologically associated domains by
cohesins. Condensin II is analogous to cohesin, but its requirement in higher order
chromatin organization in interphase mammalian nuclei is unknown because of limited
loss of function approaches. Here we show that condensin II is recruited to divergently
transcribed promoters by a mechanism that is dependent on the retinoblastoma protein
(pRB). Long-range chromosome contacts are disrupted by loss of condensin II loading
which leads to misexpression at these gene pairs. This study demonstrates that
mammalian condensin II functions to organize long-range chromosome contacts and
regulate transcription at specific genes. In addition, pRB dependence of condensin II
suggests that widespread misregulation of chromosome contacts and transcriptional
alterations are a consequence of pRB loss in cancer.

3.2 Introduction
Genomes are more complex than their one-dimensional, linear DNA sequences.
Three-dimensional organization of interphase chromosomes imparts regulatory
information that contributes to development and disease. In particular, functions are
arranged spatially in the nucleus such that transcription, replication, and other processes
are compartmentalized in discrete locations (Misteli, 2007). Understanding the
organizational principles of interphase chromosomes has been aided by chromosome
conformation based analyses (Rowley and Corces, 2018). In addition, investigation into
the genetic requirement for specific architectural proteins is now revealing chromatin
folding and compartmentalization on a whole genome scale with their underlying
molecular mechanisms (Rowley and Corces, 2018). We are also beginning to appreciate
that cell-fate decisions are driven by changes in environmental cues, triggering signal
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transduction into the nucleus, which ultimately converge on altered activity of
transcription factors and affect the recruitment of transcriptional and chromatin
remodeling machinery (Stadhouders et al., 2019). Therefore, cell identity can be regarded
as an emergent property resulting from the crosstalk between transcription factors,
epigenetic modifications, chromatin-associated proteins, and the three-dimensional
organization of the genome. Thus, it is not surprising that cell type specific chromosome
territories have been observed, and that chromosomal rearrangements disrupting
topologically associating domains (TADs) have been linked to developmental defects and
cancer, further suggesting functional relevance of genome conformation (Fraser et al.,
2015; Stadhouders et al., 2019).
Higher order chromosome organization is extensively supported by the structural
maintenance of chromosomes (SMC) family of multisubunit protein complexes (van
Ruiten and Rowland, 2018). In mammals, SMC family complexes include cohesin and
condensins I and II (Hirano, 2016). All contain two SMC subunits as well as unique nonSMC proteins. Specifically, cohesin contains SMC1 and 3, and condensins utilize SMC2
and 4. Condensins are further differentiated by their non-SMC subunits, with CAP-D3,
CAP-G2, and CAP-H2 being unique to condensin II (Hirano, 2016). All SMC containing
protein complexes form ring like shapes that can entrap chromatin fibers to organize them
into higher order structures (van Ruiten and Rowland, 2018). In S phase, cohesins ensure
sister chromatid alignment following replication (Morales and Losada, 2018), and
condensin II ensures chromatid separation (Ono et al., 2013). In mitosis condensins
orchestrate compaction of chromatin during prophase (Gibcus et al., 2018). Condensin I
is largely cytoplasmic during interphase and its access to chromosomes increases after
nuclear envelope breakdown in prometaphase (Ono et al., 2003). Cohesins and condensin
II, on the other hand, are nuclear during interphase. It is in this context that cohesins have
been determined to play an essential role in organizing the three-dimensional architecture
of chromosomes (Haarhuis et al., 2017; Nora et al., 2017; Rao et al., 2017; Schwarzer et
al., 2017; Wutz et al., 2017). Interestingly, these studies show that some long-range
chromosome contacts are preserved in the absence of cohesins, and condensin II cooccurs at TAD boundaries (Van Bortle et al., 2014; Yuen et al., 2017), suggesting it may
also contribute to chromosome organization in interphase. However, the effect of
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condensin II loss of function in mammalian cells is relatively unexplored compared to
cohesin.
Condensins have been proposed to mediate chromosome structure and
transcriptional control in model organisms. For example, condensin molecules participate
in dosage compensation of hermaphroditic worms to silence one X chromosome (Crane
et al., 2015). Furthermore, condensin II in Drosophila influences gene transvection
effects caused by interphase chromosome pairing (Rowley et al., 2019). However, these
are species specific paradigms that may not be conserved in mammalian biology.
Condensin mutations have effects on transcription that in fission yeast are largely the
consequences of aberrant mitosis and aneuploidy (Hocquet et al., 2018). Consequently,
separation of indirect cell cycle effects from direct roles for mammalian condensin II on
chromosome structure during interphase are rare. In response to estrogen stimulation,
both condensin I and II are loaded at hormone-responsive, RNA-positive (eRNA+)
enhancers to promote eRNA transcription, enhancer-promoter looping, and full activation
(Li et al., 2015b). However, investigation of basal transcriptional effects of condensin II
loss through deletion of CAP-H2 in post-mitotic hepatocytes failed to reveal effects on
transcription (Abdennur et al., 2018). From this perspective, our knowledge of condensin
II function in interphase nuclei and its effects on transcriptional control remains limited.
The retinoblastoma protein (pRB) is typically known for its role in cell cycle entry
regulation, however, pRB deficient primary fibroblasts are known to possess relaxed
chromatin (Herrera et al., 1996). In addition, pRB functions to recruit condensin II to
mitotic chromosomes in Drosophila and mammalian cells (Longworth et al., 2008).
Defective recruitment leads to mitotic abnormalities characterized by decondensed
chromosomes, misshapen centromeres, and aberrant spindle microtubule attachments
(Coschi et al., 2010; Manning et al., 2010). Two different partial loss of function murine
Rb1 gene mutations have been shown to compromise the recruitment of condensin II to
pericentromeric heterochromatin (Coschi et al., 2014; Ishak et al., 2017). One is a point
mutant allele that disrupts a CDK insensitive pRB-E2F1 interaction that allows pRB to
associate with chromatin in S phase (Ishak et al., 2016). The other is a three amino acid
substitution that disrupts the LXCXE binding site used by viral oncogenes called Rb1L
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(Isaac et al., 2006). Prior studies have shown that when pRB-LXCXE interactions are
disturbed, transcription from E2F-containing promoters can still be regulated during
proliferation and in differentiation (Isaac et al., 2006; Talluri et al., 2010). However,
defective condensin II recruitment in Rb1L/L cells leads to DNA replication dependent
damage at pericentromeric sequences (Coschi et al., 2014), suggesting that pRB may play
a role in recruiting condensin II to interphase chromosomes for non-mitotic functions.
To investigate condensin II regulation of chromosome structure in interphase
cells, we utilized primary Rb1L/L fibroblasts to disrupt condensin II recruitment. Using a
combination of ChIP-Seq, RNA-Seq and chromosome conformation capture approaches
we demonstrate that pRB recruits chromosome architectural protein complexes TFIIIC
and condensin II to bidirectional promoters. In the absence of their recruitment, reciprocal
misexpression was observed at these gene pairs, suggesting condensin II recruitment has
direct effects on local transcription through an insulator type mechanism. Defective
recruitment of condensin II diminished long-range chromosome contacts between
bidirectional promoters and distant loci. Loss of human RB1 in lung adenocarcinoma
reveals misexpression of genes at these bidirectional promoters. These experiments
highlight transcriptional and architectural functions of an pRB-TFIIIC-condensin II
complex that may represent a transcriptional insulator function that is inactivated upon
pRB loss in cancer.

3.3 Materials and Methods
3.3.1

Cell culture
MEFs were prepared and cultured from E13.5 embryos according to standard

methods (Thwaites et al., 2016). Rb1+/+, Rb1-/-, Rb1L/L, E2f1+/+, E2f1-/- MEFs were
genotyped as previously described and used by passage 4 (Isaac et al., 2006).

3.3.2

ChIP
ChIP was conducted according to protocols adapted from Cecchini et al.

(Cecchini et al., 2014). Briefly, asynchronously cycling cells were fixed in either 1%
formaldehyde in 1X PBS or in 2mM ethylene glycol bis(succinimidyl succinate (EGS) in
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1X PBS followed by 1% formaldehyde. Both fixing reactions were neutralized with
0.125M glycine. Cross-linked chromatin was sonicated so most chromatin was ≤400 bp.
Sheared chromatin was then normalized between experimental groups and pre-cleared
with protein G Dynabeads and IgG. Pre-cleared chromatin was then incubated with
protein G Dynabeads and ChIP antibodies to immunoprecipitate proteins. The following
antibodies were used to precipitate proteins: anti-CAP-D3 (Coschi et al., 2010), antiCAP-H2 (A302-275A, Bethyl), anti-H3K27me3 (07-449, EMD Millipore), anti-pRb (C15, Santa Cruz), anti-pRb (M-153, Santa Cruz), anti-pRb (M-136, (Cecchini et al.,
2014)), anti-pRb (s855, (Cecchini et al., 2014)), anti-pRb (Hyb4.1, Developmental
Studies Hybridoma Bank), and anti-TFIIIC-220 (A301-291A, Bethyl). Cross-links were
reversed at 65°C, and samples were treated with RNase and proteinase K. DNA was
isolated for qPCR and/or library preparation.
For ChIP-qPCR the following primer pairs were used: Lmnb2-F, 5’TCGGAGGCTCTATGGGAAAC-3’; Lmnb2-R, 5’-AAGGACAGTGCTTAGGGACG3’, Cdca3-F, 5’-TCTCTCGCATCCAATGAGCG-3’; Cdca3-R, 5’TACCCGCGGCGCTTTTTATT-3’; Pole-F, 5’-TCATTGGCCGAAGCCGTAG-3’; PoleR, 5’-TTCCTCAGGACCATTGCGAC-3’, Mcm3-F, 5’ATCCAGGAAGTCCAAGTAGTCTCTC-3’; Mcm3-R, 5’TTGAAGTGGTTAGCCAATCATAACG-3’; Mcm3_-2kb-F, 5’GCCAAGGCAAAACAACAATTTCTAC-3’; Mcm3_-2kb-R, 5’CTATCTCTTTGATTTTGGGTGGCTG-3’; Hist1h3b_F, 5’GTCTGTTTGAGGACACCAACCT-3’; Hist1h3b_R, 5’TTTGGGTTCCAGTTTGCACTTTG-3’; Hoxa10_F, 5’ACTGGGGATCTCGGTCCTAC-3’; Hoxa10_R, 5’-CAGATACTGGGCGGTGGTC-3’.

3.3.3

ChIP-Seq libraries and alignment
For ChIP-Seq, some previously published data were used for analysis. FASTQ

reads were downloaded from the following datasets: CAP-D3 (GSE55040:
GSM1328449, GSM1328450 and GSM1328448) Pol2 (GSE36027: GSM918740 and
GSM918761), H3K4me1 (GSE31039: GSM769028 and GSM769030), H3K4me3
(GSE31039: GSM769029 and GSM769030), H3K27ac (GSE29218: GSM851277 and
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GSM723008), H3K27me3 (GSE77993: GSM2064311 and GSM2064301), H3K36me3
(GSE53939: GSM1303764 and GSM1303761), and H3K9me3 (GSE53939:
GSM1303762 and GSM1303761) (Coschi et al., 2014; Ishak et al., 2016; Pedersen et al.,
2014; Shen et al., 2012). ChIP-Seq libraries created for this study occasionally used DNA
from multiple ChIP replicates per genotype. To obtain enough DNA for library
preparation, for CAP-H2 and CAP-D3 ChIPs, 5 IPs were combined and for H3K27me3
ChIPs, 2 IPs per library were used. ChIP libraries were sequenced using an Illumina
NextSeq (High output 75 cycle kit).
All FASTQ reads (both from ChIP-Seq data published for other studies and from
ChIP-Seq data obtained for this study) were aligned to mouse genome build mm9 using
Bowtie2 version 2.3.0 (Langmead and Salzberg, 2012). Reads aligning to multiple
locations of a particular element were distributed randomly to these positions, while
multiple reads mapping to the same location were retained as previously described
(Bulut-Karslioglu et al., 2014). The following command was used: bowtie2 -t -p 4 -D 15 R 2 -L 32 -i S,1,0.75 -x mm9 –U <reads>.fastq -S <output>.sam.

3.3.4

Peak calling and annotation
Peaks were identified using MACS version 1.4.0rc2 according to the parameters

stated below (Zhang et al., 2008). The following command was used: macs14 –t
<ChIP>.sam -c <input>.sam -n <output> -g mm -B -S. For analysis of CAP-D3
localization, only peak locations that had 10 or more tags, a P-value of at most 10-5, and a
fold enrichment of at least 4 were used for subsequent analyses. Reads and peak locations
were visualized using Integrative Genomics Viewer (IGV) (Robinson et al., 2011;
Thorvaldsdottir et al., 2013).
Peak enrichment per genomic region was determined using CEAS and the mm9
RefSeq table supplied with the program (Shin et al., 2009). To determine the number and
significance of peaks overlapping with other peaks or genomic elements, BEDTools was
used (Quinlan, 2014; Quinlan and Hall, 2010).
To create heatmaps of reads, deepTools bamCompare was first used to generate
bigWig files of ChIP reads normalized to input (Ramirez et al., 2014; Ramirez et al.,
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2016). computeMatrix was then used to calculate read enrichment scores at promoters
with wild type CAP-D3 peaks and plotHeatmap was used to plot those scores. To perform
Pearson correlation analysis and create clustered heatmaps, mutliBigwigSummary
computed the average scores for each of the files in every genomic region, and
plotCorrelation was used to plot the data.
Functional annotation of genes of interest was performed using the Database for
Annotation, Visualization and Integrated Discovery (DAVID) (Dennis et al., 2003).
Genes were submitted to DAVID and analyzed using the functional annotation tool with
the following categories selected: GOTERM_BP_DIRECT, GOTERM_CC_DIRECT,
GOTERM_MF_DIRECT, UP_KEYWORDS, UP_SEQ_FEATURE,
KEGG_PATHWAY, BIOCARTA, INTERPRO, PIR_SUPERFAMILY, and SMART.
Functional annotation clustering was then used to cluster all of the gene enrichment
results, with default parameters. The enrichment score for the annotation clusters
represents the geometric mean, in –log scale, of the members’ p-values in each
corresponding annotation cluster. Functional annotation clusters were manually described
based on their over-arching theme.

3.3.5

RNA-Seq
Total RNA from proliferating MEFs was isolated using TRIzol reagent according

to the standard protocol (Invitrogen). Three Rb1+/+ and Rb1L/L MEF pairs were used for
this analysis. All samples were further processed and sequenced at the London Regional
Genomics Centre (Robarts Research Institute, London, Ontario, Canada;
http://www.lrgc.ca). Total RNA samples were quantified using the Qubit 2.0 Fluorometer
(Thermo Fisher Scientific) and quality was assessed using the Agilent 2100 Bioanalyzer
(Agilent Technologies Inc.) and the RNA 6000 Nano kit (Caliper Life Sciences). They
were then processed using the ScriptSeq Complete Gold Kit (H/M/R) (Illumina Inc.)
which includes Ribo-Zero rRNA removal. Samples were fragmented, cDNA was
synthesized, tagged, cleaned-up and subjected to PCR with indexed reverse primers
(ScriptSeq Index PCR Primers) to permit equimolar pooling of samples into one library.
Samples were sequenced on an Illumina NextSeq 500 (Mid output 150 cycle kit). FASTQ
data files were then downloaded from BaseSpace.
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For alignment of reads, a STAR v2.5.0a was used (Dobin et al., 2013). To
generate a genome index, the mm9 chromFa.tar.gz file was downloaded from UCSC to
create mm9_full_genome.fa, and the following command was used: STAR --runThreadN
4 --runMode genomeGenerate --genomeDir <STAR_genome_indices_directory> -genomeFastaFiles mm9_full_genome.fa --genomeSAsparseD 2 -limitGenomeGenerateRAM 20000000000 (Mouse Genome Sequencing et al., 2002). For
the alignments, the following STAR command was used: STAR --runMode alignReads -runThreadN 8 --genomeDir <STAR_genome_indices_directory> --readFilesIn
<reads>.fastq --sjdbGTFfile mm9_UCSC_knownGene.gtf --sjdbOverhang 149 -sjdbInsertSave All --outSAMtype BAM Unsorted SortedByCoordinate -outFileNamePrefix <output> --outReadsUnmapped Fastx --outMultimapperOrder
Random --outSAMattributes NH HI AS NM XS --outWigType wiggle. StringTie v1.3.2
was then used to assemble RNA-Seq alignments into potential transcripts with the
following command: stringtie <STAR_aligned_sample>.sortedByCoord.out.bam -o
<output>.gtf -p 4 -G mm9_UCSC_knownGene.gtf -A <output>_gene_abund.tab -B -e
(Pertea et al., 2015). The prepDE.py script provided with StringTie was then utilized to
extract read count information from the generated files and DESeq2 was used to
determine differential transcript abundance between Rb1+/+ and Rb1L/L genotypes. When
analyzing overall gene expression, all normalized transcript read counts from DESeq2
were summed for each gene and each of the three Rb1L/L MEF preparations were
compared to the average of three wild type MEFs. Heatmaps of data were created using
matrix2png (Pavlidis and Noble, 2003).

3.3.6

Comparison of transcriptome analysis and ChIP-Seq data
To compare CAP-D3 ChIP-Seq binding sites to changes in transcription, BETA

was used (Wang et al., 2013). First, RNA-Seq data were converted to BETA specific
format (BSF) with the fold-change values being reported as wild type versus Rb1L/L so
expression changes when CAP-D3 could bind were being highlighted. The expression
data were then compared to the filtered list of high confidence CAP-D3 peaks (see above)
using BETA, taking into account CTCF binding sites using the following command:
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BETA plus –p <CAP-D3_peaks>.bed –e <expression_changes>.txt –k BSF --bl –g mm9
--gs mm9.fa –n <output>.

3.3.7

qRT-PCR analysis of expression
Total RNA from proliferating MEFs was isolated using TRIzol reagent according

to the standard protocol (Invitrogen). First-strand cDNA synthesis was performed using
random primers, RNaseOUT and SuperScript III Reverse Transcriptase according to
manufacturer’s instructions (Invitrogen). Isolated cDNA was used in qRT-PCR reactions
with iQ SYBR Green Supermix (Bio-Rad) using the following primers: Cdca3_exp_F,
5’-GTAGCAGACCCTCGTTCACC-3’; Cdca3_exp_R, 5’ATTCCGACGCTTCTGTCTCC-3’; Usp5_exp_F, 5’-ATGGCGGAGCTGAGTGAAGA3’; Usp5_exp_R, 5’-ATAGAGGCCACCCTCAGACT-3’; Pole_exp_F, 5’GAGAAGGTGCCTGTGGAACA-3’; Pole_exp_R, 5’GCTGTAGGCGGTTGGTAAGA-3’; Pxmp2_exp_F, 5’GACTGCCTAGCTGTTGGGTG-3’; Pxmp2_exp_R, 5’CCAAGGGCTGACAAAATGCC-3’; GAPDH_exp_F, 5’GCACAGTCAAGGCCGAGAAT-3’; and GAPDH_exp_R, 5’GCCTTCTCCATGGTGGTGAA-3’. Resulting target Cq values were normalized to
GAPDH, then expressed as fold change relative to the global wild type mean.

3.3.8

Flow Cytometry
Cells were plated on 10 cm plates at a density of 900,000 cells per plate.

Approximately 24 hours after, cells were pulsed with BrdU for a duration of 2 hours. Cell
cycle analysis was then carried out as previously described (Cecchini et al., 2012).

3.3.9

Nocodazole treatment
Cells were plated on 10 cm plates at a density of 900,000 cells per plate or on 6

cm plates at a density of 300,000 cells per plate. Approximately 24 hours after seeding,
cell media was replaced with standard culture media containing either DMSO only
(control) or 20 ng/mL nocodazole. One day after treatment with nocodazole, cells were
processed for flow cytometry and qRT-PCR expression analysis (see above).
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3.3.10 Chromosome conformation capture (3C) analysis
3C was conducted according to protocols adapted from Hagège et al. (Hagege et
al., 2007). Briefly, cells were trypsinized, centrifuged and resuspended to make a singlecell suspension followed with crosslinking in 1% formaldehyde/10% FCS/PBS. The
reactions were quenched with glycine and cells were then pelleted and lysed in 5 mL cold
lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1%
Triton X-100 and protease inhibitors). Samples were digested with HindIII, ligated using
T4 DNA ligase, samples were treated with proteinase K and cross-links were reversed at
65°C. Samples were then treated with RNase A followed by phenol-chloroform
purification. 3C samples were digested with a second restriction enzyme, EcoRI, to help
minimize potential PCR biases resulting from limited template accessibility. The resulting
final 3C products were quantified in triplicates by quantitative TaqMan real-time PCR
after 3C DNA was normalized to a final concentration of 50 ng/µL. Bacterial artificial
chromosomes (BACs), clones RP23-333M22 and RP23-55K5, containing the
Pxmp2/Pole and Cdca3/Usp5 bidirectional promoters of interest, respectively, were used
as control templates. To generate random ligation products of HindIII fragments at the
regions of interest, BACs were individually digested with HindIII, ligated, and digested
again with EcoRI. This ligated BAC DNA was serially diluted and used to generate
standard curves in each qPCR runs for each primer pair to which all 3C products were
normalized. The 3C signals at each locus were further normalized to those from a control
locus, ERCC3, with primers and a probe described previously (Splinter et al., 2006).
Probe and primer sequences are as follows (primer names correspond to approximate
position (in kb) relative to bidirectional promoters): Cdca3_const, 5’TAGAGCAAAGCTACACCGGG-3’; Cdca3_Probe, 5’-FAMAGAGAGATCTATCCAGGTCTCACAGGCCC-TAMRA-3’; Cdca3_-93, 5’GACCACTGCGAGACGGAAG-3’; Cdca3_-73, 5’CCCCAGATACACTCAATCCCTG-3’; Cdca3_-57, 5’-CCTCTCCCCTCCTTTCTTCC3’; Cdca3_-45, 5’-TACAGATGGTTGCGAGGCAC-3’; Cdca3_-33, 5’GCTGGGAGGATGAGAAAAATGAC-3’; Cdca3_-13, 5’ATCCAGAGATTCACGCTTGCT-3’; Cdca3_+1, 5’-CCTGGAGGAGGCCATTCAAG3’; Cdca3_+8, 5’-CCAAGTCTACCATCTCGGGG-3’; Cdca3_+9, 5’-
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TTGGGTGACTGAGATAGCCC-3’; Cdca3_+37, 5’-CCTGGCACACAGCAAGC-3’;
Cdca3_+48, 5’-ACCAGAACAGACATCTCAAGTAACA-3’; Cdca3_+57, 5’TGCATAGCGATGGGTTTCACA-3’; Cdca3_+59, 5’TGGCCAGAATGACTGCAAAGAA-3’; Cdca3_+63, 5’CCCTCTCCCAGGGTAAAGC-3’; Cdca3_+64, 5’GTTCCAGAACTTTCCTCTCTTTGC-3’; Cdca3_+69, 5’GAGGCATGCCACGTAAGC-3’; Cdca3_+70, 5’-CCCGCAGGAGAGGGACTAAA-3’;
Cdca3_+71, 5’-TCGGAATTTGCTCCCAGAGTC-3’; Cdca3_+79, 5’GTGGGGACAGTAGAGGAAGC-3’; Cdca3_+80, 5’-GCTGAGCCCAGTGGAAAG-3’;
Cdca3_+88, 5’-GGCTCTGTTTACCACAACTGTC-3’; Cdca3_+96, 5’AGAAGCTGACTTGGGCTACAT-3’; Cdca3_+123, 5’GTCTAACGGGTTGGTAGAGTGG-3’; Cdca3_+127, 5’ACATAATAACACCAGGGGCCG-3’; Cdca3_+129, 5’CACTGACTGACGCACAGAAGAA-3’; Pole_const, 5’-GGTGTCCTGCTGCCAAGG3’; Pole_Probe, 5’-FAM-TGCTCCGGCCGCGGCTAC-TAMRA-3’; Pole_-30, 5’ACAGCCAGAACTACACAGAGG-3’; Pole_-25, 5’ACTGTTGTGGACTGATGCTTAGAA-3’; Pole_-24, 5’TGCCCTTGTCTGAAGTCTGC-3’; Pole_-23, 5’-CTCAGGAGACAGGCAAGCTAA3’; Pole_-6, 5’-ATGGCAATCACAGGCACAAG-3’; Pole_-5, 5’CTGTCCTCATCTGTGCCCTC-3’; Pole_-4, 5’-TGCCAAAGTATGGGGGATGTG-3’;
Pole_+3, 5’-TTCCTCGGTGGGCATTCTTC-3’; Pole_+5, 5’AGAAGATTGTGATCAGTGTTTCTGA-3’; Pole_+11, 5’CTTGTTGAACTCCTGCTCTTGC-3’; Pole_+18, 5’-CTAATGGAACCGAGGAGCCG3’; Pole_+28, 5’-GCAATACACAAACGCTCTTGGTC-3’; Pole_+32, 5’AGCCAGACCAACCACTCTTC-3’; Pole_+36, 5’TGAGAGTTGTCCTGTATGGAACG-3’; Pole_+50, 5’AAAATGCCCACCTTGCTGTG-3’; Pole_+62, 5’TTCAGGGTTCTCTCTTTGGGAGTG-3’; Pole_+66, 5’GTGTTCTTCCTGTGTATATACTTGC-3’; Pole_+77, 5’CTCCCTTAAGTTTGTCGGGCT-3’; Pole_+82, 5’-TGGAGGAATGTGACTGGGGA3’; Pole_+84, 5’-CTGGGCGCTTGGAGGTTTTAC-3’; Pole_+101, 5’-
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TTGAAGCCTAGGTGGGAGTCTT-3’; Pole_+104, 5’ACAGGAGAGAGGCAGGTATGTC-3’; ERCC3_1, 5’GCCCTCCCTGAAAATAAGGA-3’; ERCC3_2, 5’-GACTTCTCACCTGGGCCTACA3’; ERCC3_Probe, 5’-FAM-AAAGCTTGCACCCTGCTTTAGTGGCC-TAMRA-3’.

3.3.11 Circularized chromosome conformation capture (4C)-Seq
Samples were fixed, digested with HindIII, ligated and crosslinks were reversed as
detailed in the 3C protocol above. To generate a 4C products, 3C products were
processed according to protocols adapted from Splinter et al. (Splinter et al., 2012).
Briefly, 3C products were digested with NlaIII, ligated with T4 DNA ligase, and purified.
Primers were designed for the bidirectional promoters of interest for inverse PCR
reactions. For Illumina sequencing, all reading primers started with an Illumina read
adapter sequence, 5’AATGATACGGCGACCACCGAGATCTACACACACTCTTTCCCTACACGACGCTC
TTCCGATCT-3’; followed by a unique tag 0-3 nucleotides in length. These tags were
unique to each sample and were used both to ensure that nucleotide content for every
cycle of sequencing is not the same (despite using the same primer sequence for all
samples at the same viewpoint) and to pool multiple samples together. After the tag, the
reading primers contained sequence unique to the viewpoint of interest, as close as
possible to the HindIII digestion site. For the Pole/Pxmp2 bidirectional promoter, this
sequence was 5’-GATTCACTCCAAACTCCACAAAA-3’, and for the Cdca3/Usp5
bidirectional promoter, it was 5’-AGCAAGAGAGTGTAGCTAAG-3’. For the reverse
sequencing primers for these viewpoints, the primers again started with an Illumina
adapter sequence, 5’-CAAGCAGAAGACGGCATACGAGAT-3’; followed by sequence
unique to the viewpoint of interest, close to the NlaIII restriction sites. For the
Pole/Pxmp2 bidirectional promoter, this sequence was 5’TCCAAAGGATATATGAGGTTCG-3’, and for the Cdca3/Usp5 bidirectional promoter,
it was 5’-GTCTGACTTGCAGTTTTCAG-3’. 4C product for sequencing was then
prepared using Expand Long Template Polymerase (Roche) and 3.2 µg of 4C template
split between 16 PCR reactions. PCR reactions were pooled after completion and
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purified. 4C PCR products were then pooled equimolarly into one library and sequenced
on an Illumina NextSeq (Mid Output 150 cycle kit).
Sequence reads were first trimmed to 20 bp total after the primer and bait
sequence (excluding the HindIII site) using the FASTQ trimmer from the FASTX-Toolkit
(http://hannonlab.cshl.edu/fastx_toolkit/). w4CSeq was then used to identify 4C sites,
statistically significant regions, and look at intra- and inter-chromosomal interactions (Cai
et al., 2016). For this analysis, the mm9 genome was used, 500 enzyme sites was selected
as the bin size for trans chromosomes (size_inter), 100 enzyme sites was selected as the
bin size for cis chromosomes (size_intra), 3000 enzyme sites was selected as the
background window size for the cis chromosome (window_intra), and 0.05 was used as
the FDR threshold. To compare the similarity of significant interacting regions,
BEDTools Jaccard was used (Quinlan, 2014; Quinlan and Hall, 2010). BEDTools merge
was used to combine the significant interacting regions together from each replicate for
each viewpoint, and BEDTools intersect to determine the merged regions that were the
same between genotypes.

3.3.12 Gene expression in lung adenocarcinoma
To determine the expression of genes in lung adenocarcinoma samples, the TCGA
PanCancer Atlas dataset on cBioPortal was used. Only the “complete tumors” were
analyzed, with the gene set user-defined list being entered as “RB1: AMP HOMDEL
HETLOSS mut” as well as only the gene names for the other genes we were interested in.
The plot function was then used to obtain data comparing RB1 copy number to the
mRNA expression Z-scores of genes of interest. All genes that contained an Rb1+/+ CAPD3 peak within their bidirectional promoter region that is ≤5000 bp and was the higher
expressing of the two genes from each bidirectional promoter in Rb1L/L compared to
Rb1+/+ MEFs were attempted to be analyzed in these tumor samples. However, not all
mouse genes were able to be analyzed in human, and this was particularly true for the
RIKEN genes. Z-scores from RB1 “deep deletion” and “shallow deletion” samples were
then manually grouped to obtain the deletion category, and were compared to Z-scores
from the RB1 diploid population for each gene of interest using t-tests. Data from genes
that had significantly increased Z-scores in RB1 deleted tumors (deep and shallow
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deletion combined) compared to RB1 diploid tumors were then submitted to matrix2png
to create a heatmap where the data were normalized such that each row had a mean of
zero and a variance of 1(Pavlidis and Noble, 2003).

3.3.13 EZH2 inhibitor treatment
To inhibit EZH2 in MEFs, asynchronously growing P4 MEFs were seeded at a
density of 4x105 cells per 10 cm plate. The next day, when cells were at approximately
50% confluency, treatment with GSK343 or vehicle (DMSO) with treatment volumes of
0.1% of total media volume were started. Treatments of 2.5 μM or 5 μM GSK343 were
administered once every 24 hr for 48 hr. GSK343 was stored at a stock concentration of
1000x treatment dose in DMSO at -20°C protected from light. After 48 hr of drug
treatment, total RNA from proliferating MEFs was isolated, converted to cDNA and
expression was analyzed as above. Whole cell extracts were also collected after 48 hr of
drug treatment and H3K27me3 (07-449, EMD Millipore) blots were performed.

3.4 Results
3.4.1

Condensin II and TFIIIC occupy promoters in an pRBdependent manner
To investigate genome wide localization of condensin II during interphase, we

performed chromatin immunoprecipitation followed by high throughput sequencing
(ChIP-Seq). We precipitated CAP-D3, a subunit that is unique to condensin II, from
chromatin isolated from primary mouse embryonic fibroblasts (MEFs). Regions of local
enrichment were determined using Model-based Analysis for ChIP-Seq (MACS) (Zhang
et al., 2008). Using Cis-regulatory Element Annotation System (CEAS) (Shin et al.,
2009), the distribution of CAP-D3 ChIP-Seq peaks within genomic features was
determined. This data demonstrated that 40% of 1547 total CAP-D3 peaks were within 1
kb of a transcriptional start site (TSS), which we refer to as proximal promoters (Figure
3.1A). We carried out ChIP-Seq for both CAP-D3 and CAP-H2 and used a combination
of ethylene glycol bis(succinimidyl succinate) (EGS) and formaldehyde fixation, to
preserve protein-protein interactions that may recruit condensin II to chromatin and
capture these longer distance interactions (Figure 3.1B). These ChIP-Seq experiments
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Figure 3.1: CAP-D3 is enriched at proximal promoters.
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Figure 3.1: CAP-D3 is enriched at proximal promoters.
(A) Average distribution of Rb1+/+ CAP-D3 ChIP-Seq reads 1000 bp upstream and
downstream of genes, as well as average ChIP signals on a meta-gene, where every gene
is normalized to a length of 3000 bp. (B) Schematic of captured ChIP fragments with
formaldehyde versus formaldehyde and ethylene glycol bis(succinimidyl succinate)
(EGS) fixation. Formaldehyde uses methylene bridges to crosslink and is primarily a
protein-DNA crosslinker, whereas EGS is a protein-protein crosslinker, using Nhydroxysuccinimide (NHS) esters to yield stable amide bonds (Hoffman et al., 2015; Tian
et al., 2012). Since condensin II may not be directly binding to DNA at many locations it
interacts with, EGS+formaldehyde dual crosslinking was used to have a more in-depth
look at chromatin contacts. (C) Average distribution of EGS and formaldehyde fixed
CAP-D3 ChIP-Seq reads 1000 bp upstream and downstream of genes, as well as average
ChIP signals on a meta-gene, where every gene is normalized to a length of 3000 bp. (D)
Average distribution of EGS and formaldehyde fixed CAP-H2 ChIP-Seq reads 1000 bp
upstream and downstream of genes, as well as average ChIP signals on a meta-gene.
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revealed an order of magnitude more peaks, as there were now 17576 total CAP-D3
peaks for example, but peaks still showed similar promoter occupancy (Figure 3.1C&D),
suggesting promoters are the principal condensin II binding site. Since CAP-H2 peaks
intersect with CAP-D3 peaks at proximal promoters with 72% frequency, we conclude
these represent condensin II complexes and not free subunits.
Since pRB recruits condensin II to pericentromeric heterochromatin (Coschi et al.,
2014), we compared CAP-D3 occupancy locations from ChIP-Seq data between wild
type and Rb1L/L murine fibroblasts to learn where pRB-condensin II localizes in
interphase nuclei. This Rb1 mutant encodes a three amino acid substitution (I746A,
N750A, M754A) in the pRB pocket domain designed to disrupt interactions with viral
oncogenes such as HPV E7, while preserving interactions with E2F transcription factors
(Isaac et al., 2006). Condensin II recruitment to pericentromeric heterochromatin is
reduced in Rb1L/L cells (Coschi et al., 2014), but chromatin loading of cohesin and
condensin I is normal (Coschi et al., 2010). Using MACS, 66% of all CAP-D3 peaks
found in wild type MEFs are lost in the Rb1L/L mutant. Figure 3.2A shows CAP-D3 ChIPSeq read enrichment at 52 well-known E2F regulated cell cycle promoters for both
genotypes. CAP-D3 peaks were found in 9 of these promoters in wild type and 7 of these
promoters lost peaks in Rb1L/L cells. This suggests that the large quantity of promoters
occupied by pRB and condensin II are unrelated to pRB’s canonical function in G1-S
regulation of E2F transcription. An example of one of these locations is the Timm13
promoter, which is best known as the Lmnb2 origin of replication (Figure 3.2B&C).
Previous studies have identified pRB and E2F1 at this location by ChIP, despite its lack
of an E2F DNA sequence element (Avni et al., 2003; Mendoza-Maldonado et al., 2010).
Furthermore, MACS determined CAP-D3 reads contributing to the peak at this location
was significant in both Rb1+/+ and Rb1L/L ChIP-Seq experiments (Figure 3.2B), although
read build ups are clearly reduced in Rb1L/L. ChIP-qPCR was used to quantitatively
compare CAP-D3 binding at Timm13/Lmnb2 and it showed that CAP-D3 binding was
only significantly enriched over the IgG background control in Rb1+/+ MEFs (Figure
3.2D). This indicates that condensin II recruitment is pRB-dependent, but the Rb1L
mutation does not completely eliminate it in ChIP-Seq experiments. To examine pRBdependency of CAP-D3 localization at promoters, CAP-D3 ChIP-Seq reads from Rb1+/+
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Figure 3.2: CAP-D3 binds at some promoters in an pRB-dependent manner.
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Figure 3.2: CAP-D3 binds at some promoters in an pRB-dependent manner.
(A) Heatmaps of CAP-D3 ChIP-Seq read abundance relative to input controls in Rb1+/+
and Rb1L/L MEFs at 1 kb proximal promoter regions of 52 pRB regulated E2F cell cycle
target genes. Heatmaps are divided into those promoters on the forward strand (top) and
those on the reverse strand (bottom). (B) ChIP-Seq tracks for CAP-D3 from Rb1+/+ and
Rb1L/L MEFs at the Timm13 promoter/Lmnb2 origin of replication where there is a CAPD3 peak in both genotypes. Scales of read build-ups are set to 25. (C) ChIP-Seq tracks for
CAP-D3 and CAP-H2 from Rb1+/+ MEFs at the Lmnb2 origin of replication. Cells were
fixed either with formaldehyde alone or formaldehyde in combination with EGS (+EGS)
prior to ChIP. All scales of read build-ups are set to 50 to show the relative differences.
(D) ChIP-qPCR for CAP-D3 and IgG controls at the Lmnb2 origin of replication, seen in
B&C. (n=7), error bars are ±1 SEM, *P < 0.05; determined by t-test. (E) Heatmaps of
CAP-D3 ChIP-Seq read abundance at 1271 promoters that contain an Rb1+/+ CAP-D3
peak within 1 kb of their transcriptional start sites. The heatmap shows the location of the
Rb1+/+ CAP-D3 peaks in the center, as well as 1 kb upstream and downstream of these
regions. (F) Heatmaps of TFIIIC ChIP-Seq read abundances in Rb1+/+ and Rb1L/L MEFs
at the 1271 1 kb promoter regions that contain an Rb1+/+ CAP-D3 peak. Heatmaps are
divided into promoters on the forward strand (top) and reverse strand (bottom) and are
centered on the promoter regions.
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and Rb1L/L MEFs were compared at 1271 promoters that were most enriched for CAP-D3
(Figure 3.2E). At these promoter locations in Rb1L/L cells, CAP-D3 peaks are lost 30% of
the time, or are shifted or diminished similar to Timm13/Lmnb2, further indicating that
condensin II binding is extensively reduced in the Rb1L/L genotype at these locations.
Therefore, we sought to use comparisons between wild type and Rb1L/L MEFs to study
the effects of condensin II loss on interphase chromosomes.
Condensin II recruitment to promoters has also been shown to co-occur with the
RNA polymerase III transcription factor and chromosome architectural protein complex
TFIIIC (Yuen et al., 2017). To reconcile roles for pRB and TFIIIC in condensin II
recruitment, we carried out ChIP-Seq for subunit 1 of TFIIIC in Rb1+/+ and Rb1L/L MEFs.
This data revealed that TFIIIC is abundant just 3’ of the promoter regions containing
CAP-D3 peaks (Figure 3.2F), and TFIIIC read build-ups in this 3 kb window are reduced
in Rb1L/L MEFs. Using MACS, duplicate ChIP-Seq experiments revealed 67% of these
promoter views contain TFIIIC peaks in Rb1+/+ cells, and this is decreased modestly to
53% in Rb1L/L cells as locations adjacent to the TSS are unaffected by the Rb1L mutation.
This indicates that recruitment of TFIIIC and condensin II, two known components of
topological boundaries, is pRB dependent specifically at these promoter locations.
To gain insight into condensin II’s role at mammalian promoters, we investigated
their chromatin state from publicly available ChIP-Seq datasets generated with murine
fibroblasts. Extensive simultaneous occupancy of these promoters with both Pol2 and
H3K4me3 is a strong indication of active transcription (Barski et al., 2007) (Figure 3.3A),
and there was 98% peak overlap between these modifications and CAP-D3 containing
promoters. H3K4me1, a mark of inactive/poised enhancers, was de-enriched at the TSS
of these promoters (Figure 3.3A), and overlaps infrequently with these promoters
(<20%). H3K27ac, a mark of active enhancers and promoters, is also highly abundant at
these promoters with 85% overlap (Barski et al., 2007; Creyghton et al., 2010; Wang et
al., 2008). Conversely, repressive chromatin marks such as H3K27me3 and H3K9me3
were almost completely excluded from these promoters (Figure 3.3A), with 2% and 1%
occupancy respectively. Lastly, H3K36me3, which preferentially marks exons in gene
bodies, was largely devoid from these promoter regions of interest (<6%, Figure 3.3A)
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Figure 3.3: CAP-D3 is localized to active promoters and changes in binding are
correlated with activation and repression of genes.
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Figure 3.3: CAP-D3 is localized to active promoters and changes in binding are
correlated with activation and repression of genes.
(A) Heatmaps of ChIP-Seq read abundances for histone tail modifications and RNA Pol2
in wild type MEFs at the 1271 1 kb promoter regions that contain a CAP-D3 peak.
Heatmaps are divided into promoters on the forward strand (top) and reverse strand
(bottom). (B) Top 10 most enriched annotation clusters from the genes that contain an
Rb1+/+ CAP-D3 peak within 1 kb of their TSS. Analysis was performed using DAVID
and the enrichment score for each annotation cluster represents the geometric mean, in –
log scale, of the members’ P-values in each cluster. (C) Expression from three Rb1L/L
MEF preparations relative to the average of three wild type MEFs, as determined by
RNA-sequencing (RNA-Seq). The heatmap is of transcripts with significantly different
expression that also had an Rb1+/+ CAP-D3 peak within their 1 kb proximal promoter.
(D) Heatmap of the overall change in gene expression for pRB regulated E2F cell cycle
target genes determined by RNA-Seq as in C.
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(Barski et al., 2007; Kolasinska-Zwierz et al., 2009). The most obvious conclusion from
this work is that pRB-condensin II complexes are localized to active promoters.
Importantly, this pattern of histone modifications is highly divergent from known
regulatory roles for pRB in gene silencing that are characterized by establishment of
H3K9me3 in senescence (Narita et al., 2003), H3K27me3 in terminal differentiation
during development (Blais et al., 2007), and deacetylation of histones in quiescence
(Narita et al., 2003). This further emphasizes that pRB recruitment of condensin II to
these promoters represents a different functional paradigm.
The genes bound by condensin II within their proximal promoters were subject to
functional annotation clustering using the Database for Annotation, Visualization and
Integrated Discovery (DAVID) to determine the biological paradigms that could be
regulated by the pRB-condensin II complex (Dennis et al., 2003). This analysis
demonstrates that this complex could be responsible for regulating several important
processes within a cell, such as DNA damage repair, cell division, transcription and
translation (Figure 3.3B). RNA-Seq was then used to investigate if changes in condensin
II localization in Rb1+/+ compared to Rb1L/L MEFs are linked to changes in expression of
these genes. This shows that 54 genes that have condensin II binding within their
proximal promoters have significantly differentially expressed transcripts in Rb1L/L
compared to Rb1+/+ MEFs, 25 of which are downregulated and 29 of which are
upregulated (Figure 3.3C). This is in contrast to E2F regulated cell cycle genes, from
Figure 3.2A, in which 6 genes were significantly upregulated in Rb1L/L MEFs (Figure
3.3D).
The presence of H3K27ac at condensin II occupied promoters (Figure 3.3A), may
be indicative of enhancer interactions, or may demonstrate that these occupied locations
can function as enhancers themselves. For this reason, it is not surprising that some genes
exhibited reduced expression in Rb1L/L cells at locations where condensin II recruitment
was reduced. The Tubb2a locus illustrates this effect with CAP-D3 and TFIIIC loss near
the TSS in Rb1L/L cells and approximately 40% reduction in transcript abundance for this
gene (Figure 3.4A-C). A more intriguing result is the apparent upregulation of gene
expression at condensin II occupied promoters when it is diminished from these locations
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Figure 3.4: Changes in condensin II and TFIIIC binding are correlated with
downregulation of Tubb2a.
(A) Genome browser view of the Tubb2a gene is shown. ChIP-Seq for CAP-D3 and
CAP-H2 from wild type MEFs fixed with formaldehyde in combination with EGS
(+EGS) are displayed at the top. (B) CAP-D3 and TFIIIC ChIP-Seq tracks for both
Rb1+/+ and Rb1L/L formaldehyde fixed MEFs are shown at the bottom. All scales of read
build-ups in A and B are set to 35 to show the relative differences. (C) Relative
expression of the Tubb2a gene in Rb1L/L MEFs, as determined by RNA-Seq. Error bar is
±1 SEM, *P < 0.05.
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in Rb1L/L cells. One possible explanation may be that condensin II functions as an
insulator between closely spaced promoters and reduction of occupancy enhances
transcription of an already active promoter.
Further investigation of pRB-condensin II occupied promoter locations
demonstrates that it is enriched at bidirectional promoters in Rb1+/+ MEFs compared to
their expected frequency in the genome (Figure 3.5A). Furthermore, condensin II
presence at bidirectional promoters is more than expected by chance, given the relative
abundance of bidirectional promoters (Figure 3.5B). Analysis of expression of genes on
either side of bidirectional promoters bound by CAP-D3 in Rb1+/+ MEFs demonstrates
that upregulation and/or downregulation occurs at many of these locations in Rb1L/L cells
(Figure 3.5C). The contribution of condensin II to the differential gene expression in
Rb1L/L cells was further investigated using Binding and Expression Target Analysis
(BETA), which was able to relate CAP-D3 peak locations with expression of nearby
genes (Figure 3.5D) (Wang et al., 2013). This further suggested that condensin II may
have repressive and activating influences at neighboring genes. To validate this
correlation, the locations of CAP-D3 peaks were computationally redistributed
throughout the genome, while maintaining the same number and length of peaks. These
“shuffled peaks” are not correlated with transcript changes in Rb1L/L compared to Rb1+/+
MEFs, further suggesting a functional connection between condensin II occupancy and
nearby gene expression. Consequently, we focused our investigation on condensin II’s
role at bidirectional promoters.

3.4.2

Differential regulation of gene expression by condensin II at
bidirectional promoters
We used data from our BETA analysis to determine locations of altered gene

expression between Rb1L/L and Rb1+/+ MEFs and found bidirectional promoters where
expression of one of the two genes was correlated to CAP-D3 binding. We focused on
two bidirectional promoter locations, Usp5/Cdca3 and the Pxmp2/Pole to determine
condensin II’s role in gene regulation at these locations. In both cases, CAP-D3 peaks
were found in the intergenic region between the two divergently transcribed genes in wild
type MEFs (Figure 3.6A). This peak was lost in Rb1L/L MEFs at the Pxmp2/Pole location,
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Figure 3.5: Condensin II binding is enriched at bidirectional promoters and is
correlated with changes in expression.

127

Figure 3.5: Condensin II binding is enriched at bidirectional promoters and is
correlated with changes in expression.

(A) Peaks that are within 3 kb upstream from the TSS of genes were grouped according
to whether they are found at bidirectional promoters or not. Compared with simulated
data, where peaks are shuffled to promoters at random, there are more CAP-D3 peaks at
bidirectional promoters as determined by χ2-test. (B) Peaks that are within 3 kb upstream
from the TSS of genes were grouped according to whether they are found at bidirectional
promoters or not. Compared with the proportion of promoters genome wide (“All
promoters”) that reside within a bidirectional promoter region, there are more promoters
containing CAP-D3 peaks that are part of bidirectional promoters, as determined by χ2test. (C) Expression changes from RNA-Seq of genes that contain an Rb1+/+ CAP-D3
peak within their bidirectional promoter region that is ≤5000 bp. Each row represents a
bidirectional promoter, with the higher expressing of the two genes in Rb1L/L compared to
Rb1+/+ MEFs on the left (labelled Gene A). (D) Binding and Expressing Target Analysis
(BETA) was used to establish if condensin II localization in asynchronous Rb1+/+ MEFs,
as determined by CAP-D3 ChIP-Seq, was correlated with changes of expression between
Rb1L/L and Rb1+/+ MEFs, as determined by RNA-Seq. Genes that had either an increase or
a decrease in expression in the Rb1L/L background (when CAP-D3 cannot bind to pRB)
also tended to have an enrichment of CAP-D3 binding sites in wild type MEFs. When
peak locations were redistributed randomly throughout the genome, these “shuffled
peaks” are not correlated with transcriptional changes in Rb1L/L compared to Rb1+/+
MEFs. *P < 0.05.
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Figure 3.6: Bidirectional promoters with differential expression changes upon loss of
CAP-D3 binding in Rb1L/L MEFs.
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Figure 3.6: Bidirectional promoters with differential expression changes upon loss of
CAP-D3 binding in Rb1L/L MEFs.
(A) Cdca3/Usp5 and Pole/Pxmp2 bidirectional promoter locations and their respective
CAP-D3 and TFIIIC ChIP-Seq reads and peaks in both Rb1+/+ and Rb1L/L MEFs. All
scales of read build-ups are set to 35. (B) RT-qPCR of the two sets of bidirectional genes
in Rb1+/+ and Rb1L/L, Rb1+/+ and Rb1-/-, and wild type and E2f1-/ - MEF littermate pairs.
(n=5). (C) pRB ChIP-qPCR results from asynchronously growing Rb1+/+, Rb1L/L and
Rb1-/- MEFs at the bidirectional promoter locations indicated in A. The Mcm3 promoter
and -2 kb upstream location are used as positive and negative controls for pRB ChIPs,
respectively (n=5). (D) TFIIIC ChIP-qPCR results from Rb1+/+ and Rb1L/L MEFs at the
same bidirectional promoter locations as above (n=6). (E) CAP-D3 ChIP-qPCR results
from asynchronously growing Rb1+/+ and Rb1L/L MEFs (n=5). All error bars are ±1 SEM.
*P < 0.05; determined by t-test.
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and diminished at the Usp5/Cdca3 in Rb1L/L. TFIIIC binding at these locations also
appeared to require wild type pRB (Figure 3.6A).
We used qPCR to quantitate mRNA levels for each of these four transcripts.
Consistent with condensin II regulating expression at both of these bidirectional
promoters, expression of one of the genes was increased in the Rb1L/L MEFs; Cdca3 at the
Usp5/Cdca3 bidirectional promoter and Pole at the Pxmp2/Pole promoter (Figure 3.6B).
This change was also seen at both locations in Rb1-/- cells compared to wild type, as well
as in E2f1-/- MEFs at the Usp5/Cdca3 bidirectional promoter (Figure 3.6B). This indicates
that loss of an pRB-condensin II complex may play a role in the differential expression of
these divergently paired genes.
To understand the architecture of protein complexes at these locations, ChIPqPCR was used to quantitate the binding of pRB, TFIIIC, and condensin II components.
First, pRB localization is not changed in Rb1L/L MEFs compared to Rb1+/+ MEFs at these
promoters (Figure 3.6C). Only Rb1-/- cells are devoid of pRB at these locations and this
pattern matches occupancy at Mcm3, a classical pRB-E2F transcriptional target (Figure
3.6C). In addition, TFIIIC localization is significantly reduced between Rb1+/+ and Rb1L/L
MEFs at both bidirectional promoters (Figure 3.6D). Lastly, CAP-D3 is present at these
locations in Rb1+/+ cells, but reduced to background levels in Rb1L/L MEFs (Figure 3.6E).
Collectively, these experiments demonstrate pRB dependent recruitment of both TFIIIC
and condensin II to these locations. When the Rb1L encoded protein is present, but unable
to assemble this complex, expression of one gene in each pair is elevated, implicating
TFIIIC and condensin II in this regulatory event.
Loss of condensin II function affects progression through mitosis (Nishide and
Hirano, 2014), and Rb1L/L MEFs similarly display misshapen chromosomes, mitotic
delay, and aneuploidy in daughter cells (Coschi et al., 2010; Isaac et al., 2006). Studies of
condensin mutants in fission yeast suggest that gene misexpression may be a consequence
of mitotic errors and aneuploidy (Hocquet et al., 2018). Therefore, to increase the
quantity of Rb1+/+ MEF cells with >4N DNA and to increase G2/M phase levels to a
similar quantity as in Rb1L/L fibroblasts, nocodazole was used to inhibit mitotic
progression (Figure 3.7A&B). This induced mitotic errors and delayed progression, but
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Figure 3.7: Gene expression at bidirectional promoters is not altered by microtubule
inhibitor induced aneuploidy.
(A) Differences in >4N DNA content between Rb1+/+ and Rb1L/L MEFs and the percent
of cells in G2/M as determined by PI staining and flow cytometry (n=6). (B) Rb1+/+
MEFs were nocodazole (noc) treated for 24 hours to increase the >4N DNA and the
G2/M content in wild type MEFs similarly to the Rb1L/L MEFs and the percent of cells in
G2/M as determined by PI staining and flow cytometry (n=4). (C) RT-qPCR was used to
quantitate expression of genes at the bidirectional promoters in untreated and nocodazole
treated Rb1+/+ cultures. All error bars are ±1 SEM.
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did not cause expression changes at the Usp5/Cdca3 and Pxmp2/Pole bidirectional
promoters (Figure 3.7C). This suggests that indirect effects on transcription from
defective condensin II function in mitosis in Rb1L/L cells is unlikely to explain
misregulation at these bidirectional promoters. Additionally, depletion of condensin II
components restricts progression through mitosis in mammalian cells and potentially
causes indirect transcriptional effects through synchronization. For example, transcription
of histone gene clusters is tightly linked to S phase to ensure chromatinization is
coordinated with DNA replication, and accumulation of cells in mitosis may lower
transcript levels for these genes simply because the number of cells in S phase is reduced.
Asynchronously proliferating Rb1L/L cell cultures have similar quantities of S phase as
Rb1+/+ (Isaac et al., 2006). Our analysis shows that the histone cluster on chromosome 13
displays pRB dependent occupancy of TFIIIC and condensin II (Figure 3.8A-C) and
when this is reduced in Rb1L/L cells, expression of this gene cluster is actually elevated
(Figure 3.8D). Overall, these analyses argue against potential cell cycle and mitotic
fidelity effects on transcription in Rb1L/L fibroblasts and further emphasize that loss of
condensin II occupation likely has direct effects on gene expression at bidirectional
promoters.

3.4.3

pRB-condensin II complexes mediate long-range
chromosome interactions
Because of the transcriptional changes seen at bidirectional promoters and the

ability of condensin II to affect chromatin architecture and looping, conformation
dependent interactions were investigated. Genome views of regions surrounding
Usp5/Cdca3 and Pxmp2/Pole revealed regular peak locations for condensin II (Figure
3.9A&D). One possibility is that condensin II organizes loops between these locations to
influence gene expression within these territories. For this reason, local chromatin folding
was interrogated using chromosome conformation capture (3C) analysis. We performed
3C-qPCR on cross-linked, HindIII cut, and ligated chromatin from four wild type and
Rb1L/L MEF pairs using Usp5/Cdca3 and Pxmp2/Pole bidirectional promoters as the
reference points (Figure 3.9B&E). This revealed sites of local interaction within these
chromosomal regions. Most notably, some loops appeared in locations that are unrelated
to condensin II peaks (Figure 3.9C, ~60 kb from the Cdca3 bait). Furthermore, there do
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Figure 3.8: Reduced condensin II and TFIIIC localization at the Hist1 gene cluster
in Rb1L/L MEFs are correlated with upregulation of some histone genes.
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Figure 3.8: Reduced condensin II and TFIIIC localization at the Hist1 gene cluster
in Rb1L/L MEFs are correlated with upregulation of some histone genes.
(A) Genome browser view of the Hist1 gene cluster on chromosome 13. ChIP-Seq for
CAP-D3 and CAP-H2 from wild type MEFs fixed with formaldehyde in combination
with EGS (+EGS) prior to ChIP are displayed at the top. (B) CAP-D3 and TFIIIC ChIPSeq tracks for both Rb1+/+ and Rb1L/L formaldehyde fixed MEFs are shown. All scales of
read build-ups in A and B are set to 50 to show the relative differences. (C) TFIIIC ChIPqPCR results from Rb1+/+ and Rb1L/L MEFs at the Hist1h3b gene location indicated in B.
(n=6), error bars are ±1 SEM. *P < 0.05; determined by t-test. (D) Expression changes of
individual genes within the Hist1 cluster as determined by RNA-Seq. The expression
from three Rb1L/L MEF preparations is displayed relative to the average of three wild type
MEFs. Differentially expressed genes between genotypes with an adjusted P-value of
<0.1 are indicated with an asterisk.
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Figure 3.9: Preservation of 3C-detected chromatin loops in Rb1L/L cells.
(A&D) CAP-D3 and CAP-H2 ChIP-Seq read tracks (EGS and formaldehyde fixed),
surrounding the Cdca3/Usp5 bidirectional promoter in A and the Pole/Pxmp2 locus in D.
Read build-up scale is 50. (B&E) HindIII restriction enzyme fragments are shown as
tracks in relation to the gene structure of these genomic locations. (C&F) 3C interaction
frequencies for selected HindIII fragments (indicated as dots) in the Cdca3/Usp5 and
Pole/Pxmp2 regions of interest are displayed in graphical format. The grey dotted vertical
lines relate restriction enzyme fragments to specific data points. The bait fragments are
indicated by red arrows. 3C crosslinking frequencies were normalized to the ERCC3
locus (n=4). All error bars are ±1 SEM.
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not appear to be any interactions that are gained or lost between genotypes (Figure
3.9C&F). Since local chromatin conformation does not appear to be different between
genotypes, despite loss of condensin II at these locations, short-range loops seem unlikely
to be responsible for the changes in gene expression of Cdca3 and Pole in Rb1L/L MEFs.
To broaden our search for condensin II dependent chromosome interactions, we
used Usp5/Cdca3 and Pxmp2/Pole promoter viewpoints as the bait regions for
circularized chromosome conformation capture (4C)-Seq. Chromatin were processed
from four wild type and Rb1L/L littermate pairs and alignment and analysis of data was
performed using w4CSeq (Cai et al., 2016). From this data, significant interacting regions
were produced for each individual experiment (Figure 3.10A) and these were merged
together such that each region shown was found in two or more replicates for each
genotype (Figure 3.10B).
Initially we focused on one region that was common to Rb1+/+ and Rb1L/L 4C-Seq
data, but that showed different boundaries. The Hoxa10 locus, approximately 70 Mb
away from Cdca3 on chromosome 6, contains ChIP-Seq peaks for CAP-D3 and extensive
contacts with CAP-H2 suggesting condensin II occupies this location (Figure 3.11A).
Based on 4C-Seq data, Hoxa10 interactions were detected in all four Rb1+/+ 4C-Seq
replicates using Usp5/Cdca3 as the bait, but only one in Rb1L/L cells (Figure 3.11A).
Consistent with previous experiments, ChIP-qPCR reveals that pRB localization is not
changed between Rb1+/+ and Rb1L/L MEFs at Hoxa10 (Figure 3.11B), but CAP-D3
localization at Hoxa10 is lost in the Rb1L/L genetic background (Figure 3.11C). This
suggests defective condensin II recruitment by pRB can impact long-range chromosome
interactions. Furthermore, a previous 4C-Seq report demonstrated that Hoxa10, used as a
bait, interacted with a region of DNA that contains the Usp5/Cdca3 bidirectional
promoter in MEFs (Sridharan et al., 2009), and this supports the validity of this
chromosome contact (Figure 3.11D).
The genome wide representation of locations that interact with each respective
bait in each genotype reveals that most long-range contacts are retained in Rb1L/L cells
and that some contacts were lost and new contacts appeared in Rb1L/L mutant cells
compared to wild type (Figure 3.10B). However, when interactions that were lost in
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Figure 3.10: Genome wide significant interacting regions determined for
Cdca3/Usp5 and Pole/Pxmp2 bidirectional promoters.
(A) 4C-Seq was used to determine chromosomal regions that interact with the
Cdca3/Usp5 and Pole/Pxmp2 promoters. Circos plots showing all significant interacting
regions for one of the four MEF pairs analyzed from both 4C-Seq viewpoints. Red
indicates intrachromosomal interactions while blue shows all interchromosomal
interactions. (B) Statistically significant interacting regions were determined using
w4CSeq for each of four different wild type and Rb1L/L replicates. Regions that were
identified in more than one replicate are shown as vertical red or blue bars and
chromosome position is shown across the top. The complete set of regions identified in
Rb1+/+ and in Rb1L/L cells are labeled as ‘all’, while ‘lost’ regions represent contacts
identified in wild type MEFs but absent in Rb1L/L cells and ‘gained’ regions represent
novel contacts found only in Rb1L/L cells from that viewpoint.
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Figure 3.11: Changes in pRB-condensin II complex binding correlated with altered
interaction between the Cdca3/Usp5 bidirectional promoter and the Hoxa locus.
(A) Genome browser view of the Hoxa locus on chromosome 6 showing CAP-D3 and
CAP-H2 ChIP-Seq reads and peaks from EGS and formaldehyde fixed wild type MEFs
displayed at the top (with read build-ups scale set to 20). 4C-Seq significant interacting
regions from individual replicates of each genotype from the Cdca3 4C-Seq experiments
are shown. Numbers above the bars indicate the number of replicates that had significant
interaction with each region of the Hoxa locus. (B) pRB ChIP-qPCR results from
asynchronously growing Rb1+/+, Rb1L/L and Rb1-/- MEFs at the indicated location in
Hoxa10 (n=4). (C) CAP-D3 ChIP-qPCR results from Rb1+/+ and Rb1L/L MEFs at Hoxa10
(n=4). All error bars are ±1 SEM. *P < 0.05; determined by t-test. (D) 4C-Seq data from a
study by Denholtz et al. indicating that the Hoxa10 region on chromosome 6 interacts
with a region on chromosome 6 containing the Cdca3/Usp5 bidirectional promoter in
MEFs (Denholtz et al., 2013). Contact frequency is the normalized count of sequencing
reads from each region seen to interact with the Hoxa10 locus. Data were obtained from
4DGenome (Teng et al., 2016).
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Rb1L/L cells were compared with the interactions that were gained, we discovered that the
new regions that interact with the Cdca3/Usp5 viewpoint in Rb1L/L cells were more
variable in size, while new interactions with Pole/Pxmp2 promoter were larger in Rb1L/L
cells (Figure 3.12A). From the Cdca3/Usp5 viewpoint, 15 interactions were found in the
wild type but not Rb1L/L cells, and this was increased to 22 interactions at the Pole/Pxmp2
viewpoint, averaging to approximately 18 interactions that are lost at each region in
Rb1L/L compared to Rb1+/+ cells (Figure 3.12B). One of these locations, which is shared
between the two different viewpoints, is on chromosome 12 (Figure 3.12C). Further
downstream of this location, though, chromosome contacts with each of the viewpoints
between genotypes are consistent. Despite loss of wild type chromosome contacts, there
were approximately 30 interactions that are gained with each region in Rb1L/L compared
to Rb1+/+ cells (25 from the Cdca3/Usp5 viewpoint and 36 from the Pole/Pxmp2
viewpoint; Figure 3.12D). One interesting location where we see novel interactions in
Rb1L/L MEFs, from both viewpoints, is on chromosome 4, which again is close in
proximity to undisturbed chromosome contacts between genotypes (Figure 3.12E). Taken
together, this data suggests subtle alterations in chromosome conformation and contacts
in Rb1L/L MEFs.
Overall, the chromosome interactions are similar between the two genotypes at
both bidirectional promoter viewpoints in wild type and Rb1L/L cells. However, chromatin
conformations in Rb1L/L MEFs appear more dynamic, as seen by more variable and larger
unique interacting regions, and with more interactions gained than lost. Furthermore, our
analysis recapitulates a previously observed long-range interaction between Hoxa10 and
the Usp5/Cdca3 promoter region and demonstrates that it is dependent on pRB-condensin
II recruitment to these locations. This confirms a role for pRB and condensin II in
connecting insulated bidirectional promoters with distant genomic contacts.

3.4.4

Misregulated gene expression at bidirectional promoters in
RB1-deleted lung adenocarcinoma
To determine if bidirectional promoters could also be regulated by the pRB-

condensin II complex in human cells and if this could be related to disease, we utilized
the lung adenocarcinoma TCGA PanCancer Atlas dataset on cBioPortal. At the
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Figure 3.12: Altered long-range chromosome contacts in Rb1L/L MEFs.
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Figure 3.12: Altered long-range chromosome contacts in Rb1L/L MEFs.
(A) The overall size of the significantly interacting regions that were either lost or gained
in Rb1L/L MEFs compared to wild type with the Cdca3/Usp5 and Pole/Pxmp2 viewpoints,
from Figure 3.10B. Each data point represents an interacting region and mean sizes and
the variance in sizes of these regions were compared between the indicated genotypes
using a t-test and an F test, respectively. (B) The number of 4C-Seq significant interacting
regions, from A, found in wild type MEFs and lost in Rb1L/L MEFs at the Cdca3 or the
Pole viewpoints were averaged. (C) Genome browser view of an area of chromosome 12
containing a 4C-Seq significant interacting region with both the Cdca3/Usp5 and the
Pole/Pxmp2 viewpoints in Rb1+/+ MEFs, but not in Rb1L/L MEFs, highlighted in grey.
Also shown is a region where only the Cdca3/Usp5 viewpoint makes significant contact,
and another region where both viewpoints significantly interact, regardless of genotype.
The height of the 4C-Seq bars indicates the number of replicates that had significant
interaction, and the red box on the ideogram illustrates the region shown. (D) The number
of 4C-Seq significant interacting regions, from A, found in Rb1L/L MEFs, but not in
Rb1+/+ MEFs, at the Cdca3 or the Pole viewpoints were averaged. (E) Two different 4CSeq significant interacting regions found on chromosome 4 in Rb1L/L MEFs, but not wild
type MEFs, from both the Cdca3/Usp5 and the Pole/Pxmp2 viewpoints, as highlighted in
grey. Same data display as in C. All error bars are ±1 SEM.
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POLE/PXMP2 bidirectional promoter, there is a much more significant increase in the
expression of POLE than PXMP2 in tumors that have RB1 deletion compared to those
that are diploid for RB1 (Figure 3.13A). Likewise, at the CDCA3/USP5 bidirectional
promoter, there is only a significant increase in USP5 expression in tumors that have RB1
deletion (Figure 3.13A). These results parallel the increase in expression of Pole and
Cdca3 that was seen in and Rb1L/L and Rb1-/- cells compared to wild type (Figure 3.6B).
To determine if this change in expression between RB1 deleted and diploid tumors occurs
at other bidirectional promoters where condensin II binding was observed in MEFs, genes
that contained an Rb1+/+ CAP-D3 peak within their bidirectional promoter region and
were the higher expressing of the two genes from each bidirectional promoter in mouse
Rb1L/L compared to Rb1+/+ cells (“Gene A” from Figure 3.5C) were analyzed within the
same lung adenocarcinoma dataset. In total, approximately one quarter of these genes (39
of the 159 genes with expression data in these tumors) had increased expression when
RB1 is deleted compared to when both copies are retained (Figure 3.13B), indicating loss
of pRB-condensin II insulating effects are evident in cancer cell gene expression patterns.

3.4.5

Bidirectional promoters insulate epigenetic effects on gene
regulation
We sought to test pRB-condensin II complexes as insulators through functional

experiments that explored whether pRB-condensin II could maintain divergent
transcriptional regulation in the presence of perturbed local heterochromatin. We carried
out H3K27me3 ChIP-Seq on Rb1+/+ and Rb1L/L MEFs and noted that at both bidirectional
promoters, there are regions of high H3K27me3 that are found on the 3’ side of the CAPD3 peak in these genome views (Figure 3.14A). Interestingly, this is also the side of each
bidirectional promoter where there is increased expression (Cdca3 and Pole) in Rb1L/L
MEFs. However, we did not see changes in localization of this mark surrounding
bidirectional promoters as a result of altered condensin II binding (Figure 3.14A&B). To
confirm that localization of H3K27me3 was not changing genome wide, H3K27me3
ChIP-Seq alignments were compared using the Pearson correlation method, which
showed extremely high similarity between alignments, regardless of genotype (Figure
3.14C). We treated wild type MEFs with modest concentrations of an EZH2 inhibitor
(EZH2i; GSK343) that were insufficient to diminish global H3K27me3 levels and instead
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Figure 3.13: RB1 deletion in lung adenocarcinoma is associated with increased
expression of genes at bidirectional promoters.
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Figure 3.13: RB1 deletion in lung adenocarcinoma is associated with increased
expression of genes at bidirectional promoters.
(A) Comparison of mRNA expression Z-scores from cBioPortal’s TCGA PanCancer
Atlas lung adenocarcinoma samples based on RB1 copy number. Z-scores from samples
with RB1 “deep deletion” and “shallow deletion” were combined for the RB1 deletion
category, and were compared to Z-scores from the RB1 diploid population for each gene
of interest using t-tests. *P < 0.05, **P < 0.005, ****P < 0.0001. (B) Genes that
contained an Rb1+/+ CAP-D3 peak within their bidirectional promoter region that is
≤5000 bp and was the higher expressing of the two genes from each bidirectional
promoter in Rb1L/L compared to Rb1+/+ MEFs (“Gene A” from Figure 3.5C) were
analyzed in cBioPortal’s TCGA PanCancer Atlas lung adenocarcinoma samples. mRNA
expression Z-scores were compared as in A. Only those genes that had significantly
higher gene expression in RB1 deleted tumors (the left half of the heatmap) compared to
RB1 diploid tumors (on the right half of the heatmap) are displayed. Each row was
normalized to have a mean of 0 and a variance of 1.
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Figure 3.14: H3K27me3 localization is not altered as a result of changes in
condensin II binding but pRB-condensin II complexes do insulate transcriptional
environments at bidirectional promoters.
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Figure 3.14: H3K27me3 localization is not altered as a result of changes in
condensin II binding but pRB-condensin II complexes do insulate transcriptional
environments at bidirectional promoters.
(A) Genome browser view of 500 kb regions surrounding the Cdca3/Usp5 and
Pole/Pxmp2 bidirectional promoter locations with ChIP-Seq tracks for CAP-D3 and
H3K27me3 in these regions. (B) Heatmaps of H3K27me3 ChIP-Seq read abundance
surrounding the ≤5000 bp bidirectional promoters that contain an Rb1+/+ CAP-D3 peak.
The heatmaps are centered on the bidirectional promoters and are showing 100 kb
upstream and downstream of these regions. (C) Clustered heatmap of Pearson
correlations for H3K27me3 ChIP-Seq alignments for every genomic region. The two
different ChIP-Seq replicates (denoted as “rep.” in the figure) for each of the genotypes
were all compared with each other. (D) Wild type MEFs were treated every 24 hours with
the indicated concentrations of GSK343, an EZH2 inhibitor (EZH2i), or DMSO vehicle,
for 48 hours total. Extracts were blotted for H3K27me3 and actin. Extract from Ezh2-/MEFs serve as a control for antibody specificity. (E) MEFs treated as in D had RNA
isolated to determine the relative expression at Cdca3/Usp5 and Pole/Pxmp2 bidirectional
promoters. All error bars are ±1 SEM. *P < 0.05; determined by t-test.
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perturb the epigenetic environment (Figure 3.14D). Analysis of gene expression levels by
RT-qPCR of Cdca3/Usp5 and Pole/Pxmp2 demonstrates that Cdca3 and Pole are
repressed, but their bidirectional promoter mate is unchanged (Figure 3.14E). This
demonstrates that pRB-condensin II complexes contribute to insulation of transcriptional
effects on opposing sides of occupied bidirectional promoters.

3.5 Discussion
In order to study loss of function effects caused by defective condensin II
chromatin loading in interphase, we utilized a targeted murine mutant Rb1L where pRBcondensin II interactions are impaired (Coschi et al., 2014). Using ChIP-Seq and
chromosome conformation capture approaches we demonstrated that pRB organizes
chromosome architectural protein complexes TFIIIC and condensin II in proximal
promoter regions of genes. In particular, bidirectional promoters are occupied by these
proteins and they may mediate long-range chromosome interactions. These data suggest
that pRB-TFIIIC-condensin II occupancy at these genome locations can act as
architectural organizers and insulators that partition expression potential for closely
spaced genes (Figure 3.15A). Reduction of TFIIIC and condensin II recruitment caused
by the Rb1L allele alters long-range contacts mediated from these locations and
misregulates one of the gene pairs (Figure 3.15B). Our data also indicates that loss of
condensin II recruitment does not alter the boundaries or abundance of repressive
chromatin surrounding these regions. This insight into mammalian genome organization
and transcriptional control raises new questions.
Studies from mammals and model organisms indicate that condensins localize to
TAD boundaries along with TFIIIC, CTCF, and cohesin complexes (Crane et al., 2015;
Li et al., 2015a; Van Bortle et al., 2014; Yuen et al., 2017). Data from Drosophila
suggests that TAD boundaries containing condensin II are the strongest insulators
between domains (Van Bortle et al., 2014). While this suggests a role in chromosome
organization, it also suggests redundancy of function between different components at
these locations, or that RNA polymerase movement may simply direct condensin II to
these locations without a functional purpose. Our study looks at condensin II function in
chromosome topology in isolation, as cohesin and condensin I chromatin loading are
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Figure 3.15: pRB-TFIIIC-condensin II complexes organize transcriptional
environments at bidirectional promoters.
(A) In wild type cells pRB-TFIIIC-condensin II is responsible for making long-range
chromosome interactions at bidirectional promoters where one of the two genes (Gene A)
is sequestered in an environment that reduces its expression. (B) In Rb1L/L cells pRB is
present, but is defective for recruiting TFIIIC and condensin II to bidirectional promoters.
Loss of this complex reduces contact with certain genomic locations, allowing novel and
potentially more transcriptionally active regions to influence the environment around
Gene A facilitating higher level expression.
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normal in Rb1L/L cells (Coschi et al., 2010; Manning et al., 2010). One conclusion from
this work is that most distant chromosome contacts involving Cdca3 and Pole are
retained in Rb1L/L cells compared to Rb1+/+ in our interaction maps. This supports the
concept of redundancy of three-dimensional architecture in genome organization. Our
data also reveal that Rb1L causes the consistent loss of chromosome contacts with specific
regions seen in wild type cells when TFIIIC and condensin II recruitment are diminished.
In addition, the overall effect of the Rb1L mutant on Pole/Pxmp2 promoter contacts
creates broader unique interacting chromosome territories, and more variable sizes of
unique interacting chromosome territories for Cdca3/Usp5 promoter contacts. Thus,
mammalian condensin II-dependent contributions to three-dimensional chromosome
architecture are measurable and their loss has consequences in isolation from cohesin and
its regulators.
Our data indicates that loss of pRB recruitment of condensin II and TFIIIC has
local effects on transcription. The viewpoints we investigated in detail demonstrate that
condensin II has little role in organizing short-range loops. For this reason, local effects
on transcript levels are best explained by the altered long-range chromosome interactions.
We note that our model of condensin II mediated chromosome contacts (Figure 3.15) is
consistent with gene transcription territories in nuclear organization that have been
proposed in other studies (Denholtz et al., 2013; Imakaev et al., 2012). It is possible that
our work reveals subtle reorganization, or loss of these territories. Furthermore, recent
studies of chromosome topology changes induced by degradation of CTCF or cohesin
components indicate that functional compartments created by some long-range contacts
are maintained (Haarhuis et al., 2017; Nora et al., 2017; Rao et al., 2017; Schwarzer et al.,
2017; Wutz et al., 2017). Our data suggests that condensin II may be an unidentified
factor that mediates these contacts, although this will need to await further investigation
using Hi-C approaches.
The involvement of pRB in TFIIIC and condensin II recruitment to gene
promoters in interphase may seem surprising. We note that some prior studies of
mammalian condensin II have utilized cell lines that are transformed by viral oncogenes
that target pRB (Liu et al., 2010; Yuen et al., 2017). pRB’s role in organizing long-range
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contacts would likely be disrupted in these cells, or would rely on compensatory
mechanisms to load condensin II in pRB’s absence. A number of previous studies have
demonstrated that pRB interacts with condensin II and this interaction is conserved in
Drosophila (Coschi et al., 2010; Longworth et al., 2008). Furthermore, TFIIIC has also
previously been shown to bind to pRB (Chu et al., 1997), indicating that these protein
complexes have be known to function together, but their role in long-range chromosome
interactions and transcriptional control at divergent promoters was unknown.
Cancer genomic studies have revealed that RB1 deletions often occur late in
cancer progression and are preferentially enriched in metastatic disease (Robinson et al.,
2017), or in acquired resistance to targeted therapeutic agents (Dick et al., 2018). These
are scenarios where deregulated proliferation has already been established, and suggest
pRB loss has additional contributions to cancer biology. Therefore, alterations to
interphase chromosome structure and gene expression, mediated by pRB disruption in
cancer, may be linked to misregulation of condensin II. Consistent with this, when we
analyzed genes from bidirectional promoters where condensin II was seen to bind in our
mouse model, we found that compared to RB1+/+ cancers, those with RB1 deletion
frequently upregulate these genes. This study demonstrates that organization of longrange chromosome interactions and divergent promoter insulation by condensin II is an
unexpected, but obligatorily common target for disruption during cancer progression
because of its dependence on pRB.
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Chapter 4

4

Discussion

4.1 Summary of findings
My thesis investigates different contributions of pRB to the maintenance of
genome stability. The work here suggests RB1 mutation affects the level of DNA damage
through various mechanisms as well as the organization of long-range chromosome
contacts through pRB’s interaction with condensin II. Overall, this demonstrates that pRB
has other previously unappreciated roles within the nucleus which assist in tumor
suppression through preserving genome integrity.
My work in chapter 2 identifies increased genome instability in cancer cell lines
when RB1 mutations are induced, despite an already compromised pRB-pathway. Even
cells with single copy loss of RB1 have increased levels of basal DNA damage as well as
mitotic errors. Increased quantities of reactive oxygen species as well as defects in
homologous recombination appear to be the main contributors to the increase in
spontaneous DNA damage. RB1 mutation also results in a heightened capacity to seed
new tumors in the lungs of xenografted immune compromised mice.
In chapter 3, the dependency of condensin II on pRB for its localization
throughout the genome is investigated. This study demonstrates that pRB is a recruitment
factor for both condensin II and TFIIIC at many promoters throughout the genome. The
complex of pRB-condensin II-TFIIIC is further enriched at bidirectional promoters,
where diminished localization of these proteins leads to reciprocal misexpression of these
divergently paired genes. Chromosome contacts were investigated demonstrating that loss
of condensin II binding leads to altered long-range chromatin interactions with between
bidirectional promoters and distant loci. Data from lung adenocarcinoma patients
demonstrates that a similar mechanism may occur in humans, as some genes at
bidirectional promoters have significantly higher expression in patients with RB1 deletion
compared to those that have retained both copies of RB1.
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Collectively, my work has added to our current model of pRB-mediated tumor
suppression, highlighting the fact that its contributions to tumor suppression encapsulate
more than simply maintenance of proliferative control through binding to and repressing
E2F transcription factors (Dyson, 1998). This initial finding has caused cell cycle
independent functions of pRB to be largely overlooked when assessing its contributions
to tumor suppression. However, my work demonstrates that loss of RB1 can also
contribute to cancer progression through enhanced DNA damage and altered
chromosome topology. My investigation into the various measures pRB employs to
support genome stability may elucidate answers to questions regarding pRB status in
relation to patient outcome, disease progression, and genome reorganization.

4.2 Impact on cancer therapy selection
My work in cancer cell lines with RB1 loss in chapter 2 confirms increased
vulnerability to cisplatin, agreeing with studies where loss of pRB correlated with
improved survival in response to chemotherapy incorporating a platinum-based agent like
cisplatin or carboplatin (Cecchini et al., 2015; Garsed et al., 2018; Ludovini et al., 2004).
Thus, it appears as though these platinum-based chemotherapies are exploiting the
genomic instability in these RB1-deficient tumors, which could be what is responsible for
the improved outcomes in these patients. Since I have shown that cells with RB1 loss
have impaired homologous recombination, PARP inhibitors (PARPis) might be useful to
potentially increase treatment success in patients with low levels of pRB. This is because
PARPis exhibit synthetic lethal effects when applied to cells with defective HR
(Konstantinopoulos et al., 2015). In some clinical trials of PARPis, in fact, platinum
sensitivity has been used as a clinical surrogate of HR deficiency, and thus has been used
as an eligibility criterion when selecting patients (examples are (Ledermann et al., 2012;
Liu et al., 2014)).
Only recently have PARPis been used in combination with carboplatin, and
because of the common BRCA1 and BRCA2 mutations in epithelial ovarian cancer (EOC)
and breast cancer, this combination therapy has been tested chiefly in these settings and
the results seem favourable. For example, in a recent phase 2 trial, the efficacy and
tolerability of PARPi olaparib in combination with paclitaxel and carboplatin
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chemotherapy, followed by olaparib maintenance monotherapy was assessed versus
chemotherapy alone in patients with platinum-sensitive, recurrent, high-grade serous
ovarian carcinoma (HGSOC) (Oza et al., 2015). This study found that olaparib plus
chemotherapy followed by maintenance monotherapy significantly improved
progression-free survival versus chemotherapy alone (Oza et al., 2015). However, despite
the fact that an extension in progression free survival was observed in the cohort of all
patients, the difference between treatment groups was larger in the subset of patients with
BRCA mutations, so subsequent phase 3 trials have focused solely on patients with these
mutations (Moore et al., 2018; Pujade-Lauraine et al., 2017). Therefore, it would be
interesting to determine if some of the other patients that respond well to PARPis in
combination with chemotherapy are those that have pRB loss.

4.3 RB1 hemizygozity in cancer
As previously discussed in the introduction, Dr. Alfred Knudson proposed what
became known as the “two hit hypothesis” when studying retinoblastoma (Knudson,
1971). As part of this study, Knudson proposed that loss of one RB1 allele did not
accelerate loss of the second RB1 allele; in other words, it was thought that hemizygosity
of RB1 did not create haploinsufficiency, but rather that the wild type condition was
recapitulated. However, some recent studies, including data from chapter 2 of this thesis,
has demonstrated that single copy loss of RB1 may contribute to cancer progression
through multiple mechanisms.
Genomic instability used to be thought of as a by-product of tumorigenesis,
however, through our increased knowledge of cancer progression, it is now thought of as
an enabling characteristic (Hanahan and Weinberg, 2000, 2011). Data from chapter 2,
therefore, demonstrating that single copy loss of RB1 leads to increased DNA damage
compared to otherwise isogenic cancer cells that are diploid for RB1 suggests that pRB is
haploinsufficient in terms of the maintenance of genome stability, and thus, tumor
suppression. In line with this, there is evidence of genome instability through an increase
in mitotic errors in primary RB1+/= cells (Coschi et al., 2014; Gonzalez-Vasconcellos et
al., 2013; Zheng et al., 2002), and patients with inherited retinoblastoma are more likely
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to acquire second primary neoplasms than the general population (Abramson et al., 1976;
Marees et al., 2008).
The most common non-ocular cancers patients with hereditary retinoblastoma
develop are bone and soft tissue sarcomas, melanoma and brain tumors (Kleinerman et
al., 2012). Of the bone sarcomas reported in retinoblastoma survivors, many are
diagnosed between 10 and 20 years of age, and osteosarcoma is the most common type
(Kleinerman et al., 2012).
The cancer cell line we used to investigate RB1 heterozygosity, U2OS, was
cultivated from an osteosarcoma patient. Because many of the second primary neoplasms
arising in retinoblastoma patients are of mesenchymal cell origin, and I demonstrated
increased genomic instability in osteosarcoma cells with single copy loss of RB1, it is
tempting to consider that mesenchymal cells may have a special requirement for two
functional copies of RB1. However, we also demonstrated in chapter 2 through
investigation of cBioPortal data that a variety of already established cancers have
“shallow deletion” of RB1. Although it may be true that RB1 hemizygosity might
contribute uniquely to initial cancer onset in mesenchymal cells, it appears as though RB1
single copy loss is more ubiquitous than that and thus its contributions to genome stability
are likely more universal, although this remains to be investigated.

4.4 Rb1L and haploinsufficiency
Not only does complete loss of a single RB1 allele lead to haploinsufficiency,
previous work has also demonstrated a genome instability phenotype in Rb1L/+ cells
(Coschi et al., 2014). It has been shown that pRB and condensin II localize and contribute
to the integrity of pericentromeric heterochromatin, and even in Rb1L/+ cells, localization
of condensin II to these regions is decreased (Coschi et al., 2014). Ultimately, this
resulted in a similar frequency of mitotic errors as seen in the homozygous mutants,
demonstrating haploinsufficiency. Given that a single Rb1L allele leads to reduced
recruitment of condensin II at pericentromeric heterochromatin compared to wild type, a
remaining question from chapter 3 is if this same genotype can also lead to reduced
recruitment of condensin II at promoter regions as well. Comparing the amount of
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condensin II recruitment at bidirectional promoters to the long-range chromatin
interactions at these sites in Rb1+/+, Rb1L/+ and Rb1L/L cells could help reveal the amount
of condensin II localization required to maintain appropriate chromosome topology.
Interestingly, when expression data from lung adenocarcinoma patients was analyzed at
bidirectional promoters in chapter 3, due to the small number of patients with “deep
deletion”, consistent with biallelic loss, the RB1 deleted category also included patients
with “shallow deletion”, which is suggestive of heterozygous deletion of this allele.
Therefore, since the significantly higher expression of bidirectional promoter genes
occurred in patients with both deep and shallow deletion of RB1 combined compared to
patients that were diploid for RB1, this suggests that localization of condensin II at
bidirectional promoters is gene-dosage dependent as well.

4.5 Chromosome topology and cancer
With the advent of chromosome capture technology, we are beginning to
appreciate that cell-fate decisions are driven by changes in environmental cues, activating
signal transduction into the nucleus, which ultimately converge in the activation or
silencing of DNA sequence-specific regulators, commonly transcription factors, and
affect the recruitment of transcriptional and chromatin remodeling machinery
(Stadhouders et al., 2019). The formation and continuation of cell-type-specific gene
expression programs are therefore a consequence of the interaction between transcription
factors and the chromatin landscape that they interact with. This means that cell identity
can be regarded as an “emergent property”, meaning it results from the interaction
between components at various levels of organization, namely between transcription
factors, chromatin-associated proteins, epigenetic modifications, and the threedimensional organization of the genome. Accordingly, genome conformation is partly
cell-type specific; the position of chromosome territories and regions of intermingling
between them has been seen to vary between cell types and evidence is suggesting that
10-40% of TAD boundaries are cell-type-specific and that the strength of boundary
insulation is dynamic (Stadhouders et al., 2019).
One way in which chromosome conformation has been seen to be disrupted in
cancer is through chromosomal rearrangements and mutations that disrupt TAD
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boundaries, which can lead to incorrect insulated “neighborhoods”, or DNA loops, and
ultimately incorrect promoter-enhancer connections. Recently, insulated neighborhoods
in T-cell acute lymphoblastic leukemia (T-ALL) were mapped and frequent
microdeletions were discovered that abolish boundary sites of insulated neighborhoods
containing well known T-ALL proto-oncogenes (Hnisz et al., 2016). Through database
mining, an enrichment of mutations at CTCF boundaries of constitutive neighborhoods in
the cancer genomes of 31 different tumor types were also found, showing that somatic
mutations of insulated neighborhood boundaries occur in the genomes of a variety of
cancers (Hnisz et al., 2016). Another study found that the promoter for a long non-coding
RNA gene, PVT1, competes with the MYC promoter for contact with a nearby enhancer
element in cis and that mutations encompassing the PVT1 promoter region are recurrent
in human cancers (Cho et al., 2018). The promoter of the PVT1 gene was termed a
“tumor-suppressive DNA element” since it limits MYC oncogene expression by acting as
a DNA boundary element between MYC and downstream enhancers (Cho et al., 2018).
Additionally, cancer cells can also activate novel enhancers to influence the transcription
profile. For example, the activation of super enhancers in breast cancer, T-ALL, and
diffuse large B-cell lymphoma have been seen to increase the amount of CD47, a cell
surface molecule that inhibits phagocytosis of cells that express it (Betancur et al., 2017).
Finally, a subset of gliomas have gain-of-function IDH mutations as initiating events,
which leads to hypermethylation throughout the tumor genome. This hypermethylation
overlaps some CTCF sites and was seen to disrupt its binding, leading to changes in
chromosome structure and altered oncogene expression (Flavahan et al., 2016).
Altogether, the previous examples demonstrate that changes in conformation have
been associated with cancer cell types. However, changes in chromosome topology in all
of these examples are linked to mutations or changes in DNA elements, and not from
alterations in the actual architectural proteins responsible for maintaining proper
chromosome topology in cells. Although there are some examples of mutations
specifically affecting proteins previously implicated in interphase chromosome topology
like CTCF and components of cohesin, overall, these are not mutations that are
commonly associated with cancer (Hnisz et al., 2018).
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My work in chapter 3 has revealed that loss of pRB can systemically alter
chromosome topology through loss of the architectural functions of the pRB-condensin II
complex, and this is likely happening on a routine basis in cancers when RB1 mutations
occur. When pRB is inactivated in cancer, reorganization or loss of chromosome
territories at closely spaced bidirectional promoters is expected to occur, as evidenced by
increased expression of particular bidirectional promoter genes in lung adenocarcinomas
with RB1 deletion. As previously mentioned, cancer genomic studies reveal that RB1
deletions often appear late in cancer progression and are enriched in metastatic disease
(Robinson et al., 2017), or in acquired resistance to targeted therapeutic agents (Dick et
al., 2018). From my work, it can be inferred that one reason this may be happening is to
create a state of epigenetic plasticity, where more plastic chromatin may sample
alternative transcriptional programs or gene pathways, some of which may confer a
growth advantage (Flavahan et al., 2017). To confirm loss of pRB in cancer cells leads to
a more dynamic chromatin state with novel chromatin conformations, techniques like HiC, an “all-versus-all” chromosome conformation method, will be useful. Comparisons
could be made with cell types of origin to gain insight into the extent of topology changes
from non-cancerous to cancerous cells, and additional comparisons can then be made to
cancers that have similar mutational spectrums but have different RB1 status to determine
how much loss of the pRB-condensin II complex is able to further contribute to altered
chromosome conformations that will likely be observed in many cancers.

4.6 Lack of cancer progression in Rb1L/L mice
Despite altered chromosome topology and an altered transcriptional profile in
interphase cells from Rb1L/L mice described in chapter 3, and the fact that these cells have
hypocondensation of chromatin in mitotic cells and lagging chromosomes that lead to
aneuploidy (Coschi et al., 2010; Isaac et al., 2006), these mice do not develop
spontaneous tumors (Isaac et al., 2006). This may suggest that the maintenance of proper
chromosome structure is not one of the more important aspects of tumor suppression by
pRB. Conversely, altered chromosome topology in interphase and mitotic cells does
create the opportunity for genetic change that can contribute to cancer pathogenesis, but
the lack of an inappropriate growth-promoting signal is likely what is keeping these cells
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from becoming cancerous. Evidence for this comes from Rb1L/L mice that were crossed
into the cancer-prone Trp53-/- background. Rb1L/L; Trp53-/- mice succumb to cancer more
rapidly than Trp53-/- controls and Rb1L/L; Trp53-/- mice also have a trend toward more
aggressive tumors, increased numbers of animals with multiple tumors, and more
frequent metastases, indicating that the Rb1L/L allele increases cancer susceptibility
(Coschi et al., 2010).
Interestingly, Rb1G/G mutant mice, which have a targeted mutation in the pRB
pocket that disrupts the ability of pRB from associating with E2Fs through the pocket
domain, and thus have increased expression of E2F target genes, are also viable and do
not succumb to spontaneous tumors (Cecchini et al., 2014). Except for an accelerated
entry into S phase in response to serum restimulation following serum starvation, cell
cycle regulation in Rb1G/G MEFs largely parallels what is seen in wild type cells
(Cecchini et al., 2014). Overall, studies using this mouse model suggest that loss of E2F
transcriptional repression is insufficient to cause tumor formation. Similar to what was
seen with Rb1L/L mice though, when Rb1G/G were crossed with Trp53-/- mice, Rb1G/G;
Trp53-/- mutant mice had significantly shorter disease-free survival compared to Trp53-/controls. Therefore, it would be interesting to create an Rb1G,L/G,L mouse line and assess
phenotypes. Clearly both E2F transcriptional control and genome stability are facets of
pRB tumor suppression, and if both of these are rendered non-functional in a compound
mutant, tumor formation may occur. Additionally, similarly to what is seen in Rb1-/- mice,
there is always the possibility that Rb1G,L/G,L mice may die embryonically (Wu et al.,
2003).
Intriguingly, when thymocytes from the Rb1L/L mouse were previously examined,
no aneuploid or tetraploid cells were found (Isaac et al., 2006). This implies that
endogenous proliferation rates may not be high enough to generate aneuploid cells faster
than they can be eliminated, and thus, the mitotic defects observed in Rb1L/L MEFs were
not able to be detected in vivo. This eradication of cells may be due the cyclic GMP-AMP
synthase (cGAS) protein, which is a cytosolic DNA sensor that activates innate immune
responses, including the induction of interferons (Chen et al., 2016). Delivery of DNA to
the host cytoplasm by microbial infection is pathogen-associated, while self-DNA is
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danger-associated when it enters the cytoplasm from the nucleus, as it can be the result of
DNA damage or the reverse transcription of retroelements, for example. Therefore, in
Rb1L/L mice, it is highly likely that cells with more severely altered chromosome topology
are being cleared by the innate immune system through the cGAS pathway. This could be
investigated further through a Rb1L/L; Mb21d1-/- compound mutant mouse, where Mb21d1
is the gene that codes for cGAS. Without activation of immune defenses against cells that
may be premalignant, the Rb1L mutation might lead to a cancerous phenotype in this
Rb1L/L; Mb21d1-/- background. It would also be interesting to probe if the cGAS pathway
is only killing cells with mitotic problems leading to aneuploidy, or if it is able to
somehow target cells that have non-mitotic phenotypes, like those with more plastic
chromatin in interphase. It is possible that mitotic problems and dynamic interphase
chromatin will go hand-in-hand in cells from these mice.

4.7 Further investigation of chromosome topology in Rb1L/L
cells
Although my work has thoroughly investigated chromosome conformation at
specific loci in the genome using 3C and 4C-Seq techniques, differences in TADs as well
as chromatin compartments, or regions of active or repressed chromatin states, remain to
be investigated between wild type and Rb1L/L cells. Changes in these types of
chromosome conformations in Rb1L/L cells could be studied further using an all-versus-all
approach like Hi-C. Based on my 4C-Seq data, I predict that Hi-C data would display
changes predominantly in compartments between the wild type and mutant cells, as I saw
no difference in short-range loops at the bidirectional promoters I investigated but did
find differences in long-range chromosome contacts. This agrees with previous
predictions that condensin II is important for facilitating compartment formation based on
the localization of condensin II at boundary-boundary interaction sites (Yuen and Gerton,
2018). Because of the partial loss of function mutation, use of Rb1L/L cells would be one
of the best ways to study the effects of diminished condensin II binding on chromosome
conformation genome-wide in interphase cells. However, one obvious barrier to carry out
this experiment is the amount of sequencing depth required. Generally speaking, there is a
direct relationship between mapping resolution and sequencing depth for a Hi-C assay,
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and the rule of thumb is to increase resolution by a factor of n, the number of reads needs
to be increased by a factor of n2 (Lieberman-Aiden et al., 2009). In genomes as large as
those from human and mouse, generating contact profiles with resolution from 40 kb to 1
kb requires hundreds of millions to billions of paired-end reads (Han et al., 2018).
Because many of the effects we saw in Rb1L/L MEFs using 4C-Seq data were relatively
subtle, higher resolution Hi-C contact maps might be required to observe global
consequences of diminished condensin II binding in Rb1L/L cells. Therefore, the amount
of sequencing as well as the computational resources required makes Hi-C an expensive
technique to pursue, meaning the decision to carry out this experiment merits a costbenefits analysis. There are also alternative “many-to-all” methods of chromosome
conformation capture, which enable the generation of high-resolution maps at a
subfraction of the genome through enrichment of specific regions of interest out of the
Hi-C library prior to sequencing (reviewed in (Sati and Cavalli, 2017)). Regions that
could be enriched for based on my data, therefore, are bidirectional promoters where
condensin II is seen to bind. This could reduce the cost of sequencing and the amount of
computational resources required, but could still result in more global data, and thus,
more global conclusions could be drawn.

4.8 Multiple possibilities for long-range chromosome
interactions facilitated by condensin II
Although our initial model of how the pRB-TFIIIC-condensin II complex could
be organizing chromosome conformation at bidirectional promoters in chapter 3 showed a
single condensin II molecule entrapping a single piece of duplex DNA (Figure 3.15A),
there are several possible ways in which condensin II could be mediating this interaction.
For example, since there has been evidence of condensin oligomerization (Keenholtz et
al., 2017; Wang et al., 2017), it remains feasible that multiple condensin II complexes
interact to bring chromatin close in three-dimensional space. How this oligomerization
between condensin II complexes occurs is also largely unknown. One likely possibility is
that the ATPase heads of different SMC dimers could interact and form a double ring
structure, for example (Hirano, 2006). It has also been proposed that homotypic HEATHEAT interactions (e.g. between CAP-D2 and CAP-D2) might be important for
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intercomplex crosstalk between condensins (Kinoshita et al., 2015). Therefore, some of
the other ways in which the pRB-condensin II complex could be mediating long-range
chromosome contacts at bidirectional promoters are depicted in Figure 4.1. The given
scenarios are certainly not exhaustive however; how condensin complexes interact with
DNA and form loops is still a mystery. One recent review actually listed some rather
important outstanding questions in the SMC field, which include how do SMC complexes
entrap DNA to form initial chromatin loops, how do these complexes processively
expand chromatin loops, and do all SMC complexes form chromatin loops as monomers
(van Ruiten and Rowland, 2018)?

4.9 Formation and recruitment of the pRB-condensin II
complex
While the association of condensin II with pRB has been characterized as
dependent on the LXCXE binding cleft, there are questions that still exist about the
biochemical properties of this complex. For example, we do not know if there are posttranslational modifications on either pRB or condensin II that are required for this
complex to form, or whether certain modifications may prevent complex formation. Since
pRB interacts with E2F1 using its specific interaction surface in the C-terminal domain
when forming a complex with condensin II (Coschi et al., 2014; Ishak et al., 2017), we do
know that hyperphosphorylation of pRB would not inhibit its interaction with E2F1
(Cecchini and Dick, 2011). Also, since binding of E2F1 to phosphorylated pRB has been
suggested to alter the binding specificity of E2F1 such that it can bind at non-canonical
E2F consensus sequences on DNA (Dick and Dyson, 2003; Tao et al., 1997),
phosphorylated pRB in complex with condensin II remains an intriguing possibility.
Further evidence of this possibility comes from chapter 3, where I demonstrate that
condensin II binds at many promoters in an pRB-dependent manner, largely outside of
those that are related to pRB’s canonical function in G1-S regulation of E2F transcription.
In addition, phosphorylation is also a common post translational modification that
regulates the functions of condensin II (reviewed in (Kagami and Yoshida, 2016)),
suggesting that it, too, could have specific modifications that may facilitate its interaction
with pRB.
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Figure 4.1: Additional models of long-range chromosome contacts mediated by
condensin II at bidirectional promoters.
(A) Condensin II dimerization through the SMC ATPase heads could result in the
formation of a double ring structure that is able to bring two pieces of chromatin close in
proximity. In this diagram, the hinge domain of condensin II is binding to pRB and
TFIIIC, and only one condensin II complex is physically encircling DNA. (B) Homotypic
HEAT-HEAT interactions could also be important for condensin II intercomplex
crosstalk. In this diagram, the head domains of condensin II are interacting with pRB and
TFIIIC, and both condensin II subunits are physically encircling a DNA strand.
Interactions in A and B between proteins and DNA can be mixed-and-matched, and these
possibilities of how condensin II could be mediating chromosome contacts at
bidirectional promoters are not exhaustive.
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Moreover, we still do not know whether interactions between pRB and certain
condensin II subunits are direct or indirect, and which subunits are essential for this
interaction. Work in chapter 3 has shown that TFIIIC is likely a part of the same complex,
as reduced recruitment of TFIIIC at promoters in Rb1L/L cells also occurs. Further support
of this comes from previous work demonstrating interactions between pRB and TFIIIC
(Chu et al., 1997), and TFIIIC and condensin II (Yuen et al., 2017). Therefore, one
possibility is that pRB binds to TFIIIC, which in turn is able to recruit condensin II.
However, further biochemical experiments are needed to determine how these proteins
may all interact and whether additional co-factors are required for formation of this pRBTFIIIC-condensin II complex.
As previously mentioned, condensin II binds at many non-E2F target gene
promoters in an pRB-dependent manner, begging the question of how these proteins are
recruited to these sites. Again, it is possible that E2F1 is responsible for localization of
this complex and is binding at non-canonical E2F consensus sequences on DNA (Dick
and Dyson, 2003; Tao et al., 1997). Alternatively, the recruitment of pRB and E2F1 to
sites of DNA damage suggests that these proteins may be recruited through sequenceindependent means within the genome (Cook et al., 2015; Velez-Cruz et al., 2016). One
possibility is that histone marks may mediate binding of the pRB and condensin II
containing complex. Condensin II might be responsible for interactions with histones, as
interactions with specific histone modifications have been previously demonstrated. For
example, the CAP-G2 and CAP-D3 HEAT-repeat containing subunits can associate with
H4K20me1 histone tails (Liu et al., 2010), and CAP-D3 can interact with H3K4me3
(Yuen et al., 2017). Another option is that TFIIIC could be responsible for some degree
of sequence-specific binding of these proteins, as sites of TFIIIC-condensin II binding
were previously demonstrated to be enriched for a motif similar to the consensus B box
motif TFIIIC is known to bind (Yuen et al., 2017). Overall, although my thesis has
increased our knowledge of where the pRB-condensin II complex binds and its roles at
target locations, there are still several questions about the properties of this complex that
remain to be answered.
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4.10 Summary of pRB functions in genome stability
In summary, my thesis establishes previously unappreciated roles for pRB which
aid in tumor suppression by maintaining genome integrity. Through the use of cancer cell
lines with already compromised pRB-pathways, I observed increased levels of basal
DNA damage as well as mitotic errors when RB1 was mutated. I also demonstrated
increased genome instability even when cells have single copy loss of RB1. The main
source of the increased spontaneous DNA damage in pRB mutant cells appears to be
increased quantities of reactive oxygen species as well as defects in homologous
recombination. There was also an enhanced capacity to seed new tumors in the lungs of
xenografted immune compromised mice when RB1 was mutated. Furthermore, this thesis
also reveals that pRB is a recruitment factor for both condensin II and TFIIIC at many
promoters throughout the genome, particularly at bidirectional promoters, where
diminished localization of these proteins leads to misexpression of many divergently
paired genes. Loss of condensin II binding is also associated with altered long-range
chromatin interactions with between bidirectional promoters and distant loci. A similar
mechanism may occur in humans, as some genes at bidirectional promoters have
significantly higher expression in lung adenocarcinoma patients with RB1 deletion
compared to those that are diploid for RB1.
Overall, my work has added to our current model of pRB-mediated tumor
suppression, emphasising that its involvement in tumor suppression expands beyond
solely maintaining proliferative control through repressing E2F transcription factors
(Dyson, 1998). My thesis reveals that loss of RB1 can also contribute to cancer
progression through increased DNA damage and altered chromosome topology and these
findings may shed light on associations between pRB status and patient outcome, disease
progression, and genome reorganization.
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Appendix B: List of antibodies used
Antibody

Target

Species

Source

C-15
M-153

pRB
pRB

Rabbit
Rabbit

M-136

pRB

Sheep

S855

pRB

Rabbit

Hyb4.1

pRB

Mouse

ChIP
(Ab:Chromatin)

pRB
Sp1
H2A.X
05-636
pSer139
sc-7790
BLM
sc-22760
53BP1
DNA/RNA
ab62623
damage
(8-oxoG)
A300RPA32
244A
ab83311 RAD54B
ab63801
RAD51
05-858 Histone H4

Mouse
Rabbit

Santa Cruz
Santa Cruz
(Cecchini et al.,
2014)
(Cecchini et al.,
2014)
Developmental
Studies
Hybridoma Bank
BD Pharmingen
Santa Cruz

Mouse

EMD Millipore

Goat
Rabbit

Santa Cruz
Santa Cruz

Mouse

Abcam

Rabbit

Bethyl

1:2000

Rabbit
Rabbit
Rabbit

1:500
1:2000
10 ug : 200 ug

CAP-D3

CAP-D3

Rabbit

Abcam
Abcam
EMD Millipore
(Coschi et al.,
2010)

CAP-H2

Rabbit

Bethyl

10 ug : 200 ug

H3K27me3 Rabbit

EMD Millipore

10 ug : 200 ug

TFIIIC-220 Rabbit

Bethyl

6 ug : 120 ug

G3-245
H-225

A302275A
07-449
A301291A

5 ug : 80 ug
5 ug : 80 ug

WB

IF

1:1000

5 ug : 80 ug
5 ug : 80 ug
500 uL : 80 ug
1:250
1:1000
4 ug: 200 ug

1:400
1:400

1:200

1:150
1:400
1:200

10 ug : 200 ug
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Appendix C: List of plasmids used
Name

Description

pX459

Plasmid expressing WT
Cas9

pX459+
X22B
pX459+
X22C

pX462

pX462+
X22B
pX462+
X22C

Plasmid expressing WT
Cas9 and sgRNA for exon
22 of RB1 (X22B
sequence)
Plasmid expressing WT
Cas9 and sgRNA for exon
22 of RB1 (X22C
sequence)
Plasmid expressing D10A
mutant of Cas9
Plasmid expressing D10A
mutant of Cas9 and
sgRNA for exon 22 of RB1
(X22B sequence)
Plasmid expressing D10A
mutant of Cas9 and
sgRNA for exon 22 of RB1
(X22C sequence)

Obtained/ Bacterial Selectable Stock
constructed Resistance markers Number
Addgene
#48139

Ampicillin Puromycin

0681

Addgene
#48139 and Ampicillin Puromycin
Fred Dick

0689

Addgene
#48139 and Ampicillin Puromycin
Fred Dick

0690

Addgene
#48141

Ampicillin Puromycin

0682

Addgene
#48141 and Ampicillin Puromycin
Fred Dick

0693

Addgene
#48141 and Ampicillin Puromycin
Fred Dick

0694

pDRGFP

In vivo homologous
recombination substrate

N. Bérubé

Ampicillin Puromycin

0784

pimEJ5GFP

In vivo non-homologous
end joining substrate

Addgene
#44026

Ampicillin Puromycin

0815

pCBASceI

I-SceI endonuclease
expression vector
(pCAGGS backbone)

N. Bérubé

Ampicillin

0785

pMSCVBlasticidin

Empty backbone with
blasticidin resistance

Addgene
#75085

Ampicillin Blasticidin

N/A

0816
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pCAGFALSE
lentiCRISPR
v2

pCAG promoter driving no Addgene
CDS (pCAGGS backbone) #89689
Lentiviral backbone
expressing WT Cas9

Addgene
#52961

Ampicillin

N/A

0817

Ampicillin Puromycin

0818

Lentiviral backbone
Addgene
lentiCRISPR expressing WT Cas9 and #52961 and
Ampicillin Puromycin
v2+X22B sgRNA for exon 22 of RB1 Michael
(X22B sequence)
Roes

0819

pMD2.G

VSV-G envelope
expressing plasmid

Greg
Fonseca/
Mymryk

Ampicillin

N/A

0656

psPAX2

Lentiviral packaging
plasmid

Greg
Fonseca/
Mymryk

Ampicillin

N/A

0655
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